var title_f38_6_39008="HRCT reticular pattern in scleroderma";
var content_f38_6_39008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interstitial lung disease with honeycombing in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 262px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEGAUcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyLxNr+rR+INVA1W/VFupcAXD4ADn3rI/4SnUv+gzqH/f+T/Gth7CHVfiM2nXSztBd6r9nkEBHmFXm2kLnjdg8e9cj4k059I8Q6np0kMsLWtzJEI5gQ6qGO3OfbHPfNAzW/wCEp1L/AKDOof8AgRJ/jR/wlOpf9BnUP/AiT/GuYFKKAudP/wAJTqf/AEGdQ/8AAiT/ABo/4SjU/wDoMah/4ESf41zIFOAoC50n/CT6n/0GNQ/8CJP8aX/hJ9T/AOgxqH/gRJ/jXOAU8DNAXOg/4SbVP+gxqH/gRJ/jS/8ACS6r/wBBjUP/AAIf/GsADmnAUBc3f+El1X/oMah/4ESf40f8JLqv/QX1D/wIk/xrIs7We9uktbK3murlzhYYIzI5Ppgc16l4Z+CPjLWIUF5pdvpMIPmebfTbJCDj5TGu5u2cEL160Bc4X/hI9W/6C+of+BEn+NH/AAkerYz/AGvqGP8Ar4f/ABr37Sv2ctJh2NrOt310x5EVmiwqfYs24/iMV2mkfB3wFpqBj4dhupepa9uZJyD6DJA/SgLnyWPE+pk4GtXzH0Fy5P8AOrVtqviO65trnXJh/wBMzM38q+39P0jSNN2Np2iaZaEAY8i1jQ/ntzWuLpiBiRgPY4AoC58Ow2fjuZd0Vp4pZfXybjH8qtxaH8RJQpjsPFDAjIISfp/ntX2vvdgQzu2D1JqF1k3fKSw7nNAXPjZfC3xMZto03xRn3EwqceDPigemneI/+/j/AONfXzEkHqec807Oc8M3egLnx+fBvxQBP/Eu8R8ejuf600+D/ieB/wAg3xL/AN9Sf419hMCeq4J6A9aXdIGAUt9CM0Bc+OT4T+Jw/wCYZ4o/ASmmN4Y+Ji9dL8V/hHOa+yTJPgiOPcQcfMMAfrzTiZGDbyMMMgEdDQFz4xPh34lDrpXi78ILg/0pp8P/ABJHXSfF/wCFvc/4V9ogsHUfxnqfUf41KRk89vWgLnxOdC+JA/5hPjH/AMBbr/CmnRfiOP8AmEeM/wDwEuv/AImvtvn1z70nI6/pQFz4j/sf4jf9Ajxp/wCAV3/8TVDWD4y0W3FxrMPifT4CcCS7huYlJ+rACvujk57H3ocb43jcB42G1kYBlYehHQigLn5/jxVqRGRrOoEf9fEn+NH/AAlWpf8AQZ1D/v8Ayf419WeOfgb4Q8T+bPZWzaHqLgkT2KgRFv8Abi6Y/wB3Br5m+I/wv8SeA5Wk1S2+0aWW2x6jagtCfQN3RvZvwJoC5mf8JVqX/QZ1D/v/ACf40p8UaosSyNq2pCJuA5mlCn6Hp2Ncswyp68jtXt+oSfa/CkF/q7XWnaEBCyRLci40a42uoMVtbld8UhwxLZOCso/ioC55y/ifVEVGk1bU0VxlS0soDD29aI/E+qSuEi1bU3c9FSaUk/gK3fic+vO2pTXuoiTwvNes+jwz3Pmj7PvYx/ZlJJiQIVyPl+XaPauN8NPqS63bjQtSk03VGDLBNHcNAxYjAQOvILfdGSBzyQOaAubQ1/WzL5Qv9YMu3ds3TZx649KRfEOtNOYV1HVzMBkxh5dwHrjrXeeJbrxHL4m0HT7HXNZsdXit3ik06TWy14ULoz/6YBsJlALhSdq+X0yQDq3WsNe6lrFta6rfp4njW0aC2TU9k0cKLMslk98zqGQMySMwLbsgAZG5QLnlH/CV6l31jUf+/wDJ/jR/wleo4z/bOof9/wCT/GvSNUtvBOtyXl75ekRvNeSymSOcx4CJZxeWFJHybprh92Ms0YOSM5qf8Iz4Iezt7GS60+MxCSCS9+1r5sm6a7AlbJ2hlW3gAwMYlOc7lwBczfh5reqy+MdPSXU750PmZVrhyD+7b3orO+G//I6ad/20/wDRbUUDM/xFczWXinU7q1cx3EF7LLG4GdrK5IP5iuUuZ5bq6muLh988ztJI3TczHJP5k103i3/kP61/18zf+hNXLCgTO20LwcD4atde1Gyn1C0vBN5Fva6jBayfu22k4fc7tkYCIhzkc5+WtTSPAVldWumWlw8kF1qth/aFtqMkpCghXYwJAF/esBEwL7lVcjODtDcto/izUdKsYraCOzlNtzZ3E8AkmsjuL5gfPyHcS3fDc06DxdqsWmC03QPMqGGG+ki3XcEZzlI5c5RTufgf329aBFu+8A6ta2P2pZbG5UWq3TrDI4K/uFuHQ7lA3JE6OcHB3YUswIEviH4f6toa6i8k1ldxWG/zXt3YAiNkSUqHCk7HliU8c78rkAkVJvGuvzwyRPeR+XJG0LKsCDKtbJbEdP8AnlGq/UZ607UfGfiDUoryO9vxJHeCZZ1EKLvErxySdBxloYz7bfegDnQPwpwFKBXqPwh+EOpePGW/vXk03w4rYN3t/eXJHVYQevoXPA7ZIOADz/QdG1LxBqkWm6HY3F/fSdIYFyQPVj0Ue5IFfQngT9nKFI47rxzqDSyEA/2dYPhV9pJup+igfU17j4U8MaN4T0tdP8PafFZW3BkK8ySkfxO55Y/U/StjGB7UAZfh/QdI8N2n2Xw/ptpp0AGCttGFLd+W6t17mp3WRL1CA3lOTnA4z2ye1XccdaMcY/yaAKKZaKRY9+4fwFcbfbnqKSXcSilBlQCxA5z/AIVodutNRnLyq0ZRFICNuBEgwCSB2wTjnrjPSgCmg3KMZGetOI24HX2zV7nHcUdKAKCghcg4+hxzTtzhSN2T9f61dGeOcfjSmgCi5LoAxBbudgyacCVIZckHhhVwUf5NAEaElQwGM0uPwqTHPNIBQAzbgdKCCAc4p+KDQBFnnauT70/HNLgAHJGAMn0FcV4k+JOiaLqUmmQw3+q6okKXH2exhLAxt0YOeCPXGaAOzx/9ajFeeaz8VdM08ad5Nq7vf2f2yATM0fRirK/y/KQRjJ61a8J/Eey17TLm6ktxbvFc/ZY4o5dxuH2g7Y9wG5vagDudv45pCv41lr4i0r7abQ3ieeqJI6j5hGG+6HK52njvitdCGUMjBlPO5TkH6UAM29KZLEksUkU0aSQyKUeORQyOp6gg8EVL1x60Y96APnX4r/s9292k2q+AFW2ucFn0h2xHKev7lj9w/wCyePQivmaeyl07VWttSsniuYJQk9rcAxODnlWzgrnpmv0j6jpXCfFL4X6H8QrJjfp9k1mOPbb6lEvzp6K46OnseRzgjNAHgtpbQnxDoV9rFva6ZocGqQbbTVdKgtoo4mfHl2tyrMLyNRgM7dVCv344fxRoVv4e+G8NpLNbzahPqUFySYgkyBrZvOh7nET4RucBsZANY/j/AMN+IfCWrjQ/E4nzbqfs26VpIJI+geEnjaQB0wR0IHSoPBiR3fie2W/tZ9RjAlk8vDShWClvNdBkuikb2QcsARQBzeFx0Xb+ldz8KpNZXUni0iO+n055Izf2+l2sF1eNGM/NFFICeOhcDauRnsD1t1plj/wkttqD6dpVxYywSGLULPR5Et4mRo1Z5tPPLKu7aDgAlw3Ow1w3xEtjYeIopIIrW3S5txPHJYxNbLMhdxv8knMJO3GzgfKDjmgD0fV/Cek69cahqeprFLqUt/OzS2sqRRCGJLVFh2IqgSA3OXYD78TDnJNQJ8LtBe1s7EvIL7MsE1553Dubi5jRxHnC7Raj5c8+Z7DPD/DrS7bVNN8ZpNpIv7iDRZLm3m2u7WzrIgyAOMkE8nkY4754lkXy2IA6dfwoA9E+G/8AyOmnf9tP/RbUUfDf/kdNO/7af+i2ooGZXi3/AJD2tf8AXzN/6Ea5eut8RRCfxRqkLTxW6yXkqGaYkJGC5G5sAnA6nAJ9qoW+g2Uk9zHL4r8P2ywyCNZJRdlJgQDvTbATtGcfMAcg8Y5oBmEBTwOa6y58CX1lqEtjf6lpdrd/apLK0jdpm+3SxvsZYmWMqBvwoMhQc+mSOant5ba4lt7hNk0LtFIuQdrKSCMjg4INAiMCngdqAK9L+CXw1k8f668l8Hi8O2LA3soJUzN1ECH1I+8R0HuRQB0HwF+EX/CWvH4g8SxOvhyNv3EBypv3B/MRg9T3PA719ZxIkUMcUMaRRRqESONQqooGAqjsB6U2CGK3t4oLeJIbeFBFHFGAqogGAoA6ACn8+9AAB196DxjH1peTQxAXccbR1PpQAm3ng/hio7q4gtIWnvJ4YIV6ySuFA/E15t8TvHuuaNJFp/hHQpdT1FpFMgjHmt5eMk7F5UHIG4+/pXMSah4mubO80zxF/ZN1r8dwup2lhqT+S0cAQ7whzghMZ56gtQB6Dr/xT8GaCzLqOrv8qLIDBaSyoynoVdVKn860rXxz4XuLRrr+27S3jSFLh/tZMDRxv91mVwCM4714t4e1+z/4SjTo9dsrm6HiCGJLu6tjtsIWjY7NqMuFiHU4YA5Jrf8AEvhm4nsfFX9v20+szzJHcWd1bacAzbWyiqyMd6KvbjIFAHtsDJcW8c9uyzQSKGSWM7lZT0II6il69814Foj2L67oEfhWz8RzyShLW7Zb1rYWSLgGQw/dQHqPXnjNeseGPGeneJdS1K307e9vaMireYxFKzZ+QE4IcY5U0AdKKXjNH40fzoAKKTvijsaAF7daPwoo59aACmyyJEm+Q4HTOM0/GSOOTXmnxGuvGE+qR2+gabLf6FLayo62cwRpJexaXrHtIAAHXmgC9451nTpbDW4dTurzTLXTWiidpZhbxXjyDcEV+uD03fWvIviD4smtfEFh/aOj2VrpCae1vb3the75o1bh1+0IQARx8pHrjrWj4z8G3PiDxRqdw1tr17ZrpsTtBNeItnDeFVCqHdgQqnJPX8jUvhD4R2EujX2p+INSt7rULv7jaXiSHkgEyqBhzvJBx0AyD6AHBeJ7nS73wfounafrN4bDS/O8m/lkZjNuw0iOwXGxCygAgHnvW94fbUhL4Qs7c6A+go/nfY5tTEi3LOpJlO/5g/OF29CORXp+jaZoL6lqHg3R/wCx7S7jiE15bWlorRzsNvzMGztwcDbk8nPavmPx1fjU9bu3uEeJ1kaEBkXcqLkBTxkDjAHYUAe2fFTXtZ0DVIPEXh+4+zeHZ1QLC0KIt9JgKRIBiSRdo4J46c10fw115/FXh671Cz8Q/Yrl5iIoRDl7MKAXjVW4MZ4IHbkZNfO6+I7+x8P/AGDTb3WMPEiwhSNkEfVlIIPyk9MYrpfhZ8RpNI07Ube6t2uWtlkuYoWBMc7sAHBIx5Zxg5zggY4oA+stJvJ7qMrdW7rIh2mURlEfj7wB7fTNaJrwvwb8QXsdYtNMvNV0y8tJbWWZl0pZHS1JO5AWOSW7Ec9uaxPD/wAcb3TfEk6ay41PR3k2OtuD5lrgkFlyMt2JT8vcA+j8fnSdAO1Q2N3bahY297YTpcWdwgkhmjOVdSOCKmoA57x34N0fxzoL6Tr0G+LJaGdMCW2f++jdvp0Pevhzx74Q1n4feKW0/URLFNC/m2d7HlBOoPyyxkHg9DgHKmv0D3cjB4HUY71yfxN8C6d8QPDMml6gFiuY9z2V5tJa2lI69eVPQr0I9wDQB8Hza/rU2sR6tNrOpyatHgJfPdSG4XAwMSZ3Dgkde9U767ub+7lur+5nurqVt0k08hkkc+rMeSfrV7xNoWo+GtcvNI1q2a3v7R9kiHofRlPdSOQe4NZZoAuabq2paWJhpeo3tkJwFlFtcPF5gGcBtpGep6+tUW/1bY9DS0j/AOrb/dP8qAPQvhv/AMjpp3/bT/0W1FHw3/5HTTv+2n/otqKBkV4WXx9OUufsrDU2IuPk/dHzfv8A7xlTjr8zBeOSBzVlbO6uNY1HULHT7DTryKRUjn1K4htoFYIpMyNI+x5nz5mFyFDBl4IrO1wRHxfqAuJkgh+3Sb5Xh85Y18w5Yp/GAOdvfpW/e+Mra91vUdT1K/8AOlVLdEtbnT479b144kQzh3ykMjhByUYr0OcYoBknw/udSjg1LRItG1MahaxTXF3DDtRbpVyzLemU5ChflATBIPqRXnM0q3E8s8cMUCSu0ixRZ2RhiTtXOTgZwMnOBXomg/EqAeJJtT8ReHdOuvPnurmSW3adZN80ToF2iVVZRu2gtkqpbHNcBZWs99eQWthamW6uZBFBbQ5JZmOFRc5Ptz260CNvwD4S1Dxr4ntdF0obXk+eacjK28II3SH6Z4HckCvufwtoGneF/D9no2jQCGytU2rn70jfxOx7sx5Jrmfg/wDD+2+H/hkW7BJtauwJL+5A6sOka/7C5wPU5Peu76UAKaSgUd+vFAFXUb6306ze6u5Nsa8AdS57KB3Jrxvxh4s1a8157RjHpkcli81rHd3ISJ9gLl/L4ZzjHUgZHQ13PitdevfM+xT22lotwkUU8sQl8qInDysd21SRkA9RnnFeC+LtDk8SaxdanHfafpsj3QsvtNyzsHRcAcjcVPGd3A7UAbvhrx9p97ruhQ6nZiVNTtjBqF7JhJ7+THyt5oIIQYxt4o8N6p8OdMu77V7fX9Y0/UZIpUhi1K1NzJbJJ8oWNhuBHXvkg4rnde8BaP4d02TXdY1M31n5DLbyxypDCbjB2wNGcyBsAtgbRXS+Bvhdqtxb2dpb3M9jHPppmu3uAbmKVXyBDwihGGQ3PzDPGaAOD1nT9Sg1LTrS5udU8QaPqaRmzMaSW1tKzcMuznYwGeOMcHpXXzReKtd8KW8Oj2b6RLpuqRS6fPPcPFcyMymPaOoZQQAWwBx061qXXhHxN4c8C/8ACPWOjWtnBc6g1xcPYXst1MUC7fPOAGEedoxyR3FT/Ajw74g0fX5Lm78ORxrb2jQnULi6dfPjZiymOM5yDz8wA/WgB2k31noFlqWt2sllrmsQBH1a7MrMPtW/iJNxChVw2X6+1WNd1/UrjVfDl5oGlaTLLPZS3qRxSPsLSOQCUTEZkG3lm65wOlaEnhnS/C2gve6Z4T06O+u5GfGqQyzoJWOMRxscquM9cZ+lY2tXfh7T7CW38Xa/pWtpbTb7XT7BfszQNIPmjyn3Il4I4LBqAPTvCfj/AEzVteuvD011u1e2fyy5ICzSbdzooHQqcgjGOOCa7bOe/NfN2i/Fnw/F4mtNTu/CNlDeAfZV1WOTfPFEONzAjLnHVsg9a+jo5FliSSJw0bqHQ+qkZB/KgB9J3zjmkySe2KU+3egA7/Slzz0/Om96BQBn+I9Wi0PQr3UZ3jRYYzt8w4DPjhfqa+Udc+JviC6tnttGKWej2MbPHFZjb5Ktwd5Jy2c9+5r1f9qK6uI/CemW6R+ZaSXO+YYzyPu/zNfMVxdvbtKLW4U29ygEoj43KTkIwPPBHT2oAbd6tfXazR3V1PO1xt84yyM28qflz9K6P4ZRtdeL7exu9RnttOZv9JMchAdAeVAJxkkgD3rkTsIiSMH/AGiTjLdMD/Peu88LeHtUs/COpeJVE0Qmt5obB4nAZpEK7zj027h+BoA7LVdQj+HPjHUr3TraZL+aOC6WMuJBHISzPFK5ORgHBx1PavJrJrjxF4uM7xRST3Mxup/OkEabS25znoBgnpz6VmtLJdyyzXs8weclmlYFi7f7Rz+vvU+nyJpt7b3CzRvdxyJKhblYtpz83XOfSgD0Pxj8TVsLdNE+Hun2uk6FasIzOqCZ7lgd2CzjdtBzjNc5pnxQ8SWGq3V6s0Aa4ge22Q20cQVG67cDgn161y/iDUf7V1m7vFt7a1E8rOsNuu1EycnGeazGDqcHkY6jkUAbfhzWtX0jxDFqlhczLqK5aNiu4yZznOeDxXqNjbT+JPG13d65pEmmzvYLeoYVENx93lkhbiVCRgngj1rzXwV/YSNdz+IdQu7N4tn2X7NEZGYluTjOAAOea9+1L4oaR4otF0bSPEaWV2tk0UupX9hulnjK7XVG5IJHPSgDX+DcmoeH/Ec1jdavbaj4e1uM3ti9qd0MEgwWyRxHnONp7ivaz75zXzT8IPhpptnb3V3ea/d3OlSEiaytVMKziNt0chIOcDuvuMkjivYLTx1Ha63a6Zr9ommQ3ilrK5kuEKuCwCBgCdu73P8AOgDthknvSn6UdDjGCOMUnagDyb9oT4aL438O/wBpaTBnxJpyFodoG66i6tCT6jqp55yO9fFjAg9wfQ9RX6WqcHIPPWvkT9qPwANA8SL4l0q32aTq0h+0bfuxXZyzfQOMt6ZDUAeF0jj92/0NOximv/q3+h/lQB6D8N/+R007/tp/6Laij4b/API6ad/20/8ARbUUDMrxZ/yMGs/9fU3/AKGa54Cui8Wf8jBrP/X1N/6Ga59fagGOUV9JfsqeCgsdz4y1CEEtutdM3DoOksw/9AB/3vWvn/w5o114g13TtG08E3V/OtvGcE7dx5Y47KMsfYV9/aFpdroWi2Gk2ChbSygS3jwAMhRjdgdyck/WgRd47UHhsD0zil70e1ABXKan4usB4on8N+Y8M8MKS3FweEj3/dXPr79Peuomligiead1jijBd3c4CgdzXk3xh0CXWPBmry6f/Z6ancSiaH7LKTLfRoMlS3c7Twg49+aAOa+K/ijw39tGj3uqXkcyy+bKmmEG2fI4Zm6/Uc5pLv4qaPa+Ho47i9j1xZYibfTn04KkbKNqo7DAdcc56/yr54NvOkrRvC8bIQrRkYKn0PpTZXCuirjEfYElTzzQB7t8N/iNY65rGoaTrg0jw+mpJtt5ILJTDFIB8ud525x0JHUdRxWL4a8X6BZnVNCm1LxPE93emb+1/tKJIkiHClVBwvTuSDnmvHdwIbKnHb0BzUrzCXzGnTzZX75x+frQB9Q3l9p2nR6xceL/ABbDq1hqkKbZ4rdre53qFAgj8ttoX+JscEtmp9F+JVjrtrdab4W07U3uIYSIpLSSMSpgYVyjfw7sDqcCvFvE8Ta/4Q0HVNP069TQtFgjsZWeZXLMWJkxxw3PHB4+lHhTxW+k3z2fhOC6stP1GYRTQTzJPKeeGEmxSuBxgCgD3rw146j1Wz8JaR4qitp9bu5pIrv5toS5hYEDA4yQQewrwr4keCNa8O+MNbL6XJDpzSS3FtcQxjymiJzwfUZwR1rk59WuLfXdQuLGZctNLtkx2ORkenFXvEPjLxRqmm29rqep3s9rHGPJhuTlWUDAbpz3+b60AP8ABmrPa6zFC9np99BKRHJFfR7lZcjjcOU7civtPStSs7ny7WCWL7R5IkaCJxIsIxjbuHbg4zjIr4/1TU9O8PalqsehaDYqvkokFzfyNNPAJE+fZhtpcFjg4JCgVi+A/EN54U1ZdS0u6ktrkOkYmdiYWXI3iVed3yZx6UAfdnrRjHfFR2t1bX1rDd2M0c9pOgkilibcjqR1B9Kk6UAHpR+dBNA7UAcp8SvCi+L/AAxLZJJJHdxMJrZo3CksP4CSCAD0zjivJpNJ0HxRrtvYaPpVxb+LbKQDULO4VLV50UgG43nIYZ/u9fQV9CdcVyvxC8Eab43sLeO/Vo720fzLW5jkMTg942dfm2N0OOe4oA8C8f8AgC68QeMtQuPBtpKl59oIktLgCAxuuBvTPVT97Nafxh0TVvC/g3wB4Q0dZL+8h86X7RBGS0s/dFHod7fUCux+BV9qR1zXtG1TwjaaBNpaBWe3EpEm5sY3SFt+QM7geRivTV13R5/Fcnh9Z4pNdtbYXrQmPJijY4BDY4PTgc4I9aAPmTx/8GpfDfgq31+HU911KIo7iznAXZI+MKrdzk4wcV4rNE9vcPDMGSSMlWUjkEcEV9y/F/wZc+OvBUmj6feRWdyJ0uEMwPluV/hYjkeucGvkzxd8OPGXht5rrX9Il+zg5a9SRZomJOAdwPU+/NAHGLLuyojhBZh8zD9M9hSX7oJDDBKZoIzhZNmzd6tj/Htipfs02JdikbU3OpOCV7fWqkpwxxyOxoAWFWdlRNuX+UbsAVr6FaweXq8txLcwy21qXiihO1mfcBhm7AZ5rEIBOFJYH0GK1Wt3XTre9mvLXfe7oxHu3yKFYAtIv8I7gnrg0Adb4b8bHS9GsrafR7e8trC4MqXU8khZS/3lypAcHGQp4B5r0W91NfiH4YbV9T8LwOks3kC4mkkBQYAXyETlSCO+c8cin6BomgfEHU7NLXTrmDwH4btClwXdRJNcFd37sISdzHHct2GM4qfwP40nvNQ/sey03W9I0yadbWytEtw8iFST5skrqTnIAb6+1AHungvWrXVdPktbUXYbTRFbu91y0o2ArJu/iyOp65zXQfrXlWl6imk/E7RrUWMkM+o6cRqE7s2xm3EIEA+ViGB5/wBqvVPUGgBR75zWJ418NWfjDwtqWg6gAIryLYr4yYpByjj3VgD+dbQ/Ogd6APzi1rS7vRdWvNM1KLyr6zmaCZPRlODg9x3HsRVCT/Vv9D/KvoL9rfwj9g8RWPimzhC22pqLe7KjgXCDhj/vJ/6DXz7IPkcex/lQB6B8N/8AkdNO/wC2n/otqKPhv/yOmnf9tP8A0W1FAzL8V/8AIwax/wBfU3/oZrAHNb/ir/kYdY/6+pv/AEM1hBgqMx6KCTQDPoH9kvw002tav4muIv3VnF9itXIHMz8yEe4TAz/tmvpvGBXEfBPQG8N/C/QrOUg3E0RvZ8HI3zfPjp2BUV3FAgyaO/Sj8aXvQBW1KC2ubKWC/wBn2WQbZA7YUj0Jrl/EOlQaQ9lrn2tbaw0mVrjyQRGixmMoyA9CGJXr0xxVzxrfJFax2ZuLWJpkd3W4GVZFGT2IH1NeU67f/wBg6Pd+HPFc11qWi30SXdttmRFnhYDMSPjkoeQB25oA8++KGkJpVo99olrPZWl/dOjLJcI01xGFDeYFAzsLE4IznFeVCMMM7wOORnJ/Ku48RDSr6GOPwzeS38XkxRi3vGP2m3dRzsHRh2G3sK57XdIvdJis11GyNuZ4hKspY/Oue47Y70AYrBt23k4PGaFOByM4PrWo1pd3MMG7bKsjqscvAADHaCx7DOOTxXXeD/hXrXiTWtS0zzrSzuLDespeQOC64+QFeDnI55FAFr4Oapptv4pGj6xOzaHqa+RL5nC+b/ASufUkZ6817nqPww0zw1JqureHdOae4aEukMjmR45B/wA8/r1/SvJfDHwU8YQ+KNLN/YxRWcVzHLLMJ1ZAitkjI6njpX1jI6h3kLBVGWLMcBR1yfSgD5u+JvgZ9V0Sw8U6d4SvLS9uwY77T7df3qyk/LOVHABxyMZ5HevDtWOoPKI9WN2Z4IliVZ8gxxrwq4PQDkAV9haL8WvB2ueL4ND0y/u5b6Zmiin8hlglYc7Qx65wcHGD61r/ABA8JDxP4fvbaweKy1Z1Pk3JQYZuyycElT+lAHx74G8J3vjjWJNNsru2t7vy2lRrpyqfL1zgEjqOgrJ1XT7rTL24sby3gWawkaGd42DqWycHeOD7Yr6I8Pab4D07wpqLX8ttJ4m0WwkttUnllltyZG3bvK6bjv8AlDAdMDNfOE+o3M1pFbvI62iOZFt85VWPVvc+9AHuv7NvxDtdLt5PC2tTCG0aQy2UzBiEdz8yMeiqTgjpyT619JsCpKsMEdq/PRC9vONjOjjptbBGfevqr9mXxFqGt+DtSs9Vu57yXTbpUilnfewjdchc9Tgg4z2OO1AHr+PzoOc8UY5JJpaAE980opPcUfh1oAZcedJGgicqVYHnoR3H5Vk2/hzSLTxPf+KBAqatdwpay3Mr7QsYwAoB4BOBz1PStnr1r5p/aX0PxrrPi2BLWy1LUvDhiQ2cFkhdEkA+feq/x5yQT2xjpQB9LkbSQcg+leSftQXf2b4ZRxq22W4v440JGQMAk59OO9dn8MbbV7L4eeHrXxJv/teK1CTiRtzqMnarH+8F2g+4qT4g+G7XxZ4TvNJvolkDgPETjdHIDwynsaAPg26zHKVlXBRsFCcMMfyFRCB55FZiI4nO1ZX4TPvXvmsfs/a/HDZTadd2moXfmOt0Jn8oNFgbD0OWHOefSvGvE2i3vh2+m0q/hhSe0mZSuQzA8ZyR6jFAGAExjdwe2DzW94Tezm8RafFfKkqTzRxM8jGMRJn5iSOvGap6odMuLi1GkxXUKi2T7T9pdSPPA+coRj5OmAeapwxiI5dGLEYHOMUAezeMfirp2nXkOifDfSrey0fT5zMk6na1zcDjzfoBnGeT1rrvAHxL8V+M9Q1GS+1O20yx+zrChgt2l8gFsFy2QEY9mbqeBXzakMRV8o8sjL8mG24PqT3rttC8VC4S30O6Mei6QRmcaLEyzXLDpvJYA8jOTwD0BoA9V1bXZtQ8YWzaXr13YpYA21vC84mSY2/LwOCN3mOvKtnBwc819A6NqMWsaRZajApWO6iEoU9VJ6qfocivnj4ReKPDOuadP4XutCg+1+RJm5unDXF8VcshG1fvqDnPt1r2TwHrmnTT3vhq0kuJbrR40aSWRMJKH7q3Q4Oc4oA7DPPPej2pBTv8/SgDjfjD4WPjH4cazpUS5vBH9qteP+W0fzKB/vDK/wDAq+BXIMRYcArn9K/S5TtcEjIHbsa+AvjB4fXwx8RfEWlRKVt47hpYRjGI5BvUdT03Y/CgC98N/wDkdNO/7af+i2oo+G//ACOmnf8AbT/0W1FAzL8Vf8jDrH/X1N/6Gag8H6Sde8V6LpAJAvr2GAn0UuMngHtntU/ir/kYdY/6+pv/AEM13P7MWmm++LljP/Dp9rcXZ+bHO3yx9eZOlAM+x22lvkACdFA4AA6Cj1xmmjAwTzQDzzxQIUH14pe1IMU7v60AeMfGG/1Cw8Vi60iGPUb6OxFtHpc/3WViWeYbSCCAMZJx1rmfHo8T+KPB2otpelm20u0t4JpLW3dHVBj59vJJHBJIx93oetZ/xW1vWE+J/iGS0e4hs0WOxlEOTHLBgAqxA3KWPHBFQeEE17T/AA9oWt6cswsbeUPeW9pKd93EH2CBomxkKCdx5BBz1oA8WZo8W8sBYSr82R+YZSORXT2Vjr3jHTbu+tjdale6QsSFFBkkMTFsH1OCMYrupPh5YtNq17q+mSRFb0QxWWnymyih3twsjzAqoAK8qe+Kd9gufDuiavpmmz2NncmaGMz2MzLgBjtaaXsSePvKvHA5oA8/0/wv4s1DUHgtNOvXvbmMsYnjMZkT6NgY9q7LSNKv/CqR3/jq+fw64Al06KSMTXEzxnBwi8gAHv61y03jbXm8S2t1qWsamk0LAPK90yjcThnGOAvpjNdHDZaFq/hXXrrXZtQuL63uRLbXlmzzkqwyUcucDfgkEk8/qAfTfgDxhpXjbQjqGjyyyCCT7POJovLcSBQfu5OAQQRXRuiSRukiho2BVgejA8EV5P8ABW78O+H9H/svTtZt5bO9lE9uJFCyLKRh43cfKzAgDtXrWOeaAPKNO+EWjeDdR1LxN4fhvdR1WCKSTTNPmdfLhlYHG3jLdeN3Qe/NdZ8LbfxNbeC7RfHExm1t5JJJMsGZULZVWI4zjsOgwK6ocUfjQB8j/GfwX4m/4WHr122nXmpWt1N9qt7iGFpMRt0QEDgr0I9q8o3YJBO0rkEHgg98jtX6IIXUkh2APYHFY2peFPDuqXbXWp+H9IvLlmDNNNaIzMR0JOKAPgUvGuC0iAe7Cvqb9ljQL3T/AAtqmr3Ykih1SZBbROuNyRggyYPPJYgey/SvUrPwh4ZsZfNtPDeiwS5zvSyQEH16Vtn8OAAPYUAJz6UmKXI+lAznigBDSk/nSAEfX0oOMUAB705WZfukj15xTc0hOTzQAdgCSfUmhtydQQQOmMGoL2JprWWJJpoGZcLLEcMh9RXD3fhrxPpt3a3PhfxEXiikM1xZaqS6XLMfmy4+6AOQAOooA6x9d0uGdbW+1Kxs7tjtFvPcoshJ6DGa+V/2g9ZtvEXxA+zWtldwXNjGIJY22De2chjg8gjv6V7X4m+CHgvxDrEupXdpcW11MweY2kxVZGxycHOPXjFYmv8AwHsNavkVL+7sLC2hKwhmWYt79AQo9zQB80+ILa3gnhljW0Esqb3s4Q3+jMCRsPJz0zkcc1JpGoqkFzGltgRxNMqwL/F6tnOV9q9p8WfBbwV4Y8Pm61DxVfJcOwSOVUTa7NwoCjt+PavMtK8BW+oXGpW0XinToZU+S0W6JiW6bPQHoMj9aAORsTYS3JuNTllghCsUitYhIxcDjIJAC5xnJ9cCr/hq3W71qy1PW5bb+zBdKLprmTy1cdSgAO45HpXR+IfhJ4q0XR01Aab9rszGJfPtJhMGBPA2jvXFPYXn2f7Q1tcNsLLIPLbdFjHUY4HvQB6z8Ndd8M+CPEOsar/aUlxZyObKxm+zjcY9wJYMfu4HB6kjjIr6G8K3Vm89lfaXAlvbXkIjkhIMRj3EvG20jJDZ4+tfEmr6XfaXJFDqSPBM0YljhkHIjYZDY/hz2HWvpD4HapBq/gWL7Vp909/pQMdtdSu0qy7CX78Ky5IGegNAHvoJ60ZOT/jVawukvbG3uoQwSdA43deR3qyOufWgBQTnkEe/UV8qfthaUsHi3RNWRQPt1i0D/NyWib0+jda+qg3z7fbPFeIftdacLn4dabqCrI0llqIU7cbVSRCpLfiFA+tAHgfw3/5HTTv+2n/otqKPhv8A8jpp3/bT/wBFtRQMy/FX/Iw6x/19Tf8AoZr2P9kGx3674mv2iQiG0hgWU43IXckqO+CFGfoK8c8Vf8jFrH/X1N/6Ga9z/Y+IEXjAY72p/wDQ6AZ9F9h39aQEE5zQO2aQHkDFAh69e34U5QdwwOc4qMAd+KUHH4UAfInxH123t/il4ie2tXmt/tMsE8MsgQM+MbwydcHkZ9KpaZcmQ2Zj1KZGWNQIdqPL5sbbsxv8oEZz83cgEc8V1HxX0qyg+L2ozadB5N1GyXknmY8l22bnbGfm7ZHr2rP0Ge8kGo+KpNMtXtol8m3tmCCRIyfndQRuVRnO4Z4JFAHpFoPBdhpBt/E+u21lql0rX0kcVzJNburkAsIpAQiv93YefSvMrjSX0rW7vUdE8KajDYXbeZ5GoEyQxRDPEYibfIO4JwV96msLu21LX/Edyzadb22uJG0H2p1dDIZAFG6MZVTtONxA9RXQ6lJ4ob4b6RpenppekajLcTxTRaeyq8iqOWMnRWOSCAcmgCrp/wDYp8MeH4NYivzNcpcXDRQQebb2sUilFDyMNyIG5IUk8c4rsfCfwwub34Ztpj6zYrpd7AMeQRcwh1fK3MUvykZGflOcZxXB/D/TPEOj+HtS1K3sbS6vrGRo7m3muwzQWoTcW8sEhlJ68ZrC1H4t61eRDy4baFlYNA4XekMY5CrGfl/E80Ad9cfCnWPBupWl14Ktz4i1POI5b1FhtbMY/wBYRu/eN6Z4HXBNe6aBFqkemQLrs8U2olB572/Ee/vt4Br5i0T42+NJr+1gl1GxJldIEWa1BXLMBuYjn9a99+IOqeLtE0M6j4c0211O4gmVZLIo26aPB3snfrjGM/jQB19vF5MSxiSR9v8AFI25j9TUlU9Lmurq1iubuA2vnxRyC0cfvLdioLI7A4JB9KuUARq2RwrDnjPGal/HpSfeHt70ZyffNAC96TPpSnj0pP8A9VACZ/OkpccmkPfnigApMnnNKTwQCQcUg6d+ORQAoNIPY8Uvf2pDx1oACPwqKaNZYmjcZRhgj1FSDgcU3PvQBxni691DwtotzeadG8lkgJKQqGdDjhgWOBz9fpXyDq/ivxB4g8SfbLrWL83s7iIb5iixZOAoGcKM/wCNfd7AMpDgMCMFSMgj3ryb4k/BXS/E0wvtEki0nUhu3gxkxTZ6528qfcZ6mgDwXTfHuq6cbjw54vle7shdLFdSMyzyRIhIKoeVPJyD7cGp/Bng/WZ/F7Ppx8+yXMkU8kWI3DA+W7Bv4emetdCfgvr+ja3YNcafa31uSI5fKmynXG7GMkbe3XuTXs8/ge9m15dYN0Gj0+BYdK06KRooRtGAJR3H86AKVh4Cl1XQki8Xy3E16YDDJZ6ZdNHbqA2cAHucDkHjtT9L8OaJ4KlvP7I1AGW7ijhnh1a+8wxKDwEGM9fUnOK722juBH+9UwygZypyhJ5IHtXnmt+EL5/Huj6yNNhurJNzXM0Tb3LjJUsr5+Ueo5oAy9R+HHhHxLdz6v4j0/WLTUJLjDm11AzRzgEBWBwdqkY44I9q63w74a0rSLC3s/Dc89tZM8lvJBdSfM6ZJdVIwdxOPmOTgVlfEttaTwHqg8PQLZvEQ8lvEuZBk5yCDj6gjpXiHwOtdYvfitZrM1zM1mXuZxdO4jTjBPpu5GOxoA+s9GhFrZfZl3BIGKpuGPl6gDk8DOPwq+fXrzVOzEXmzSRsu6QKzqD0NXB7nmgBc5JBXI/SvN/2jbRbv4MeIQzspgEVwMY5KyqMH2+avRVDAg9j94HtXJfGS1iuvhL4vSdSyjTZZMA4+ZMMvT0IFAHyJ8N/+R007/tp/wCi2oo+G/8AyOmnf9tP/RbUUDMzxT/yMer/APX3N/6Ga9x/ZE3A+LwxGNtqc595K8O8U/8AIxax/wBfU3/oZr2v9kM/6R4wAwP3Voen+1JQDPo/t/LFJkLkk4A7mkViQKB+FAiToxzn6UHFNz3xzQBjPvQB4j8ZdFuf+E4tp7WKye31iza2Fu0Ujvc3C4PRCPmwBgnjAPWuC0OHWtQ8RQa8Li4gntrXfqEMKgfZfLbBgZGO478KMYx82T0r274jeEP7cv7bUU1W7sH8j7FIIySoTfuDKo5354z6V5roPgvQ/Bup2/iPxFr19pUBuzbFbmEmW7x1ZmUnEbjOdwzjvQB6XoV9a2fg60lvPC9notvNNlbW4nj27C2Q7P0J5zjqe1UrfxLq2oTWcGh6fp8mni6ljvpL1CggiVsGVQW/1ZGSDXDfEDW4fHmj3FrZ2s4sdJPmGwtrhGjniU5M0OOS4TI2gcZzVzwvoiLZwapezXOp6jdW8k9nZ2Lo8kluqhY1mQ8krnHyge+TQB2S2ELXTi3t9PsdFs1eezliBZLlWUjEjIx3jqcH2r5m8YeHbzTdb8tLdp4rs+bbSQWzosinsARjj0FfQXw90TWNMW/07SHt9EEqJcNZ3NybuS23DDHYqhUzz8pP5V3On+G/Nhkj1W81e4h3MFinmREZTxkLGAVHXjNAHyr4R8A+INRY6jYWURNirXbvdp/o0YTkBj/ExI+4AenPFes/s032ta7qHifxXr11dXKXSxQx3U7YR5ASWVB90BRtHyjA6etdZ8WvE3/CGeHNM8M+E4TBrOrMLXT47dARbpuAaTB784Ge+T2rj/F2ieP5vFenaNbJdvpVtCkUEi7SMbRvlbBUFid3XmgDofi58S9V8M3lvYaJBbbZoTK+oEiYRjpwoPBB55rW+BviTX/FHhq/u/ETiYR3IitrkRiMyrtycgehxz71wqaTcjxc+meG3TWLuGcyXcNxFteKE4V43Z8pxndt69K9z0fSrHRLBLHS4Et7VCWCIOCx6n8aAL/r60d6TPvS5496ACgnjn86BSfSgApAMDB7Up6U0d8UALgdRwTQOvNJx155FB9OnbNACtTAexB9qccZ603rQAde1NJyTR+eaTsaAAnPcfSj1pufTpSMQoyzAc8ZoAeDjnofXpSZBGc8dM0nBHJNIT+NACnkc9KAee+c0Ac+o+tNZtilsFsAnA70AUmtI7Z2eC3RvMJ8xR0Oepx71WkvdEsb2SzuVt7GacB8TIEWcZwCD354rSUs0DsIyXI3Kmec9gfQ9q4LQ7TTdR8eXWqW08U+uWkZgvYpp3lPknoqqflXaR2FAHf2lvHAZDGqB5DucqMZPvVkc84qtbJtLEZwzbue3tU4J4/nQA8DjgYwOK5f4rKP+FWeMRnP/Epuf/QDXUfhXIfGO5Fn8J/F0pQuDpsse0HHLjZn/wAez+FAHyH8N/8AkdNO/wC2n/otqKPhv/yOmnf9tP8A0W1FAzL8Vf8AIxax/wBfU3/oZr2P9kW6iXWvFNoxInmtIJUG3IKo7Bsn/gS/WvHPFX/Iw6x/19Tf+hmvQP2XdQ+yfFAWxlSNL6xnh2sP9Yy4dVHv8rH6A0Az649fw7UoxgHPvSLTu3196BB9aXNJ369aQnjJ65x1oAg1BGktJAgZnAyqq20sR0GR0r558W22o2PiGbUfE95a2OnS3SWM9rKzTQToRkhduSrD+8QMV9G5ByCDggjj6V5ZF4W8QQxW+mXt3bzWIvjcXUzoQtzC33lkzxhV7ggmgDh/D2j6LFIJ/CUeoXEGnpJBc/Y5i6eXKxP72RgC8Z6EIoIAPJra0DU9E028vvCcD6mgIKvcJGYorSMJuzbE5fySRgl2x3GM1yi2Elq0fhVrKbwtLdamXSRbkvFcoxKxRgL8y8fMCcgfjiux8O+GtJjRraBnTxHBbypHdTXayRybwVPmIe3op9eBQB1ng28n13UNM1fTdWivVZX/ALReJTCgAJ2L5f8AEe2c4712uvata6LpNzf3snlwwIZG9SB2HqT0ri/h9d29nc2djIha8ubQea4dmWFo2IEfTaBycc59axfjl4g1vRPD+owiPSWtdTmjsbITRl5ArqfMJGcZGOPTOeaAMHwnrcHiH41QXmuaXdW+s3aH+yWe4DR2sSRnrGOpPJycDJ6V1Grt4burSfw7p/ii80zU3mZpr2Rj5jShuQd2Bgk9BjjpXz34i1aGHV4m0LdYzx2y2s89lPJIGKrtOwn5gD3BJrDi8y/kRrpwcDG9slpCOnuW+tAH214P0/VLHSIx4lu7W/1ti3nXkEIj3pn5AcAZwuOa2zx7VwnwY8TReI/A1qrSyvf6eotbpZlKtkD5W9wR/I13fX8KABetO4po6HkUvTOKAFzR3Jo9eaCBjngUAI27admM+9Az7UMwUcnH1pe/60ANGeNxz+lLSf5zR1+lAAfSmEEU49etJ9DQAg4H+FMIp/pim45J5NADcbuwNMwAoGOalIyv1ppBB+tACHjAGaMdPSlxz+NAHT+lABg+vPemn1zinjr1+lAXJANAGG866ffiOdJ/J3Ltumbc0rseFwB0HrWM3g60sPEEWu2UCLPDdPcSEkrLPuQqV3AjPOCFIxXZyLuC5bAU5PH8q57xfrD6ZZxpDGsslwdgTcFf8M98ZoA3NOlM9nHJseIsCTG/JQ56GrPIOKqaRI0+l28rR7GdQSpHI+vvV3nOR9KAAY4FefftB3D2vwY8UOiK++KKEg9AHlRSfqM16Fgc14x+1pdpb/C61tTjfdanEFAYA4VWYnHUjpQB89/Df/kdNO/7af8AotqKPhv/AMjpp3/bT/0W1FAzL8V/8jBrH/X1N/6GatfDDVjofxD8OaiGZVhvo1cqQCUc7GGTxgqxBqr4r/5GHWP+vqb/ANDNYPJQ7fvdRn17frQDP0YdSkhU9iQcfWmnuOlYfgjXE8TeDNE1qNtxvLVGkPAIkA2uDjjO4HgVtnOeBQIVXJLhkwoIwxIO78O2DxzR16c0D1/yKBnHJxmgAPWsXxdam90WW3aR1hl+SRFYqHB7cc8+1bXXAodFkR0OQGXB2nB/A0AeZSWumeHr+0khkZZrUDM8sBkM5clY4hIuWUIT1OeM1hfEu6Ft4QT7JprQXsN+ZriAjf5j4wZEZuoHv27V7AsENhaLFbJ5MYIUGNNxBJrhPiX47s/Du2yuktJJGcNNC6s7yQdCy4GN3pn0oA8A1DX9agvFvdKhvtLu4xulljZl3NnkhT90HjjpXs3xYeHxDpPhO0vH8i+nu4t9+oCRQStETsJ7E5/CsDxTYwXYlvvDkeoXYvLf+0o7yYK1v5QGPlwOXHTB6Gsrx9Pa3fwh0CbTI5HsLPUczvIwJupSh3OTzyDxzQB5t4l8H6/4Xu4P7RsJV+0E/Z57Z/Oim7/K69T6iqekpqdvI11ZJKjL9+Ty/kRe5JxgD3ro/BfxK8Q+ENMnstNkWWwkybeC5xIsLE/eAPbrkcVl3vifWr62lWN4orZyXmhsl8qHrnJReBz3oA+gf2brQR+G9XvWjuxNdXKHzpY2SKZAmVaMNyeWbJ+levfhXkH7O/jW68R6TqGlavczXGoWjLNC8zAloGABAwBwrD8mFev0AKMdPalHA4oBBHU0fzoAUdORQOlB9qO1ACNggZA4557Gk69silOPcUUAHakHpSg0nrQAhoxxxn3pSP8A69Iw4+lADfx4pD+tKpyqtgjcM4IwfxpOv+NAB/n60gHOcdPQU4+9BHHGMUANA6Zo6e9GBkkd/WgjGcUAA/pRnmgd/SlAoAi8wmUqQVUDr6muf8YW2kapFa6fqEyRXHnLJA23J3g9PxpqrcXHiPUriZCsMcaQoDgMOpyD6VS1jRrLUtattkt3FfIok82I5TOTt3DPH4UAdfZwfZrZIdxYxjBOKsfTNRwR+VCke5m2KBljyeOv1qT/AB4oAX8a+Z/2yNR/03wrpeeUhmu2G3+8Qg5/4CeK+mo1JIH8R4r4b/aD8Rw+Jfipq9zaMHtLTbYQuP4hHkMf++i1AFX4b/8AI6ad/wBtP/RbUUfDf/kdNO/7af8AotqKBmX4r/5GDWP+vqb/ANDNYC1veLP+Rg1n/r6m/wDQzXPqaAZ7j+zd8Ro/D2pv4Z1qdY9I1GXdbTSH5ba4PGCeyPwPZsepr6oZSjMp4I65r86eCCrDIIwQa+m/gN8Xo72C18L+LrlY71AIrC/lbAuB0EUh7OOAGP3unXqCPeQce49qMkn29KeQVYggg9wab780ALzn3NL29aaaX1IoACocFWGQRivO/HK+FdVtdQ1LVrOxuE0cyw3F1MXK28y7SEZV5YkHtxXoq4LDt6/415tfwWfxA1DU9K1TT77SL/SrhxFJDONtwCMBpFHJyORnqOhoA4q+utXsPhZF4i06fSofMuxsFmjywRw8ja6k7Rz1UjANSx6ZbfEr4cXNxotrbaTf20qQmAssFtO4wSygHClskfXitvwElvZ+Jdb8BaJqV3eaWLKWSSSaCNVt7gkbmj4ywy3KkdRXOfDj+yrXT9egOo3GuXlrknTZoQkNy6HJdVxnjGeMY70AeP8Ai7QZvD2q/ZL2OW3nZFcRTxlGQnquM8/UE8VkQSsjSRwt8rjyyeRu+o9K9z1Tx1oF74Zslk8Ot4gsE3Nei7JZ7RN331kGXA54zjHTis/xR8OdE8Q6KPEHwxudPFgqhZrG4nKPGe5y5OD7H8KAOU+C3iCXwx8Q9JlmeJbG+b7HO7cgI/A+bHGG2nAr7GOVJVhhgcYr4di8Pa2+tadpYtZYbuSZVtwgLruJB3BhlT68Gvt9d6xorkO4UKzDuQME/nQBICBnrS5/Wmr+Y+lL+NADunQc0mfl54oHQ/5zQM/TvQAH6Ck6k/lSnkc9aB7E0AIR3xR1GKCcH/Gg8E5oAD7UmDjnpS9xSHpQAg6Y7evWg9OaU49qMcUAJjPuRRjgDpS4zjg0mMmgBB3x1pDgc/zNOPU009BQAD6UvHXtS9+eaZKMxvtJzg0AZt7AkLvNEy+ZMQhDng59ql02wS2jVmKvJjJIHeuX066mv/GFkk9vKTbwyP5jJtXJz0GecdOe9dweOPTpQAdqcPbFIOvahmSON5ZZFjiRSzu5wFUDJJJ7Ac0AcD8bvGq+C/BUrwMBqmoBre0UNhlGPnk/4CD+ZFfCrtkk9yc816R8bPHB8b+KLjUIGb+zV/0WwjIxiBTkuR2Ltz9MDtXmx5oA774b/wDI6ad/20/9FtRR8N/+R007/tp/6LaigZleLP8AkYNZ/wCvqb/0M1zqn1rovFv/ACH9Z/6+Zv8A0M1zQoBkwPvUgIZSGAIPrUAP1qRTQI+i/gp8axbpB4f8c3RMIxHZ6rKclOwjmPcej9u/rX0YR05BzyCDkEHuPWvztU8YIBFewfB/4x3fg9IdH15ZL/w6DiMr801kP9j+8n+z27elAH1icf8A16XAJ7VV0nUrHWNNt9R0i7hvbCcbop4WyrD+hHcHkVb/ADxQAN754rm/FOlXZuItb0KSKLWbRCmZE3CeHuh9x2rpMeo/ClB2ng9DQB88+OHa68QxaN4TJt9U1WXZfXXmfLc7sERK/UDOSVPoBXEXFlNpuvw20UkdnrVjeBIJW3AOdwyjAcAe9fQfjnwBBrU51PTI4otVDK5DHasxXpz/AAt0+YfjmvHpvA3irVfGP2690y8gv2u1klkMmVLBgcq44A4zzx+dAHQ3Rk0H4x/ZfC+m2E0lyix6hpzsQ0gf/WYB+UgjJ4445rzy+gfQfFmoaaLhNI09rh1uRIMRvFu4BTn5QOARyOte++MTeWGv6k9ppr3kuqJEtrcIrYtnAIbcyjcuTgjHFeLF7G78VQWPixWe7uEFtdXlvvU7w/Dlsct05xzj8aAPXfhJPZaXqWoaDpumT2Gnyqt9ayXF+Ljzw2BmP0UjnHtXp4688Gvn/Rvhzqj/ABKJa4i0/wDspkaEW5LARDozejP1I+tfQPfJJzQAo647UvbqBTRnPFOHSgAyPSjODQcUvagBoJJIyOO1KepoGMk+vpS5oATnI7Cj8fyp386Qge1ACdqTsc/lSngY5OTSdPSgAB470uMDnPFAGD/nig9eehoATtn8aKD6mgdccH1oAQ9cZApOwxTwMUn8jQAnQ0N9KUDApCPSgDP0zTEsri5n3bmmb5R/zzXrtHrzzWieOvSjNLjmgA714t+0t44/snQ4/CemXATVtXUG4KnmG2JxgnsXPH0Br1TxV4gsPCvh2+1vVn22lom8qDzI3RUX3Y4FfCXiPxHe69reqeItVk3aheSEqAThCeAq/wCyi4AoAw9WlWS9cRNujjAjU5znHf8AE1T5FJ04oJoA7/4b/wDI6ad/20/9FtRR8N/+R007/tp/6LaigZleLf8AkP6z/wBfM3/oTVzANdP4u/5D2tf9fM//AKG1csKAZIDxUgNQg04GgRYU1IpxVdT+dSBs0Adr8O/iDrngO/abR5Vks5WBuLCYkwz+/wDstj+Ic+uRxX158P8AxzonjvSzeaLKyTxD/SbGUgTW7e47r6MOD9eK+Ega09A1rUdA1WDU9FvJbO/gOUljPbupHRlPcHg0AfoEF7/pQc/hXmvwh+K+n+PLdbDUVh0/xIg+a2DYjuQP44c/qvUe45r03HNADcegzms2+0iO71OzvTLLE9ud2I2K7/Zh3HtWpxgZIJPSlxQBma1JcxWhewRjNuAkeNsNEv8Af24O7HHy9a4u18HaT4qln1C/sbiwvYZvId4v3XnBf4x6Z7jFd7c6fb3NzbXMiN59u/mIysV5xjn1HPSrhz3OTQBWs7b7LCqFzI6qFLsMs2OmT1NTEYOMe9Lj1o+uPrQAd8A0oHBpAMZ60vbmgAxwCBS980cgUdqAEFLjn2pjuFdV5y3Q4JFPA79x6UAGOCKO3pSjH4/WkHueKAA0EZPX9KOcY7UfzoATrRjjvS5yR6UpP5UANHt1/lRgZP60uB9KUjPp+NADccYNGMjJ6U7HFIR7HNACc5wAKTp9KUde2PrR/WgBQPWlVSxAAznik9MV5X+0N49bwb4SFjpswTW9WDRQnvDDjDyex52j3Oe1AHi/7SPxCHinxKNB0ucPomlSEFkIK3Fz0Z891X7o/E14tdS72VF5SPge57mllYIu1eMjA9hVc9aAEJoopDQB6D8N/wDkdNO/7af+i2oo+G//ACOmnf8AbT/0W1FAzK8Xf8h7Wv8Ar5m/9DauVrqfF3/Ie1r/AK+Z/wD0Jq5XvQDHCnA9KZ2pQaBEinipEbGahBp4NAFhTinqagRuxqQUAW7aaSGWKaGR4pomDxyI21kYchgR0INfV3wT+MEXikwaH4neODxBjbBccKl7jtj+GTHboe3pXyWpqeJyjqyMVdSGDKcFSOQQexoA/RERASM2Bk8Yx/n/ACKWvGPgV8Wf+Elih8P+J51GuoMWt03H21QOh7eYB/30PfNe0UANzigHjNKelGOOKAE4zkHrzxS98GlxRyTwBQAgxnGKXA70dxQe3FAAAMUvbgn8aTH+FHagBDnI29+vsKTGQeSM9CKdj9aXBBoATAAA6AUY5BopaAGnqePrRjjmlOMdKBQAn170Dkc/rQO5paAEpf5+1JjPSl6gckUAGfcGk6d/1petH9KADr6UgHPfFL34zSfzzigCO5uLeztJ7q9mWC1gjaWaV+FRFGST9BXwd8UvGM/jXxhf63MXW2dvKtIif9VCvCr9T94+5NezftOfEiN0m8F6NOf3bA6rMp+UkciAEe+C34D1r5mmk3tnt2oAYzFmJPWmmikoAKUkFQAMHuc9f8KSkJoA9C+G/wDyOmnf9tP/AEW1FHw3/wCR007/ALaf+i2ooGZPi7/kPa1/18z/APoTVygrq/F3/Ie1r/r5n/8AQmrlKAYopRTaBQIeKcDUYpwNAEoNW7GI3VzFbq6I8rBELkAFjwASSAPqTiqINOBGMHmgDv5vhb44ht3nXw5d3EaDJ+yvHOwH+4jFj+ArkriKW0uXtruKW3uYyQ0MyFHU+hU4IqtYzfZJllty8EqnKywsUdT7EYNd5afEnXjZxWmvCw8TWEeQkOtQid0B67JhiRT77j0oA5KKV0aN4ndJEIZXQkMrA8EHsQa+u/gZ8Tl8a6d/ZesyIniS1TJOMC8jH/LRf9ofxL+I46fOB1TwXfAtc+Htb0ksemlakssYHoEmXPXtmtDSNH0Ka/t7rwz48h03VIpA1uNWtHs5Yz/eMqbo/bt3zQB9qCjHP+FcJ8P/ABP4hvbKKPxXpkMrn5Y9Y0eZLq1ucfxMsZLIfwx9K7wDjnp2NACYGeKXFDEfSkzmgBeOvej86Bxx6UnTrQAuPSjFHPc0mM0AKaMeopaSgA6fSio7q4hs7Wa6u5VgtoULySN91VH+eleRWXx40aXxR9jvrJrLRXysd88oaQMD96SMfdU9ucigD2DHrRVbS9RsNWgSfS761vInGVaGRWyPp1q4UcdUI98UAM6jnv7Ue9Lz+NO2MRnacfSgBnelxz0qvPe2duCZ720iCg7t86jHqetVYNf0W5Ki31nTJWYkKEu4ySR1wM84oA0c801cgfMQeeMCq13qmnWcLS3d/aQxrjcXmUAV5/4p+MWiaPAx0yx1XWJhwDDaSRw7s4x5jqMn2UGgD0xVJJC14j8Y/jVaaHb3Oj+EZorrVgNtxehsw2qng7WH3n7ccA15l8Rfid4w1+0uI9SNxoXh98hI4oHgNz/sbm5c45xx714rfXSzykQx+Tbg/JGDnHuT/nFAC6hdC5nZo02R5JAySTznJJ5JqoaKSgAoopPwoACaSlpKAPQ/hv8A8jpp3/bT/wBFtRR8N/8AkdNO/wC2n/otqKBnReIfhxq0+u6lILiw2SXMrAF36Fj1+Wsz/hV2p/8APXTP++m/+IoooGL/AMKu1T/nrpn/AH03/wARR/wq7VP+eumf99N/8RRRQAf8Kv1T/nrpn/fT/wDxFH/Cr9U/566Z/wB9N/8AEUUUAH/Cr9U/566Z/wB9P/8AEUf8Kv1X/ntpv/fT/wDxFFFAC/8ACsNV/wCe2m/99P8A/EUo+GWrgYFxp2P99/8A4iiigBf+Faaz/wA/On/9/H/+Io/4VrrGMfadPx6eY/8A8RRRQBPZ/D/xDZTCaz1G1t5gMB4p5EYfiFrcj0/4jRqFj8Z3yqOAF1S5AH6UUUAH9m/EUnJ8ZX2f+wpc/wCFJ/ZvxF/6HG9/8Glz/hRRQAv9nfEX/ocb7/waXP8AhR/ZvxF/6HK+/wDBpc/4UUUAINN+IoJI8Y3oJ6/8TS45/Sl/s34i/wDQ5X3/AINLn/CiigA/s74jf9Dlff8Ag0uf8KP7O+I3/Q5X3/g0uf8ACiigCtqHh/x1qVqbbUfFE13bkg+VPqE8iZ9cEYrDPww1U5Jm00565Z//AIiiigB0Xw01iIgxXOnoRnBWRxjPX+Cty30Tx9bRrHb+K7iKNRhVj1G4UAewAoooAm/s34i/9Dje/wDg0uf8KqXvhrxtfjF94kkuR6TX07/zFFFAFSz8D+J7KTfZavDbvkndFcyocnryFrVbTPiI4w/jC9Yeh1O4P9KKKAHJp/xGQfJ4zvl+mqXI/pTvsXxJ/wCh11D/AMGtzRRQBl634Q8Xa8YTruuLqRhz5X2y7mm8vPXbuU4zgdPSsv8A4Vfqn/PXTP8Avpv/AIiiigA/4Vdqn/PXTP8Avpv/AIij/hV2qf8APXTP++m/+IoooAT/AIVdqn/PXTP++m/+Io/4Vdqn/PXTP++m/wDiKKKAD/hV2p/89dM/76b/AOIpf+FXap/z10z/AL6b/wCIoooA6HwL8PdVtPFVjPLcWJRN+QrvnlGH92iiigR//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT in a patient with scleroderma and&nbsp;interstital lung disease&nbsp;showing a reticular pattern,&nbsp;honeycombing, and traction bronchiectasis&nbsp;in both lung fields. This pattern correlates with fibrotic changes on lung biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39008=[""].join("\n");
var outline_f38_6_39008=null;
var title_f38_6_39009="Basic case 7 with answer";
var content_f38_6_39009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventricular fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 100px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extremely rapid, erratic ventricular activity due to ventricular fibrillation during cardiac arrest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39009=[""].join("\n");
var outline_f38_6_39009=null;
var title_f38_6_39010="WHO weight for age girls 0 to 24 months";
var content_f38_6_39010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39010=[""].join("\n");
var outline_f38_6_39010=null;
var title_f38_6_39011="CephaloceleB";
var content_f38_6_39011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetus with posterior cephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Same patient showing the cephalocele using transvaginal sonography. Note that transvaginal sonography provides greater detail of the contents of the sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39011=[""].join("\n");
var outline_f38_6_39011=null;
var title_f38_6_39012="Methylene blue: Patient drug information";
var content_f38_6_39012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methylene blue: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     see \"Methylene blue: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/61/20438?source=see_link\">",
"     see \"Methylene blue: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11989653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cyanide poisoning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691954",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat methemoglobinemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methylene blue or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Citalopram, fluvoxamine, paroxetine, or sertraline. Do not use within 2 weeks of other antidepressants.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine or stool to blue or green.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11814 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39012=[""].join("\n");
var outline_f38_6_39012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11989653\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014414\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014413\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014418\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014419\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014421\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014416\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014417\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014422\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014423\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=related_link\">",
"      Methylene blue: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/61/20438?source=related_link\">",
"      Methylene blue: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_6_39013="Heart rate in mitral stenosis";
var content_f38_6_39013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of heart rate on mitral valve gradient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneously recorded pressures from the left atrium (LA) and left ventricle (LV) in a patient with mitral stenosis who has a persistent diastolic gradient (shaded areas) across the mitral valve. Top panel: When the RR interval is shorter, the mean pressure gradient is greater and the mitral valve area smaller. Bottom panel: A long RR interval results in a gradual equilibration of the LA and LV pressures and the mean gradient is smaller. There is no pressure gradient present by the end of diastole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kern, MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39013=[""].join("\n");
var outline_f38_6_39013=null;
var title_f38_6_39014="Certolizumab pegol: Drug information";
var content_f38_6_39014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Certolizumab pegol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/54/4966?source=see_link\">",
"    see \"Certolizumab pegol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6027445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6019485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cimzia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9477197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cimzia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6027450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Tumor Necrosis Factor (TNF) Blocking Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6027509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Each 400 mg dose should be administered as 2 injections of 200 mg each",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Crohn&rsquo;s disease:",
"     </b>",
"     SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose; Maintenance: 400 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose; Maintenance: 200 mg every other week.  May consider maintenance dose of 400 mg every 4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6027510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7822930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe renal impairment: The pharmacokinetics of the pegylated (polyethylene glycol) component may be dependent on renal function; however, data is insufficient to provide a dosing recommendation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6027523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cimzia&reg;: 200 mg [contains sucrose 100 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cimzia&reg;: 200 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6027448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088571.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088571.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6027511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Bring to room temperature prior to administration. After reconstitution (of vials), draw each vial into separate syringes (using 20-gauge needles).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Administer each syringe subcutaneously (using provided 23-gauge needle) to separate sites on abdomen or thigh. Rotate injections sites; do not administer to areas where skin is tender, bruised, red, or hard.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6027452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderately- to severely-active Crohn&rsquo;s disease in patients who have inadequate response to conventional therapy; moderately- to severely-active rheumatoid arthritis (as monotherapy or in combination with nonbiological disease-modifying antirheumatic drugs [DMARDS])",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6027463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (6% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (38%; serious: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (5%), fever (3%), fatigue (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (&le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (6% to 7%), back pain (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (&le;6%), nasopharyngitis (5%), bronchitis (&le;3%), pharyngitis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (7% to 8%), positive ANA (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;5% (Crohn&rsquo;s disease), &lt;3% (RA) (limited to important or life-threatening): Alopecia, anemia, angina, anxiety, aplastic anemia, arrhythmia, atrial fibrillation, bipolar disorder, cytopenia, demyelinating disorder exacerbation, dermatitis, diarrhea, erythema nodosum, heart failure, hepatitis, hepatitis B reactivation; hypersensitivity reaction (eg, dyspnea, hot flush, hypotension, malaise, serum sickness, syncope); intestinal obstruction, leukemias, leukopenia, lupus erythematosus rash, lupus-like syndrome, lymphadenopathy, lymphomas, malignancy, MI, myocardial ischemia, nephrotic syndrome, optic neuritis, pancytopenia, pericardial effusion, pericarditis, peripheral edema, peripheral neuropathy, psoriasis, pyelonephritis, renal failure, retinal hemorrhage, seizure, stroke, thrombocytopenia, thrombophilia, thrombophlebitis, transaminases increased, transient ischemic attack, tuberculosis, urticaria, uveitis, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6027458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6027459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disorder: Autoantibody formation may develop; rarely resulting in autoimmune disorder, including lupus-like syndrome; monitor and discontinue if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Demyelinating CNS disease: Rare cases of optic neuritis, seizure, peripheral neuropathy, and demyelinating disease (eg, multiple sclerosis, Guillain-Barr&eacute; syndrome; new onset or exacerbation) have been reported. Use with caution in patients with pre-existing or recent-onset CNS demyelinating disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Rare cases of pancytopenia and other significant cytopenias, including aplastic anemia, have been reported with TNF-blocking agents. Leukopenia and thrombocytopenia have occurred with certolizumab. Consider discontinuing therapy with significant hematologic abnormalities. Use with caution in patients with underlying hematologic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: Rare reactivation of hepatitis B virus (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions, including angioedema, dyspnea, rash, serum sickness and urticaria have been reported (rarely) with treatment. Discontinue and do not resume therapy if hypersensitivity occurs. Use with caution in patients who have experienced hypersensitivity with other TNF blockers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunogenicity: A small number of patients (8%) develop antibodies to certolizumab during therapy. Antibody-positive patients may have an increased incidence of adverse events (including injection site pain/erythema, abdominal pain, and erythema nodosum).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Patients receiving certolizumab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including certolizumab. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.",
"     </b>",
"     Caution should be exercised when considering use in the elderly or in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not initiate certolizumab therapy with active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lymphoma and other malignancies have been reported in children and adolescent patients receiving other TNF-blocking agents.",
"     </b>",
"     Use of TNF blockers may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. Lymphoma has been noted in clinical trials. Chronic immunosuppressant therapy use may be a predisposing factor for malignancy development; rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn&rsquo;s disease or ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Tuberculosis has been reported with certolizumab.",
"     <b>",
"      [U.S. Boxed Warnings]: Patients should be evaluated for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment;",
"     </b>",
"     active tuberculosis has developed in this population during treatment. Use with caution in patients who have resided in regions where tuberculosis is endemic. If appropriate, antituberculosis therapy should be considered (prior to certolizumab treatment) in patients with several or with highly significant risk factors for tuberculosis development. Carefully consider benefits and risks of treatment prior to initiating therapy in patients who have been exposed to tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in heart failure patients; worsening heart failure and new-onset heart failure have been reported with TNF blockers, including certolizumab pegol; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use has not been studied in patients with renal impairment; however, the pharmacokinetics of the pegylated (polyethylene glycol) component may be dependent on renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anakinra: The manufacturer does not recommend concurrent use with anakinra due to the risk of serious infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biologic DMARDS: Do not use in combination with biologic DMARDS, including abatacept and rituximab.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor necrosis factor (TNF) blockers: Do not use in combination with other TNF-blocking agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, may be at higher risk for infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Malignancies have been reported among children and adolescents receiving TNF-blocking agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be up to date with all immunizations before initiating therapy; patients may receive vaccines other than live or live attenuated vaccines during therapy. There is no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6027484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Certolizumab Pegol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: May enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6027487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Echinacea may decrease the therapeutic effects of certolizumab; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6027453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6027454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal reproduction studies. Certolizumab pegol was found to cross the human placenta. Serum concentrations in 12 infants of 10 mothers were &ge;75% lower than the maternal serum at delivery (last maternal dose of 400 mg given 5-42 days prior to birth). Although placental transfer was low, infants may have a slower rate of elimination than adults. In one infant, certolizumab pegol serum concentrations decreased from 1.02 to 0.84 mcg/mL over 4 weeks. Adverse events were not reported. The safety of administering live or live-attenuated vaccines to exposed infants is not known. Healthcare providers are encouraged to enroll women exposed to certolizumab pegol during pregnancy in the Cimzia&reg; Pregnancy Registry (877-311-8972); patients may also enroll themselves.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6027456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Cimzia Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 X 200 mg (1): $2525.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 X 200 mg/mL (1): $2525.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6027513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor improvement of symptoms and physical function assessments.  Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cimzia (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, NL, NO, NZ, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6027505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Certolizumab pegol is a pegylated humanized antibody Fab&rsquo; fragment of tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Certolizumab pegol binds to and selectively neutralizes human TNF-alpha activity. (Elevated levels of TNF-alpha have a role in the inflammatory process associated with Crohn&rsquo;s disease and in joint destruction associated with rheumatoid arthritis.) Since it is not a complete antibody (lacks Fc region), it does not induce complement activation, antibody-dependent cell-mediated cytotoxicity, or apoptosis. Pegylation of certolizumab allows for delayed elimination and therefore an extended half-life.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6027491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 6-8 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: ~80% (range: 76% to 88%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 54-171 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dommasch E and Gelfand JM, &ldquo;Is There Truly a Risk of Lymphoma From Biologic Therapies?&rdquo;",
"      <i>",
"       Dermatol Ther",
"      </i>",
"      , 2009, 22 (5):418-30.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleischmann R, Vencovsky J, van Vollenhoven RF, et al, &ldquo;Efficacy and Safety of Certolizumab Pegol Monotherapy Every 4 Weeks in Patients With Rheumatoid Arthritis Failing Previous Disease-Modifying Antirheumatic Therapy: The FAST4WARD Study,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2009, 68(6):805-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/19015206/pubmed\" id=\"19015206\" target=\"_blank\">",
"        19015206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keystone E, Heijde D, Mason D Jr, et al, &ldquo;Certolizumab Pegol Plus Methotrexate is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(11):3319-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/18975346/pubmed\" id=\"18975346\" target=\"_blank\">",
"        18975346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(9): 898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/22948700/pubmed\" id=\"22948700\" target=\"_blank\">",
"        22948700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2011, 23(12):1150-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/21941193/pubmed\" id=\"21941193\" target=\"_blank\">",
"        21941193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rutgeerts P, Schreiber S, Feagan B, et al, &ldquo;Certolizumab Pegol, a Monthly Subcutaneously Administered Fc-Free Anti-TNFalpha, Improves Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease,&rdquo;",
"      <i>",
"       Int J Colorectal Dis",
"      </i>",
"      , 2008, 23(3):289-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/18071721/pubmed\" id=\"18071721\" target=\"_blank\">",
"        18071721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, Feagan BG, Stoinov S, et al, &ldquo;Certolizumab Pegol for the Treatment of Crohn's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(3):228-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/17634458/pubmed\" id=\"17634458\" target=\"_blank\">",
"        17634458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al, &ldquo;Maintenance Therapy With Certolizumab Pegol for Crohn's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(3):239-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/17634459/pubmed\" id=\"17634459\" target=\"_blank\">",
"        17634459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schreiber S, Rutgeerts P, Fedorak RN, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2005, 129(3):807-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/16143120/pubmed\" id=\"16143120\" target=\"_blank\">",
"        16143120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolen J, Landew&eacute; RB, Mease P, &ldquo;Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2009, 68(6):797-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/6/39014/abstract-text/19015207/pubmed\" id=\"19015207\" target=\"_blank\">",
"        19015207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8644 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39014=[""].join("\n");
var outline_f38_6_39014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027445\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6019485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9477197\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027450\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027509\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027510\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7822930\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682568\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027448\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874551\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027511\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027452\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027463\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027458\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027459\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299004\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027484\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027487\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027453\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027454\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027456\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321823\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027513\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390217\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027505\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027491\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/54/4966?source=related_link\">",
"      Certolizumab pegol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_6_39015="Survival estimates in advanced terminal cancer";
var content_f38_6_39015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Survival estimates in advanced terminal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     Elizabeth B Lamont, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     Nicholas A Christakis, MD, PhD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     R Sean Morrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./survival-estimates-in-advanced-terminal-cancer/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./survival-estimates-in-advanced-terminal-cancer/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival estimates are critical factors in physician and patient decision making in all phases of a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness. However, prognostic estimates in patients with advanced terminal cancer may have increased importance as they approach the end of life, since this is a natural time to formally reevaluate the goals of treatment, with palliative care becoming more prominent, and disease-directed therapy less so.",
"   </p>",
"   <p>",
"    However, despite its importance, prognostication in advanced terminal cancer is imperfect. Physicians are typically optimistic in their estimates of patient survival, and the prognostic estimates they communicate to patients may be even more optimistic. In an effort to improve these estimates, investigators are integrating previously established prognostic factors into easy to use models that physicians can use in the clinical care of their patients with advanced terminal cancer. The goal of improved prognostication is to provide patients with a better understanding of their expected survival and thereby allow them to make informed medical and social choices regarding their treatment path at the end of life, whether disease-directed, palliative, or a combination of both [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we discuss general aspects of estimating survival in patients with advanced terminal cancer. Prognostic estimates and the factors that influence outcome in specific cancers are discussed in separate topic reviews that cover individual tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACCURACY OF SURVIVAL ESTIMATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival estimates that physicians make, guided only by their intuition and clinical experience, are called formulated prognoses. In the clinical setting of advanced terminal cancer, these formulated estimates are usually incorrect and the direction of the error is almost always optimistic [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. That is, physicians tend to believe their patients have longer to live than they actually do. The disparity in actual versus estimated survival varies in different studies (",
"    <a class=\"graphic graphic_table graphicRef76199 \" href=\"mobipreview.htm?10/24/10636\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/3-7,11-17\">",
"     3-7,11-17",
"    </a>",
"    ]. In an illustrative study, 343 physicians referring 468 patients to one of five Chicago-area hospices were asked to provide an estimate of their patient's prognosis (\"What is your best estimate of how long this patient has to live?), and they compared these prognostic estimates with actual survival [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/6\">",
"     6",
"    </a>",
"    ]. The median observed patient survival was 24 days, and the mean ratio of predicted to observed survival was 5.3.",
"   </p>",
"   <p>",
"    Nevertheless, formulated prognoses are of value, particularly when integrated with other methods to estimate the length of remaining life [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/5,6,18,19\">",
"     5,6,18,19",
"    </a>",
"    ]. As an example, in one study, multivariate regression models that included physicians' prognostic estimates were more accurate than models without physician input [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, while it is true that statistical models can be more accurate than human intuition alone [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], it is also true that physicians provide important information that is not captured in the models alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMMUNICATION OF SURVIVAL ESTIMATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the inability of physicians to accurately predict survival, patients expect open and honest communication regarding their prognosis. In a survey of 126 patients recently diagnosed with cancer, 98 percent wanted their doctor to be realistic about their prognosis and provide an opportunity to have their questions answered [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/23\">",
"     23",
"    </a>",
"    ]. The physician behaviors that were most important to the patient included offering information about the current treatments, being knowledgeable about the cancer, and providing reassurance that pain would be controlled.",
"   </p>",
"   <p>",
"    Although medical oncologists report routinely informing their terminally ill patients that they will die, most do not routinely communicate an estimated survival time to their patients [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/24\">",
"     24",
"    </a>",
"    ]. For those that do, just as there is unconscious optimism in the prognoses physicians formulate about their patients, there is also additional, and likely more conscious, optimism in the prognoses that physicians communicate to their patients. This was illustrated in a study in which investigators asked physicians referring terminally ill cancer patients for hospice care how long they thought their patient had to live [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/25\">",
"     25",
"    </a>",
"    ]. They also asked physicians what prognosis, if any, they would communicate to the patient if the patient were insistent on receiving a temporally specific estimate. The median survival the physicians would communicate to patients was 90 days, their median formulated survival was 75 days, and the median observed survival was 24 days (",
"    <a class=\"graphic graphic_figure graphicRef82659 \" href=\"mobipreview.htm?33/46/34541\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMPROVING PROGNOSTIC ACCURACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within clinical oncology, there is a growing literature focused on identifying clinical predictors of survival for advanced cancer patients. Multiple prospective and retrospective cohort studies have identified three broad classes of clinical predictors of patient survival:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Performance status",
"     </li>",
"     <li>",
"      Clinical signs and symptoms",
"     </li>",
"     <li>",
"      Physicians' clinical predictions (formulated prognoses)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Researchers are seeking to integrate these prognostic factors with each other and with new prognostic factors to develop easy to use composite measures for the clinical care of patients with advanced terminal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Performance status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance status is a measure of a patient's functional capacity [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/26\">",
"     26",
"    </a>",
"    ]. It has consistently been found to predict survival in patients with cancer, and it is used in that capacity as an entry criteria and an adjustment factor for clinical trials of anticancer therapies. A number of metrics have been developed to quantify performance status; among them, the ECOG performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ) and Karnofsky performance status (KPS (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 3",
"    </a>",
"    )) are the most commonly used.",
"   </p>",
"   <p>",
"    The KPS ranges from values of 100, signifying normal functional status with no complaints nor evidence of disease, to 0, signifying death (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 3",
"    </a>",
"    ). Numerous studies have described an association between survival in patients with cancer and their KPS [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/3,5,9,13,27-41\">",
"     3,5,9,13,27-41",
"    </a>",
"    ]. The magnitude of the association is described differently depending upon the statistical methods employed in various trials, but a KPS of less than 50 percent consistently suggests a life expectancy of less than eight weeks for patients enrolled in palliative care programs (",
"    <a class=\"graphic graphic_table graphicRef56650 \" href=\"mobipreview.htm?3/36/3660\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/3,5,13,28,42\">",
"     3,5,13,28,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar relationship has been reported in studies in which the KPS was augmented with information about self-care, oral intake and level of consciousness, a scale referred to as the palliative performance scale (PPS) [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/39,43-47\">",
"     39,43-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of clinical signs and symptoms as independent prognostic factors was first described in 1966 [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/48\">",
"     48",
"    </a>",
"    ] and has been reviewed in a qualitative systematic review of prognostic factors in advanced cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/49\">",
"     49",
"    </a>",
"    ]. In examining over 100 different variables from 22 studies, the authors of the latter review report that after performance status, certain discrete signs and symptoms were the next best predictors of patient survival. Dyspnea, dysphagia, weight loss, xerostomia, anorexia, and cognitive impairment had the strongest evidence for independent association with cancer patient survival in these studies. The following table shows the range of median survivals for the various signs and symptoms reported in univariate analyses from these and other studies (",
"    <a class=\"graphic graphic_table graphicRef56650 \" href=\"mobipreview.htm?3/36/3660\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dyspnea is strongly and inversely associated with survival in terminally ill cancer patients [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/9,13,28,38,49-51\">",
"     9,13,28,38,49-51",
"    </a>",
"    ]. One study found that the presence of dyspnea was associated with a median survival of less than 30 days [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anorexia, confusion, and xerostomia have been associated with median survival times of less than 60 days [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/13,42,52\">",
"     13,42,52",
"    </a>",
"    ]. These findings suggest that for patients with advanced terminal cancer, such as those referred to palliative care programs, the presence or absence of these symptoms may help physicians estimate patient survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Integrated prognostic models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasingly, clinical researchers are developing easy to use prognostic models that combine elements from established prognostic domains (eg, physicians' clinical prediction, patient performance status, patient-reported signs and symptoms, primary and metastatic sites) to render more accurate survival estimates. To select the most appropriate integrated prognostic tool for the patient at hand, clinicians need to understand the clinical features of the patient group to whom the tool applies (ie, its generalizability). &nbsp;",
"   </p>",
"   <p>",
"    Broadly, tools have been developed through study of at least two distinct types of patients with advanced cancer; those who have already been referred for purely supportive care and those who may still be receiving or at least are still candidates for systemic therapy. While the models have been derived in these two different patient populations, it is not clear that prognosis differs all that much. A systematic review of cancer presentations with a median survival of six months or less concluded that there was little evidence that treatment improved survival in the terminal stages of disease [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/53\">",
"     53",
"    </a>",
"    ]. The authors established a series of clinical factors that were associated with a median survival of six months or less in a variety of tumor types (",
"    <a class=\"graphic graphic_table graphicRef87452 \" href=\"mobipreview.htm?8/21/8543\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93043526\">",
"    <span class=\"h3\">",
"     Patients receiving supportive care only",
"    </span>",
"    &nbsp;&mdash;&nbsp;One group developed an advanced terminal cancer survival model that incorporates patient performance status and certain clinical signs and symptoms to render a final score termed the Palliative Prognostic Index (PPI) (",
"    <a class=\"graphic graphic_table graphicRef71424 \" href=\"mobipreview.htm?7/61/8156\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/50\">",
"     50",
"    </a>",
"    ]. After first developing the PPI in a sample of 150 patients with advanced terminal cancer, the investigators then tested it on a second sample of 95 patients. The PPI predicted three week survival with a sensitivity and specificity of 83 and 85 percent, respectively, and six week survival with a sensitivity and specificity of 79 and 77 percent, respectively. The PPI was developed in advanced cancer patients who had already been enrolled in a palliative care treatment program and results are thus generalizable to similar patients.",
"   </p>",
"   <p>",
"    Several other groups have developed similar scoring systems that rely on integration of all or some of the previously described classes of prognostic indicators of patients with advanced cancer who are already receiving palliative care [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/14,38,52,54-57\">",
"     14,38,52,54-57",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Other investigators used information on ECOG performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ), time from initial diagnosis to diagnosis of terminal disease, serum albumin, LDH concentration, and lymphocyte count from 406 terminally ill cancer patients to construct a nomogram (",
"    <a class=\"graphic graphic_figure graphicRef70086 \" href=\"mobipreview.htm?0/46/751\">",
"     figure 2",
"    </a>",
"    ) to predict the probability of survival at 15, 30, and 60 days [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/58\">",
"     58",
"    </a>",
"    ]. The predictive model was validated in an independent dataset of 474 terminally ill cancer patients.",
"   </p>",
"   <p>",
"    Prognostic scores derived from these clinical prediction models are all highly predictive for patients with advanced terminal cancer who are receiving supportive care alone, and it is not clear that any one is preferred over another [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another place for physicians to look for information about survival in advanced cancer is in the survival curves from studies that include patients who are not treated with anticancer therapy. Natural history studies and randomized clinical trials that include a \"best supportive care\" arm are two such examples. Natural history studies tend to be single institution case series of untreated patients with mortality follow-up. Median survivals from natural history studies in breast cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/60\">",
"     60",
"    </a>",
"    ], head and neck cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/61\">",
"     61",
"    </a>",
"    ], and hepatocellular cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/62\">",
"     62",
"    </a>",
"    ], and from patients on the \"best supportive care\" arms of randomized clinical trials in advanced non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/63-66\">",
"     63-66",
"    </a>",
"    ], stage IV colorectal cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/67\">",
"     67",
"    </a>",
"    ], stage IV or recurrent head and neck cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/61\">",
"     61",
"    </a>",
"    ], unresectable hepatocellular cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], stage IV pancreatic cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/70\">",
"     70",
"    </a>",
"    ], and stage IV gastric cancer [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/71\">",
"     71",
"    </a>",
"    ] are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef63336 \" href=\"mobipreview.htm?12/17/12572\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93043742\">",
"    <span class=\"h3\">",
"     Patients receiving active anticancer therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also studies predicting survival in which patients who are still receiving anti-cancer therapy (ie, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy) or are at least candidates for it and not yet referred to formal palliative care programs have been included [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/37,40,72-76\">",
"     37,40,72-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One such study of patients referred for palliative radiotherapy utilized a model composed of only three predictor variables (ie, KPS [&gt;60 versus &le;60], location of the primary cancer [breast versus nonbreast], and site of metastatic disease [bone only versus others]) to stratify these radiotherapy patients into three prognostically separate groups with relatively short median survivals (10 to 11 weeks), longer median survivals (ie, 21 to 29), and even longer median survivals (ie, 53 to 64 weeks) [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study used KPS, number of metastatic sites, low serum albumin, and LDH concentration to stratify 177 hospitalized patients with solid tumors into three prognostic profiles with short (&le;two months, with no patient alive at four months), intermediate (25 percent alive at four months) and long survival (80 percent alive at four months) [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prognostic consultation from colleagues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research from a number of groups suggests that prognostic estimates from colleagues may be more accurate than those formulated by the treating physicians. Two studies found that survival predictions averaged across physicians were more accurate than a prediction from a single physician [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Another study revealed that physicians who know little about the patient may provide more accurate predictions than physicians with an emotional or other stake in the outcome of a patient's care, and that older physicians (those in the upper quartile of practice experience) rendered the most accurate predictions [",
"    <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/6\">",
"     6",
"    </a>",
"    ]. The cumulative evidence from this research suggests that disinterested senior physicians may be a good source of prognostic information. More generally, through \"curbside\" consultations or more formal avenues like tumor boards, physicians may find colleagues helpful in determining patient prognoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prognostication in advanced terminal cancer is a difficult but critically important task that will become easier as researchers develop better tools for clinical prediction. Ideally, such efforts will correct the pervasive and systematic optimism in both the prognoses physicians formulate for themselves and the prognoses physicians communicate to their patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Accuracy of survival estimates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In an effort to improve estimates, investigators are integrating previously established prognostic factors into easy to use models that physicians can use in the clinical care of patients with advanced terminal cancer. The goal of improved prognostication is to provide patients with a better understanding of their expected survival and thereby allow them to make informed medical and social choices regarding their treatment path at the end of life, whether life-prolonging or palliative. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Improving prognostic accuracy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Integration of physician estimates with predictors such as performance status and clinical signs of symptoms (eg, in the Palliative Prognostic Index, (",
"      <a class=\"graphic graphic_table graphicRef71424 \" href=\"mobipreview.htm?7/61/8156\">",
"       table 6",
"      </a>",
"      )) appears to be the best current means of predicting survival among patients receiving supportive care alone. Among untreated patients with advanced terminal cancer, disease-specific survival curves that are derived from studies in which patients received supportive care only (",
"      <a class=\"graphic graphic_table graphicRef63336 \" href=\"mobipreview.htm?12/17/12572\">",
"       table 7",
"      </a>",
"      ) may improve predictive accuracy. (See",
"      <a class=\"local\" href=\"#H93043526\">",
"       'Patients receiving supportive care only'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most prognostication metrics are targeted at patients undergoing palliative care; metrics that are focused on patients undergoing active cancer therapy are less common, and it is not clear that any specific tool can be recommended. At least one systematic review of cancer presentations with a median survival of six months or less concluded that there was little evidence that treatment improved survival in the terminal stages of disease [",
"      <a class=\"abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/53\">",
"       53",
"      </a>",
"      ]. The authors established a series of clinical factors that were associated with a median survival of six months or less in a variety of tumor types (",
"      <a class=\"graphic graphic_table graphicRef87452 \" href=\"mobipreview.htm?8/21/8543\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Integrated prognostic models'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/1\">",
"      Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998; 279:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/2\">",
"      Lee SJ, Fairclough D, Antin JH, Weeks JC. Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001; 285:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/3\">",
"      Evans C, McCarthy M. Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1985; 1:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/4\">",
"      Forster LE, Lynn J. Predicting life span for applicants to inpatient hospice. Arch Intern Med 1988; 148:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/5\">",
"      Maltoni M, Nanni O, Derni S, et al. Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. Eur J Cancer 1994; 30A:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/6\">",
"      Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000; 320:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/7\">",
"      Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003; 327:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/8\">",
"      Chow E, Davis L, Panzarella T, et al. Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys 2005; 61:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/9\">",
"      Gripp S, Moeller S, B&ouml;lke E, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007; 25:3313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/10\">",
"      Twomey F, O'Leary N, O'Brien T. Prediction of patient survival by healthcare professionals in a specialist palliative care inpatient unit: a prospective study. Am J Hosp Palliat Care 2008; 25:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/11\">",
"      Parkes CM. Accuracy of predictions of survival in later stages of cancer. Br Med J 1972; 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/12\">",
"      Heyse-Moore LH, Johnson-Bell VE. Can doctors accurately predict the life expectancy of patients with terminal cancer? Pall Med 1987; 1:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/13\">",
"      Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/14\">",
"      Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 1999; 17:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/15\">",
"      Oxenham D, Cornbleet MA. Accuracy of prediction of survival by different professional groups in a hospice. Palliat Med 1998; 12:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/16\">",
"      Chow E, Harth T, Hruby G, et al. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 2001; 13:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/17\">",
"      Stockler MR, Tattersall MH, Boyer MJ, et al. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2006; 94:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/18\">",
"      Vigan&ograve; A, Dorgan M, Bruera E, Suarez-Almazor ME. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 1999; 86:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/19\">",
"      Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/20\">",
"      Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med 1995; 122:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/21\">",
"      Muers MF, Shevlin P, Brown J. Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model. Thorax 1996; 51:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/22\">",
"      Lee KL, Pryor DB, Harrell FE Jr, et al. Predicting outcome in coronary disease. Statistical models versus expert clinicians. Am J Med 1986; 80:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/23\">",
"      Hagerty RG, Butow PN, Ellis PM, et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 2005; 23:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/24\">",
"      Daugherty CK, Hlubocky FJ. What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognosis disclosure. J Clin Oncol 2008; 26:5988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/25\">",
"      Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med 2001; 134:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/26\">",
"      Zubrod GC, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen and mustard and triethylene thiophosphoramide. J Chron Disease 1960; 11:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/27\">",
"      Christakis NA. Timing of referral of terminally ill patients to an outpatient hospice. J Gen Intern Med 1994; 9:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/28\">",
"      Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988; 148:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/29\">",
"      Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997; 33:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/30\">",
"      Allard P, Dionne A, Potvin D. Factors associated with length of survival among 1081 terminally ill cancer patients. J Palliat Care 1995; 11:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/31\">",
"      Rosenthal MA, Gebski VJ, Kefford RF, Stuart-Harris RC. Prediction of life-expectancy in hospice patients: identification of novel prognostic factors. Palliat Med 1993; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/32\">",
"      Loprinzi CL, Laurie JA, Wieand HS, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol 1994; 12:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/33\">",
"      Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/34\">",
"      Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/35\">",
"      Hyde L, Wolf J, McCracken S, Yesner R. Natural course of inoperable lung cancer. Chest 1973; 64:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/36\">",
"      McCusker J. The terminal period of cancer: definition and descriptive epidemiology. J Chronic Dis 1984; 37:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/37\">",
"      Barbot AC, Mussault P, Ingrand P, Tourani JM. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol 2008; 26:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/38\">",
"      Pirovano M, Maltoni M, Nanni O, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 1999; 17:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/39\">",
"      Morita T, Tsunoda J, Inoue S, Chihara S. Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manage 1999; 18:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/40\">",
"      Janisch L, Mick R, Schilsky RL, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994; 74:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/41\">",
"      Lau F, Downing GM, Lesperance M, et al. Use of Palliative Performance Scale in end-of-life prognostication. J Palliat Med 2006; 9:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/42\">",
"      Llobera J, Esteva M, Rif&agrave; J, et al. Terminal cancer. duration and prediction of survival time. Eur J Cancer 2000; 36:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/43\">",
"      Anderson F, Downing GM, Hill J, et al. Palliative performance scale (PPS): a new tool. J Palliat Care 1996; 12:5.",
"     </a>",
"    </li>",
"    <li>",
"     Components of the palliative performance scale (PPS) available online at file://pallipedia.org/term.php?id=504 (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/45\">",
"      Lau F, Maida V, Downing M, et al. Use of the Palliative Performance Scale (PPS) for end-of-life prognostication in a palliative medicine consultation service. J Pain Symptom Manage 2009; 37:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/46\">",
"      Lau F, Downing M, Lesperance M, et al. Using the Palliative Performance Scale to provide meaningful survival estimates. J Pain Symptom Manage 2009; 38:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/47\">",
"      Seow H, Barbera L, Dudgeon D, et al. The association of the palliative performance scale and hazard of death in an ambulatory cancer population. J Palliat Med 2013; 16:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/48\">",
"      Feinstein AR. Symptoms as an index of biological behaviour and prognosis in human cancer. Nature 1966; 209:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/49\">",
"      Vigan&ograve; A, Dorgan M, Buckingham J, et al. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 2000; 14:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/50\">",
"      Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 1999; 7:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/51\">",
"      Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23:6240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/52\">",
"      Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996; 11:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/53\">",
"      Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/54\">",
"      Chuang RB, Hu WY, Chiu TY, Chen CY. Prediction of survival in terminal cancer patients in Taiwan: constructing a prognostic scale. J Pain Symptom Manage 2004; 28:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/55\">",
"      Martin L, Watanabe S, Fainsinger R, et al. Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction. J Clin Oncol 2010; 28:4376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/56\">",
"      Gwilliam B, Keeley V, Todd C, et al. Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ 2011; 343:d4920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/57\">",
"      Scarpi E, Maltoni M, Miceli R, et al. Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist 2011; 16:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/58\">",
"      Feliu J, Jim&eacute;nez-Gordo AM, Madero R, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst 2011; 103:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/59\">",
"      Maltoni M, Scarpi E, Pittureri C, et al. Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist 2012; 17:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/60\">",
"      Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol 2000; 73:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/61\">",
"      Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/62\">",
"      Attali P, Prod'Homme S, Pelletier G, et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 1987; 59:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/63\">",
"      Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/64\">",
"      Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/65\">",
"      Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/66\">",
"      Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/67\">",
"      Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/68\">",
"      Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/69\">",
"      Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/70\">",
"      Keating JJ, Johnson PJ, Cochrane AM, et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989; 60:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/71\">",
"      Glimelius B, Ekstr&ouml;m K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/72\">",
"      Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Invest 2004; 22:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/73\">",
"      Glare PA, Eychmueller S, McMahon P. Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer. J Clin Oncol 2004; 22:4823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/74\">",
"      Chow E, Abdolell M, Panzarella T, et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol 2008; 26:5863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/75\">",
"      Tr&eacute;dan O, Ray-Coquard I, Chvetzoff G, et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 2011; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/76\">",
"      Tassinari D, Montanari L, Maltoni M, et al. The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Support Care Cancer 2008; 16:359.",
"     </a>",
"    </li>",
"    <li>",
"     Christakis NA. Death foretold: Prophecy and Prognosis and Medical Care, University of Chicago Press, Chicago 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./survival-estimates-in-advanced-terminal-cancer/abstract/78\">",
"      Poses RM, Bekes C, Winkler RL, et al. Are two (inexperienced) heads better than one (experienced) head? Averaging house officers' prognostic judgments for critically ill patients. Arch Intern Med 1990; 150:1874.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2206 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-B5358D1A5F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39015=[""].join("\n");
var outline_f38_6_39015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACCURACY OF SURVIVAL ESTIMATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMMUNICATION OF SURVIVAL ESTIMATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMPROVING PROGNOSTIC ACCURACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Performance status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Integrated prognostic models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93043526\">",
"      - Patients receiving supportive care only",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93043742\">",
"      - Patients receiving active anticancer therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prognostic consultation from colleagues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2206|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/46/34541\" title=\"figure 1\">",
"      Communicated survival estimates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/46/751\" title=\"figure 2\">",
"      Nomogram to predict survival in terminally ill cancer patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/24/10636\" title=\"table 1\">",
"      Survival estimates cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 3\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/36/3660\" title=\"table 4\">",
"      Predictors of survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8543\" title=\"table 5\">",
"      Cancer presentations with a median survival of 6 months or less",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/61/8156\" title=\"table 6\">",
"      Palliative Prognostic Index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/17/12572\" title=\"table 7\">",
"      Median survival advanced ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_6_39016="Management of new onset atrial fibrillation";
var content_f38_6_39016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of new onset atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Robert Phang, MD, FACC, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39016/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/6/39016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;New onset atrial fibrillation (AF) is atrial fibrillation identified for the first time by an electrocardiogram or other electrocardiographic rhythm recording device, such as ambulatory or inpatient monitoring.",
"   </p>",
"   <p>",
"    There is overlap between &ldquo;new onset,&rdquo; &ldquo;acute,&rdquo; and &ldquo;first identified&rdquo; atrial fibrillation, but each represents a distinct clinical presentation with unique features mandating different assessments and management. Typical symptoms associated with new onset atrial fibrillation include palpitations, a sense of the heart racing, an irregular pulse, fatigue, lightheadedness, increased urination, weakness, and mild shortness of breath. More severe symptoms and signs include dyspnea, angina, hypotension, and presyncope. Infrequently, myocardial infarction, syncope, or pulmonary edema may occur. In addition, some patients present with an embolic event (particularly stroke) or the insidious onset of right-sided heart failure (as manifested by peripheral edema, weight gain, and ascites).",
"   </p>",
"   <p>",
"    Occasionally, the first detection of AF will occur incidentally and in the absence of symptoms at the time or during a routine examination or on an electrocardiogram obtained for other reasons, but such episodes may be present for extended periods or simply missed on prior examinations. Rarely, a patient with arterial thromboembolism is found only in retrospect to have new onset atrial fibrillation. Episodes at presentation can be paroxysmal and stop spontaneously, persistent and stop only with cardioversion, or permanent and present for prolonged periods.",
"   </p>",
"   <p>",
"    This topic will address the following management decisions, which need to be made soon after a patient presents with new onset AF:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is cardioversion indicated and if so should it be urgent?",
"     </li>",
"     <li>",
"      When and how should rate control be carried out?",
"     </li>",
"     <li>",
"      Who should be anticoagulated immediately and how?",
"     </li>",
"     <li>",
"      Does the patient need hospitalization?",
"     </li>",
"     <li>",
"      Are there any correctable causes of atrial fibrillation?",
"     </li>",
"     <li>",
"      What should be done with the patient who spontaneously converts to sinus rhythm?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More detailed discussions of these issues, as well as the causes, evaluation, and general management of AF, including the role of anticoagulation and rhythm versus rate control, particularly as they apply to patients with paroxysmal or permanent AF, are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521215556\">",
"    <span class=\"h2\">",
"     Important first steps",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those patients in whom the diagnosis of new onset atrial fibrillation is made in an office setting and who may need either urgent cardioversion (either electrical or chemical) or parenteral anticoagulant therapy, timely transfer to a facility with those capabilities should be carried out.",
"     </li>",
"     <li>",
"      A complete history and physical examination should be performed in all patients with new onset AF. Old records should be searched for evidence of a prior episode of AF or other atrial tachyarrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=see_link\">",
"       \"The electrocardiogram in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448750704\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR URGENT CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four circumstances for which urgent or emergent cardioversion may be needed (",
"    <a class=\"graphic graphic_table graphicRef72962 \" href=\"mobipreview.htm?12/49/13084\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef52051 \" href=\"mobipreview.htm?0/50/815\">",
"     algorithm 1",
"    </a>",
"    ) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active ischemia (symptomatic or electrocardiographic evidence)",
"     </li>",
"     <li>",
"      Evidence of organ hypoperfusion",
"     </li>",
"     <li>",
"      Severe manifestations of heart failure (HF) including pulmonary edema (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The presence of a preexcitation syndrome, which may lead to an extremely rapid ventricular rate due to the presence of an accessory pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a patient with any of these indications for urgent cardioversion, the need for restoration of normal sinus rhythm (NSR) takes precedence over the need for protection from thromboembolic risk. Intravenous anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should be started, but it should not cause a delay in emergent cardioversion.",
"   </p>",
"   <p>",
"    However, these four circumstances differ with regard to the urgency of cardioversion and in most cases rate control is possible as a temporizing measure. Further, indiscriminate cardioversion may have dire consequences or be futile if the cause for the initiation of the problem is not at least in part corrected (eg, immediate cardioversion in a patient with pulmonary edema will be dangerous to the patient and may not be effective without diuresis, oxygen, blood pressure control and other measures). Careful review of comorbidities and absolute need for immediate cardioversion must be weighed against its benefits as the atrial fibrillation may not be the cause but the consequence of the initiating process. Cardioversion of patients with AF is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701654#H8701654\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'DC cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION FOR AN UNDERLYING CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When faced with a patient who presents with new onset AF (particularly if the ventricular response is rapid), there should be a quick assessment for an underlying cause, such as heart failure (HF), pulmonary problems, poorly controlled blood pressure, or hyperthyroidism. Therapy for a precipitating cause should be initiated prior to cardioversion in stable patients and may result in reversion to sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following tests, in addition to the electrocardiogram, should be performed on patients with new onset AF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs including oxygen saturation (in the ER setting and beyond)",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone (TSH) and free T4. These should be obtained even if there are no symptoms suggestive of hyperthyroidism (and if thyroid function has not been measured recently), since the risk of AF is increased up to threefold in patients with",
"      <strong>",
"       subclinical",
"      </strong>",
"      hyperthyroidism (",
"      <a class=\"graphic graphic_figure graphicRef55024 \" href=\"mobipreview.htm?19/0/19469\">",
"       figure 1",
"      </a>",
"      ). The latter disorder is characterized by low serum TSH (&lt;0.5",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      with the newer sensitive assays) and normal serum free T4. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23913?source=see_link\">",
"       \"Subclinical hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum electrolytes and assessment of renal function",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      A transthoracic echocardiogram should be performed to screen for cardiac causes of new onset atrial fibrillation, even in the face of a normal physical examination.",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"     <li>",
"      Other blood tests dependent on underlying comorbidities and based on medical therapies prescribed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AF is rarely the only manifestation of an acute coronary syndrome, although AF with a rapid ventricular response and hypotension can provoke demand ischemia with or without angina. We suggest evaluation of myocardial infarction with serial troponin measurements, especially in patients with ECG changes, hypotension, symptoms, history or additional risk factors. Evaluation to rule out myocardial infarction may not be effective, however, or cost effective in patients without signs or symptoms present suggesting ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532809012\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will address the role of antithrombotic therapy in patients with new onset AF. The larger discussions of anticoagulation surrounding cardioversion and recommendations for the use of long-term antithrombotic therapy in patients with more than one episode of AF are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Antithrombotic prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710306792\">",
"    <span class=\"h2\">",
"     Patients requiring delayed cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients in whom the duration of new onset AF is suspected to be more than 48 hours (or when the duration is unknown), the risk of embolization is measurably increased. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link&amp;anchor=H2#H2\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'Left atrial thrombus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In these patients, it is preferable to anticoagulate and use transesophageal echo (TEE) to rule out left atrial thrombi. If TEE is not readily available, then anticoagulation for approximately three to four weeks is preferable before attempted cardioversion to allow any left atrial thrombi to resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link&amp;anchor=H9#H9\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'AF of more than 48 hours duration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This recommendation includes patients with a low CHADS2 score (0 or 1). While there is little published evidence that the risk of embolization after planned (either chemical or electric) cardioversion is greater than after spontaneous reversion, some of our authors and reviewers are concerned that delayed return of atrial mechanical function (atrial stunning) after electrical cardioversion could increase the risk of a thromboembolic event after this approach with cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In this case, even with the lower CHADS2 score, oral anticoagulation is recommended for three to six weeks.",
"   </p>",
"   <p>",
"    Other patients for whom delayed cardioversion and anticoagulation is reasonable include those whose AF duration is less than 48 hours and who have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Associated mitral valve disease or significant cardiomyopathy or HF.",
"     </li>",
"     <li>",
"      A prior history of a thromboembolic event.",
"     </li>",
"     <li>",
"      A prior history of transesophageal echocardiography evidence of left atrial thrombus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H710307197\">",
"       'Role of TEE'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"       \"Role of echocardiography in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is chosen as the anticoagulant, the recommended target international normalized ratio (INR) is 2.5 (range 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710307197\">",
"    <span class=\"h3\">",
"     Role of TEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with AF of recent onset (but more than 48 hours or unknown duration) who are not being anticoagulated, an alternative approach to three to four weeks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ) before cardioversion is transesophageal echocardiography (TEE)-based screening with cardioversion performed if no thrombi are seen (",
"    <a class=\"graphic graphic_table graphicRef72971 graphicRef54077 \" href=\"mobipreview.htm?4/54/4973\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This regimen may be of particular use in the patient who requires hospitalization or has an increased risk of hemorrhagic complications during prolonged anticoagulant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link&amp;anchor=H13#H13\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'TEE-based approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACUTE trial directly compared a TEE-guided strategy (anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    immediately before TEE or with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for five days [target INR 2.0 to 3.0] before TEE, followed by cardioversion and then warfarin for four weeks after cardioversion), with a conventional strategy (three weeks of anticoagulation before cardioversion, followed by four weeks of anticoagulation after cardioversion) in 1222 patients with AF of more than two days&rsquo; duration who were undergoing electrical cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/8\">",
"     8",
"    </a>",
"    ]. There was no difference between the two groups in the incidence of ischemic stroke, TIA, or all embolic events within eight weeks of cardioversion (0.8 versus 0.5 percent for the conventional strategy). However, patients undergoing the TEE-guided strategy had a lower, but not significant, incidence of hemorrhagic events (2.9 versus 5.5 percent) a shorter mean time to cardioversion (3 versus 30.6 days), and a greater incidence of successful reversion (71 versus 65 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526865111\">",
"    <span class=\"h2\">",
"     Early cardioversion or spontaneous reversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is only a small amount of observational evidence that can be used to formulate recommendations regarding the approach to anticoagulation in patients who present with new onset AF of less than 48 hours duration. With the exception of certain high-risk patients, the embolic risk appears to be very low if cardioversion is performed within two days of the onset of AF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link&amp;anchor=H16#H16\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'AF of less than 48 hours duration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts have recommended cardioversion without anticoagulation or a transesophageal echocardiogram (TEE) prior to or following cardioversion in patients with new onset AF of less than 48 hours duration. The logic for doing so is that the risk of bleeding from anticoagulation is probably greater than the risk of embolization (particularly in those with CHADS2 scores of 0 or 1), and the risk of thromboembolic events from short duration of atrial fibrillation appears to be relatively low (but not zero). Others start intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin before cardioversion and continue it for at least 24 hours after the procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H22#H22\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, our authors and reviewers differ on the approach to long-term anticoagulation in these patients, with some suggesting no oral anticoagulation for the first episode of AF (less than 48 hours duration) and others suggesting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for patients with CHADS2 scores of two or greater.",
"   </p>",
"   <p>",
"    Guidelines from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association and the American College of Chest Physicians suggest periprocedural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with new onset AF of less than 48 hours duration, but make weak recommendations against the use of prolonged anticoagulation (three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. The 2011 European Society of Cardiology guidelines for the management of AF make a weak recommendation for periprocedural heparin in all such patients, as well as long-term oral anticoagulant in patients at high risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our authors and reviewers believe it is reasonable to defer cardioversion and start oral anticoagulation in selected patients with AF of less than 48 hours in whom cardioversion is planned. Longer duration of AF prior to cardioversion (for example 40 hours as opposed to 10 hours) or a higher CHADS2 score are two reasons to lower the threshold for the initiation of anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute AF do not require urgent cardioversion. Initial treatment directed at slowing the ventricular rate will usually result in improvement or resolution of the associated symptoms. Even for patients with minimal symptoms, rate control should be carried out to block a more rapid ventricular response as a result of a new trigger, such as anxiety, caffeine, or hypovolemia. We believe that attempting to get the rate below 110 beats per minute is reasonable. The prevention of tachycardia-mediated cardiomyopathy is a principle reason for this recommendation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=see_link&amp;anchor=H4#H4\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Rate control goals'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link&amp;anchor=H10#H10\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, this can be achieved with beta blockers, calcium channel blockers (primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . Occasionally, IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be needed for patients with poor left ventricular function. The drug selected and the route of administration (oral versus intravenous) are dictated by the clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      are the preferred drugs in the absence of HF, since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is less likely to control the ventricular rate during exercise (when vagal tone is low and sympathetic tone is high), has little ability to terminate the arrhythmia, and often does not slow the heart rate in patients with recurrent AF.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      may help control rate when the other drugs are ineffective or cannot be given.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      is the preferred drug ONLY in patients with AF due to HF. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link&amp;anchor=H2666291#H2666291\">",
"       \"Atrial fibrillation in patients with heart failure\", section on 'Rate control'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition to the direct vagotonic effect of digoxin on the atrioventricular (AV) node (which may require several hours to become apparent), the improvement in left ventricular function and systemic hemodynamics result in withdrawal of sympathetic tone and a further decrease in the ventricular rate. Not infrequently, the improvement in hemodynamics results in reversion of the arrhythmia. Digoxin can also be used in patients who cannot take or who respond inadequately to beta blockers or calcium channel blockers. The effect of digoxin is additive to both of these drugs.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"      IV is recommended for rate control and for attempt to cardiovert atrial fibrillation with preexcitation when urgent cardioversion is not available or recommended. Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is an alternative option. Intravenous AV nodal blockers, in particular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , are contraindicated in patients with atrial fibrillation and preexcitation. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers and nondihydropyridine calcium channel blockers are also effective if HF or hypotension is due to the rapid ventricular rates and should be given intravenously if rates exceed 140",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    or are not well tolerated but not in need of urgent arrhythmic cardioversion. If, however, there is doubt about the origin of the HF, the initial dose should be small (since these drugs impair contractility), with upward titration based upon heart rate slowing, blood pressure, and symptomatic improvement. The decision between intravenous or oral therapy depends on the clinical presentation and the need and urgency for controlling the rate.",
"   </p>",
"   <p>",
"    The choice between a beta blocker,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is frequently based upon physician and patient preference, although it may be influenced by other problems that are present. As an example, beta blockers are particularly useful when the ventricular response increases to inappropriately high rates during exercise, after an acute MI, and when exercise-induced angina pectoris is also present. Intravenous beta blockade is more effective than intravenous calcium channel blockade for rate control, but also for conversion to sinus rhythm especially after cardiac surgery. If there is a question about tolerance of the beta blocker, a short-acting drug with a short half-life would be recommended. On the other hand, a calcium channel blocker is preferred in patients with chronic lung disease. The use of both a beta blocker and calcium channel blocker is reasonable when rate control is not adequate with single therapy. Careful monitoring is required to prevent excess AV nodal blockade, hypotension, and precipitation of heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step after control of the ventricular rate in patients with recent onset AF, who are hemodynamically stable (with only mild to moderate symptoms), is deciding whether an attempt will be made to cardiovert the patient and if so when. We believe that most patients with symptomatic new onset atrial fibrillation should have at least one attempt at cardioversion (either electrical or chemical) to sinus rhythm, particularly after reversible causes have been identified and corrected. The rationale for cardioversion is that some patients will never have a second episode, or will have very infrequent episodes; cardioversion will likely improve symptom status, particularly in young people.",
"   </p>",
"   <p>",
"    Circumstances in which it is reasonable to",
"    <strong>",
"     not",
"    </strong>",
"    attempt cardioversion in a patient with new onset AF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are",
"      <strong>",
"       completely asymptomatic",
"      </strong>",
"      , particularly those who are very elderly (&gt;80 years) with multiple comorbidities, where risks of undergoing cardioversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacologic rhythm control may outweigh the benefits of restoring sinus rhythm.",
"     </li>",
"     <li>",
"      A patient with a high CHADS2 (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"       table 3",
"      </a>",
"      ) score who has a bleeding risk and cannot be anticoagulated during and after cardioversion. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of cardioversion (except in patients who are unstable) is determined in large measure by the duration of the episode. There is a low risk of systemic embolization if the duration of the arrhythmia is 24 hours or less (and the risks are acceptable up to 48 hours)",
"    <strong>",
"     and",
"    </strong>",
"    there are no cardiac abnormalities (particularly mitral valve disease or significant left ventricular enlargement due to a cardiomyopathy) on transthoracic echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/14\">",
"     14",
"    </a>",
"    ]. Most patients with new onset AF of longer than 48 hours duration should have cardioversion postponed. (See",
"    <a class=\"local\" href=\"#H526865111\">",
"     'Early cardioversion or spontaneous reversion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The choice of electrical or pharmacologic cardioversion depends upon the comfort of the clinician to use one or the other approach. Longer durations of the arrhythmia are less likely to respond to antiarrhythmic drug therapy for conversion (",
"    <a class=\"graphic graphic_table graphicRef58616 \" href=\"mobipreview.htm?24/39/25212\">",
"     table 4",
"    </a>",
"    ). For patients with paroxysmal episodes of atrial fibrillation, drug therapy is preferred if they will have sinus rhythm maintained with long-term antiarrhythmic drug therapy, and as patients with paroxysmal atrial fibrillation will likely convert anyway with or without electrical cardioversion. For persistent episodes, electrical cardioversion is preferred. In some patients, antiarrhythmic drugs are administered prior to cardioversion to increase the chance of successful reversion and to prevent early, intermediate, and late recurrence (",
"    <a class=\"graphic graphic_table graphicRef67853 \" href=\"mobipreview.htm?38/24/39307\">",
"     table 5",
"    </a>",
"    ). Our recommendations for cardioversion are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521214080\">",
"    <span class=\"h2\">",
"     Antiarrhythmic therapy after reversion to sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the American Association of Family",
"    <span class=\"nowrap\">",
"     Physicians/American",
"    </span>",
"    College of Physicians",
"    <span class=\"nowrap\">",
"     (AAFP/ACP)",
"    </span>",
"    guideline recommendation that maintenance antiarrhythmic drug therapy NOT be routinely used after cardioversion in patients with newly detected AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701722#H8701722\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Recurrence of AF after cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, extensive attempts to maintain sinus rhythm are appropriate only in rare instances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link&amp;anchor=H19#H19\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Patients early in their natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710307544\">",
"    <span class=\"h2\">",
"     Spontaneous reversion of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;New onset AF often spontaneously reverts to normal sinus rhythm, with the incidence of reversion related to the duration of the arrhythmia. This was illustrated in a study of 1822 patients admitted to the hospital because of AF: 356 had an arrhythmia duration less than 72 hours, 68 percent of whom spontaneously reverted to sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/17\">",
"     17",
"    </a>",
"    ]. Two-thirds of those with spontaneous reversion had AF duration of less than 24 hours, which was the only predictor of spontaneous reversion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal antithrombotic therapy after spontaneous cardioversion of a first episode of AF (lasting less than 48 hours) in patients without structural heart disease is discussed above. (See",
"    <a class=\"local\" href=\"#H532809012\">",
"     'Anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We do not recommend the initiation of drugs to maintain either rhythm or rate control, unless the patient is felt to be at high risk for recurrence and a rhythm control strategy has been chosen. (See",
"    <a class=\"local\" href=\"#H521214080\">",
"     'Antiarrhythmic therapy after reversion to sinus rhythm'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521214863\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with new onset AF, particularly those without spontaneous reversion, have often been admitted to the hospital.",
"   </p>",
"   <p>",
"    One frequently cited reason for admission is to \"rule out\" an acute myocardial infarction. AF is rarely the only manifestation of an acute coronary syndrome, although AF with a rapid ventricular response and hypotension can provoke angina. As a result, there is no reason to admit the patient unless there are other clinical reasons to consider an acute coronary syndrome such as ST segment elevation or major (&gt;2 mm) ST segment depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, the use of high-sensitivity troponins allows ruling out of MI in the emergency department within a few hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'AF as a presentation of ACS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible indications for hospitalization in patients with new onset AF are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or other anticoagulant therapy.",
"     </li>",
"     <li>",
"      Patients in whom ablation of an accessory pathway is being considered, particularly if the AF was highly symptomatic and associated with hemodynamic collapse and rapid ventricular response rate.",
"     </li>",
"     <li>",
"      Treatment of an associated medical problem, which is often the reason for the arrhythmia. Examples include the treatment of hypertension, infection, exacerbation of chronic obstructive pulmonary disease (COPD), pulmonary embolism, persistent myocardial ischemia, or acute pericarditis.",
"     </li>",
"     <li>",
"      Treatment of elderly patients. The elderly are more likely to have a high risk of thromboembolism. There may also be difficulty in controlling the ventricular response rate without causing the development of sick sinus syndrome The elderly are more likely to have comorbidities that can complicate drug management in the treatment of atrial fibrillation, whether it be rate control or rhythm control approaches.",
"     </li>",
"     <li>",
"      Further management heart failure or hypotension after control of the rhythm or rate",
"     </li>",
"     <li>",
"      Initiation of antiarrhythmic drug therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of hospitalization will depend on factors such as control of an underlying medical problem and time required to complete anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521214870\">",
"    <span class=\"h1\">",
"     DISCHARGE FROM THE EMERGENCY ROOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients who do not have one of the above clear indications for hospitalization, an important initial issue is whether patients presenting with new onset AF (less than 48 hours duration) can be managed (including cardioversion) in the emergency department or an observational unit and then discharged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. This issue was addressed in a study of 289 such patients who were stable, did not have heart disease, and did not have another indication for hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/21\">",
"     21",
"    </a>",
"    ]. Pharmacologic cardioversion was attempted in 62 percent and was successful in 50 percent; 28 percent underwent electric cardioversion with a success rate of 89 percent. Overall, 97 percent of patients were discharged home directly from the emergency department. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701755#H8701755\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Antiarrhythmic drugs used in cardioversion'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Similar results were noted in another report of 51 patients who underwent attempted pharmacologic cardioversion with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , followed by electrical reversion if AF was still present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/22\">",
"     22",
"    </a>",
"    ]. All patients were successfully reverted and discharged from the emergency department.",
"   </p>",
"   <p>",
"    Thus, emergency department or observational unit treatment of new onset AF in clinically stable patients, who have no other important comorbidities such as underlying structural heart disease, is safe and cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39016/abstract/20\">",
"     20",
"    </a>",
"    ]. The role of anticoagulation in such patients (ie, low risk and duration less than 48 hours) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link&amp;anchor=H16#H16\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'AF of less than 48 hours duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461234550\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine follow-up after an episode of acute atrial fibrillation is necessary to evaluate the safety and efficacy of antiarrhythmic and anticoagulant therapies, to reassess the need for these therapies, and to assess the functional status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=see_link\">",
"       \"Patient information: Atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461234558\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;New onset atrial fibrillation (AF) is atrial fibrillation identified for the first time by an electrocardiogram or other rhythm recording, such as ambulatory or inpatient monitoring. The early steps in the management of a patient with new onset atrial fibrillation (AF) involve an assessment of the need for cardioversion, rate slowing therapy, and antithrombotic therapy. The following summarizes that process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom early cardioversion (within 48 hours) or parenteral anticoagulation are being considered should be transferred from an office setting to an acute care facility. (See",
"      <a class=\"local\" href=\"#H521215556\">",
"       'Important first steps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent or emergent cardioversion should be considered for patients with active ischemia, significant hypotension, severe heart failure, or the presence of a preexcitation syndrome associated with rapid conduction using the accessory pathway.(See",
"      <a class=\"local\" href=\"#H448750704\">",
"       'Indications for urgent cardioversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should undergo an evaluation for precipitating cause. If found it should be corrected as soon as possible. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation for an underlying cause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with symptomatic new onset atrial fibrillation should have at least one attempt at cardioversion (either electrical or chemical) to sinus rhythm, particularly after reversible causes have been identified and corrected. The timing of cardioversion depends in large part on hemodynamic status and the duration of the AF episode. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardioversion'",
"      </a>",
"      above.) If the patient is highly symptomatic or if delay in cardioversion poses additional risks or problems and the episode is less than 24 hours, an urgent cardioversion can be performed. &nbsp;",
"     </li>",
"     <li>",
"      Most patients with new onset AF who have sinus rhythm restored do not need maintenance antiarrhythmic drug therapy. (See",
"      <a class=\"local\" href=\"#H521214080\">",
"       'Antiarrhythmic therapy after reversion to sinus rhythm'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our specific recommendations are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend rate control to improve symptoms and to reduce the risk of tachycardia-mediated cardiomyopathy for all patients who do not require urgent or emergent cardioversion. We believe a goal of less than 110 beats per minute is reasonable. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial rate control with mild to moderate symptoms'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Beta blockers and nondihydropyridine calcium channel blockers are preferred as first-line agents in most patients. Intravenous preparations are preferred to oral preparations when rapid control of rate is necessary. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial rate control with mild to moderate symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with AF less than 48 hours in duration, the use of periprocedural",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ) to reduce the risk of embolization can be considered. Our authors and reviewers believe there is insufficient evidence to make a recommendation for or against its use. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H22#H22\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Bleeding'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The decision to start long-term oral anticoagulation in these patients should be made based on an assessment of the long-term risk of embolization based on the CHADS2 score.",
"     </li>",
"     <li>",
"      For patients with AF of longer than 48 hours duration, we recommend four weeks of therapeutic oral anticoagulation prior to cardioversion, as opposed to immediate cardioversion. TEE-based screening for the presence of atrial thrombi is recommended among patients with AF of recent onset (but more than 48 hours or unknown duration) if semi-urgent cardioversion is necessary. Though this strategy does not require the minimum three weeks of anticoagulation leading up to cardioversion, the patient should be on therapeutic anticoagulant therapy at the time of",
"      <span class=\"nowrap\">",
"       TEE/cardioversion",
"      </span>",
"      as well as for one month post-cardioversion. (See",
"      <a class=\"local\" href=\"#H710307197\">",
"       'Role of TEE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible indications for hospitalization in patients with new onset AF include (but are not limited to) (See",
"      <a class=\"local\" href=\"#H521214863\">",
"       'Indications for hospitalization'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ablation of an accessory pathway",
"     </li>",
"     <li>",
"      Treatment of an associated medical problem, which is often the reason for the arrhythmia.",
"     </li>",
"     <li>",
"      Treatment of frail elderly patients.",
"     </li>",
"     <li>",
"      Further management of heart failure or hypotension after control of the rhythm or rate",
"     </li>",
"     <li>",
"      Initiation of antiarrhythmic drug therapy",
"     </li>",
"     <li>",
"      Initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/1\">",
"      Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995; 92:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/2\">",
"      Guo H, Shaheen W, Kerber R, Olshansky B. Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. Prog Cardiovasc Dis 2004; 46:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/3\">",
"      Maria Amuchastegui L, Cravero C, Salomone O, Amuchastegui M. Atrial Mechanical Function Before and After Electrical or Amiodarone Cardioversion in Atrial Fibrillation: Assessment by Transesophageal Echocardiography and Pulsed Doppler. Echocardiography 1996; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/4\">",
"      Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/5\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/6\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/7\">",
"      Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/8\">",
"      Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/9\">",
"      Silverman DI, Manning WJ. Strategies for cardioversion of atrial fibrillation--time for a change? N Engl J Med 2001; 344:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/10\">",
"      Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997; 29:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/11\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/12\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/13\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/14\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/15\">",
"      Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/16\">",
"      McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/17\">",
"      Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/18\">",
"      Zimetbaum PJ, Josephson ME, McDonald MJ, et al. Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 2000; 36:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/19\">",
"      Dell'Orfano JT, Kramer RK, Naccarelli GV. Cost-effective strategies in the acute management of atrial fibrillation. Curr Opin Cardiol 2000; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/20\">",
"      Kim MH, Conlon B, Ebinger M, et al. Clinical outcomes and costs associated with a first episode of uncomplicated atrial fibrillation presenting to the emergency room. Am J Cardiol 2001; 88:A7, 74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/21\">",
"      Michael JA, Stiell IG, Agarwal S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 1999; 33:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39016/abstract/22\">",
"      Domanovits H, Schillinger M, Thoennissen J, et al. Termination of recent-onset atrial fibrillation/flutter in the emergency department: a sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation 2000; 45:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1057 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39016=[""].join("\n");
var outline_f38_6_39016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H461234558\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521215556\">",
"      Important first steps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448750704\">",
"      INDICATIONS FOR URGENT CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION FOR AN UNDERLYING CAUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H532809012\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H710306792\">",
"      Patients requiring delayed cardioversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H710307197\">",
"      - Role of TEE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526865111\">",
"      Early cardioversion or spontaneous reversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL RATE CONTROL WITH MILD TO MODERATE SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521214080\">",
"      Antiarrhythmic therapy after reversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H710307544\">",
"      Spontaneous reversion of AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H521214863\">",
"      INDICATIONS FOR HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H521214870\">",
"      DISCHARGE FROM THE EMERGENCY ROOM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461234550\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461234558\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1057|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/50/815\" title=\"algorithm 1\">",
"      Algorithm for management of new onset AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1057|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/0/19469\" title=\"figure 1\">",
"      Increased incidence of AF in subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/49/13084\" title=\"table 1\">",
"      Electrical cardioversion AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/0/32779\" title=\"table 2A\">",
"      Conventional approach to cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/35/2620\" title=\"table 2B\">",
"      TEE approach to cardioversion of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 3\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/39/25212\" title=\"table 4\">",
"      Pharmacologic cardioversion AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/24/39307\" title=\"table 5\">",
"      ACC AHA ESC precardioversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_6_39017="Mucous membrane pemphigoid gingivitis";
var content_f38_6_39017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73874%7EDERM%2F52208%7EDERM%2F63997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73874%7EDERM%2F52208%7EDERM%2F63997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC9Pdrk4NZ8t4W4B5rMR5ZenAq7bW+WGRxXj+9M+s92G45JJJTgVct7YnlqmjSOIDAFPe4UD6VrGko6sylVctETxxqgGDT2mCfdNZT3oORmq7XJ9f1qnUS0QlFvVmy1xu4oBwMlqyBPhc5pj3u0cmp5r7jsbJuQo4IxVaa/AzlqwrjUgB1FZN1qJOcNUObLjTub11qeM4esq41Nueawp74k8mqE19yQDms3eW50Riom5LqBbOTVR7ssTtOKxTMzNkninGcIuB1oUC3M1xcAZLHJqCa664asl7vJIFV5Jmc89KfKTfuy9NdkZ2nmqTytIeW4qF5VQZYj6VWmvVHTGa0jAynXjHctuVxmq1xeKgwvX1rNmu3ccGq7MW6k1uqXc4auNb0iWJbhpDnPFRFsnnrTR+lKBlq0SscTm5O7FGSeaeKTuKXHOaGCJFpVpF6c09RUM3gSL1FSJxUa9qkXoaR10i5bYGD3rasSc4ArEgPQVsWLncMnpUWsdMXY24HIYdgRWvakEZzWDHw3Jz3FadpJgDHQdak2TbRtQORwBgGpyd5BOeOKz47jAwFBqdJcAnHvVXKV76F359vIAUVC2ARuwfbHSohdMwC7abuDMc9utQzohdbk23dnBwPajBb7wxUXmlScfdFNeUuSB6ZqWaK6LbJjHOcU1WUAgnrTYnDDDHnFN2bhu6YPFML9xd2GAB28c/SlVwOpyc1Vm+9y1MkyuChpFNJmkXUp8xBqAFfmJrPeXaMg59qmtpGfIJ6ii9w5OVXJy/zEKOKRVzkA9BzScKDu5Pamb85LcD0FMkVsDH9KjdlA6ZpzSAdwPaq7kluMEZzSY0RznJDKMVEmWOTxnirIPmKQBUDRlTgHnNBpF9BCo3AnpnmrMvBCjAWmIo2kYyQaAxZCG4IoBu7IWQebtI60jw5BAFS+apU5GHHQ4psRxkFuT0z3qdh3ZTdA0ijGEHBzVS7j+bKnAHNXpR0bgnPNU7n5uxz2BpDeqN7w5e5hVSRlTzXa2dwGjU5ryuxuDbXCkt8rcGu30m6EkYwwJqXozza1O2518DdGU81OZVfG5gDWLBckAHNXY5A6kMOTVJnG4l+JWj+hqeKQtlW7VRhdlAIOV6VNuDHI4z2rROxnKN9y/ETFyACrUVRV5AQOoFFVzmXszhIIUUfN1qdiAOKzzdKvUj8DVa4vvRqtySWhGrZpS3O3IzVaW796x577rVWS9A61k5G0VY2HnHPzComusfWsGW/UAndWfPqp+6pzUm1jp5dQ2jqKzrvVeSNwrmXvnc8monnJos2OyNebUCercVRnvCc7TVAy+tNL801ArnsWGldurU0OB3zVd5lUcmoXvI075NWoNmcq8Y9S8ZSeAQBTGfH3jxWXLf8A9wH86qvcu1WqTOeeNitEa0k6KCc1UkvuwrOLnuTS5rRU0jmnipS0RLJO7nk8VEScUZpDVpWOdyb3DniigDingDii5KEX0qRfpSBO9PC4oLSEAz04qTb7UAU6puaKIgqRaaBzT1HJqTaKsOWpU61EKlj61J1QLUA5rWtSFAJ61jwtg1p2kgwM1DZ0xNyDaVFWICwOQcCs6CXpjpVxZRnpgUjaJqQyfMM9T1qeRmCnH4VnwzZ+UgVbEgXAOaLFp2YiyMQDk4zxUyS/N9TVbAIIHQGlVti8+tSdKdy75m1h+VLK6gcHj0qmsi9TyaVW3McdKQ0upbRlxgdad521SB2quzBCCOnekDqwIXqetFwsmTLIDG2eW7VCZmK9Ohpm7Z0oJAIZTj+tBVkiKMlize9WonCE444pibW5JBz2obBXBIGKEhuV9B/m7mHOc1LwDmqfI2471ZiwRyelArCkDnPfpTEQHdjt1NWJISwyMbSKrt+7baAQD1pBGz2AYSEle/am+X8uX4YcinBQGPBp52tgNnNMrYgXcRuT8acf7rc0/KxNtXqe1PnKBUK9e49aOgN6lMuVcFl4FNuegKYH0qbJbeSBntVeRmQ4I681BSQ0feweSeaguBvbHQihHZZjnp2qR+cscc0FNNFGaHfG4A6c1f0DUGRxE5IdTzmo4gCMHrmqGpxtbyrcRdutDV0ctZXPRYZwY8n61etrj5RXF6NqyzwquRnGOTW9a3PAycH3qbnG42OijY/eBOP61Y3kqGzyDWXFOMAoee4q7DKJFPTPoK1WxhJF9J+x79xRWes2DtbqOoooI5TyWfVBjG6qM2p9ea557k+tQPcj1qvZ3MrxibkmpHnmqkl+7chv1rIe7wTUTXR7CqVIl4iKNJ7ktksTUZmHrWYZ3NRtI56mtFTRk8VbY02nAGS1RPeqOhrOYnHJprHIqlBGMsTLoXJL9s8CoGupD3xVftS1fKjF1ZS3Y9nZjkk0zJNFLTJbfUZk0AmgD1pw+8KCQxS0dKKBpWCgZ9M0oHNSKACDQUkIo/CpAOeRQBTh1qLlJIQU4Ud6cKGy0hKUU4D86XYR1FI1SEx0xTwOBQMgdKU/dqTSKDvUg4NMFOFBtBk6Gr0AZsYGc1TiGRzWlZ4U5zilY3TL9oNpAbqK0FZenT04rPhk3FsYA9anFxwABz0zUuxrG5ejGRxwfWrAlK5z0rPjc8gnmnLIAOWqTeO5faQMuVpqMWJ4yKh3BYwc4pySAYwck1LRtFlrHAPrxU4Xagz29KoeeVPPY96ke6DYz8v0pOyNFFsss43daQt8uFyD61TEucYqZZA3NIq1iwpAz6GlKBuEOKriTd14ANSKeP1p3EwMTLycgimM3XrUyyZ4ao9pL4AHNMF5i27DKnHWro2N9PWqezgY6VbhUBMbSTQkNsnQNkjHy9jSbGJYyYxT137BikGwuecj0p2MyFFJYDPy+hp0kcaOW3fN2qeRk2Yxz61TcgOM5OTn8KNC022MmVgdzYweeKiWUMvbjjFWJMbTnpjpWaRycHA9qhmkdR7SHoPWnKQ2N5yahkDBypOfSpoyQGyvzYoRbsiLytkjP1HalVQzhePXNWBcFosAAkDAqvHzweCetSOLbWpCkbGQ4Py560+aIylweeKsN8uD3Hakhctv4xVRMKquc07SabebkJKZ5FdbpV6lxEGDbgRWNqtqJYi3BaszSLttPvgjn90x6elEo66HNLY9Et7oghR25/Cti0n3AEGuWSQuNy/pV6wuiHCg85qIuzMJRujppXU4bB44J9aKpwzbxtcYyPWitdzG1j5yO49etRmpqjK811HkSQzFJgYp5WkxTuRYZTSOKkIzSFaaFYiOaTGeBUu3rTcbR0oE0RYpOacaBTIaEAxzRmnAUhFFxjRSigcDGKcBQFgAz0609QfXpQq89KcBg0hoQAk81IBSgc04Dmk2WkNxSgcinbaUe+aRoogOvtUsaBmAyBnuajpwJ7c0jRItRxqo3BtzdsDpTGbfJukOMdgKk/fwqT5TruHBIzTYbhI/mMW6UcZZuKdh3GtznCNsHrUQ46VO07yRlTGAvXIqEYqWaLUVFJPFTGIr1GM01DjHIpxYvjJJFI2iiWMcmrUJJ+UVTwAoxndU9vL5bBhyc1N9TeJeQlRknA9KlRzuHOD71XeV2AztwPSpI5QzDpUdTZGhvyoOePWpYmDAkjg9KrIcKQ33RTolKDrnNNoaZNIzKpGPl96VWKkMvIP6UokUjaynI9afGBn7nFI1TaH7S+c5H1qB07gmpHlZGBHKk4qJtxOVzjPIpNGsJvqOickbckEVZjcrHgc1AhRO+SfSnlgAME4FSkaORZBIUYI96mikIxkiqSSk4AHNW7dCSAVypp2BvQsqwY+56U6AZk5BpqxbSQ2eO9WQVRM4GD3FNIhvsP8ALw2Vxj+VWkBzgcZFVPmY/J8u6n7yDg9V68079wSbJC204UnJPakIQy8HAqEMzZ42g9Kb5u0AnGQam5XKTXJ4A6EdDTSA2GYA1XmlLHjkVEXYBVUnB71PUpLQlvpNsbbRnFVLZt2GI49KtSsucL6c5qJMMD8uMelMItoaWy4JU8nH0pWLK6570zd5TZPrQ8u5g3BxRsXuxrLhhu4I9KliUnoAarNK0spK4Aq2qkxqFPNTuarbUkjQyLgmlRQHZcdqmgjKx8nLGm7NmSTiqWhhLW5VuogOADgjiuZ1a22vnjFdZfHaVI6dKyNShLxg9femzLluiTw3qPnQiKZv3i8HnrW+FIYMhPH5156HeyvFkUkBT83uK7nTrtZ4kcMDkcGs5I5J+6zbtLott3sPrRWfny5Mjv8AlRTTaMpRvqjxbHODUnljbndSSFSeKaDg57V1nk3GsuDzmm4FSZDHml2fLkGmFiLaKNop9FAuVEZT0prISKm6VHI/YU0TJJFZ+DjFNpzHJoxwKsxsC9KXGaO1HakDQygZp9CjigQ9TyKevWmgZIqRRSuaRQo5NSLTeh4pak2SsP3AIVwOe9Moo70FBT4VLOACAM/ePamEc0oycAd+3rSBGoLgsqwi4yo4O7jIpl1NAUCxbhIOpA4NUivlnHG4dQD0oGN3zZ98U7j5R7MGVcKQQOeetMxTuN/yggehp52Ae9S2axXcYFBFPQjaR3PShAGI9KsGOM425GOxNFzVaCRlyNoAFOCNnGPm60oTbwMEfWnBTu4H5GpZpEkiVgPmOPapW2hgV4YVXCt0bP1NTKu04I5zU8prGRoxurH1z2q1sGVyfwrPQ7O3HqKttKgQYbg9T6VVh3vsXCVUDB+vrSMchSG/Cqv2iNVGCHHc0ineQVIRfUmpcki4p9S2JC/BA47U0suDkZP1rNnncSHa/wCVSQMWXJznqam9zZEgc78bflzV6HDg4FQRsrgBgM1bgHl47DvRYfOxVgYuNoC8YzmrkWY8AkE1Esqqwzg56U8zKCpwAD2HrT0K1aLCvu3e1PypQAkCq6yg8Lx60mSSAvGO9JtDii/DOIY+mR2BqGafDEpgg1UuZW2jn7v61QlkYuPSkzWmluaklw2QR16cVA0rMQCcCs/zyEwTikE27OTzjNTY0NVJcucHAoYZXd3zjNZ0Mj544B9alkmITGT1psjqTFyrEZz9alWcqCcD86yXmZXOTnPrTDM7IVpFNF+4uMg45PtVSSdhg8EmohKRgA0sSh0y3NK9xxsi7Y7i3zjitOEsoIx04561nWLZBC9Qau+ZIEbkZHXNBcrlmF9mTngGknlDxcfeJqK3zJHgjBqK4VlYincSim7Mkupd1uPY4qq3zpyeBSyNmIgHBqFnOxeuT3oJkkjE1NRubjPNT+Hr1oXMDk4zlajuwZHbHPNZ7FopgyfeU9ardHFViejRSiSMc8HpRWLpN4JIlb8xRWdzldzzLNKT61WMpPQCml2Nd3KeHzk7SAE47U9ZRjrVQA554z6U4ZHSnYFNlsGlY1CGoLE9aVi+dkpPHNQOcn2pST603GeKFoS3caq5NK9SIBmmycnjtT6k20G0jYzTu1Nwe9O4WBeaeBSADPFP2mpbCwqjHvT+1LGucAYzUkgAOBSNoxGUUUoFIuw2nAUu3I4pQOKAS7jcUo4OakAGKawGM0FqImPXpTyPSmY4pc0ikh2eOetLgtyMUzNPQ8cii5aQLkHvTw26pIBFJkO5U44xQEGeAwFFjRMZz3pyM4Py8fSniLJ9qMBH55ApOyRUW2SLNJ0c5+tWVlCgNxn1zVBpN2c9KbvAqTRGkt3zzj3GKkFzGcnbg+lZJfjigP65qbGqaRqRXKruKryTT2kkkHDHHcZrNhlA7VoWsyE8HBpcoOWpMqblGw/UGrtmyQktJHnIxVUPgnAAqXdkgFgR6VNyoyvoXhCsih4ioI6ipF3AgH8azGnEWQrMMdqYLpiwyxp8xtFGvG4D5ONuc5pWlhJxuxk5HvWO0pYnB4qEznce5HSkbWR0AnhUgs67fQetJcXa7MLgr7VgF9xyPShZGbgCkNJGnJc7o+TjPeqzXDHvntUaQuRycA9zSeRhhlsjuaZSkhZJsjA60sUjNg9DUhhQRb1qSNFYbQuDinYmUydXGFFQSvsYjPBOc1I/CA8EjioblCQCcEH9KdiVIheRmbGTSGXb3JpkgYdB0qJmxjHXvUtFcxOshPOBipY2+UYbA9KpB8D3qSA5NIqMjYs3UN8zEHtitHOVAAyKyoYx5q4znb3rTSVV64DYxj3oehtuyS2n2NtwcGn3Dhvm71QMmJASatD5osipQSVncq3LYJHrUEchYhGPTvUlxzIqnOR1x1qA4MwPYVSFLYr3jbZTjnJqnOmWzVm4JebdjAzxSohdcdxVo5KkdLkenTG2mAY4Rv50Ut1EVj5HNFEoJs5bHCYHpSj0o9utGeQcV1nztgA5qRBmkB3CnL1FJjSFIpPwp1LSKsRrwKcBS4oHtRcLABjNMYZJqUDg0m2i4NEeOKTB3VIRQo70XEIBk08DApRS7cnJpXNIxFU8Yp2TQq08qB1pGyiMpR1p20Ypo4NILMUkCkzR2oAoKSDPPenZHQYpAKXGO9BaiJg96MUv0pQpoLUGIBSgGnBTUiKcUjRQsQgEHgVMszbduTil2H0p3lYXLHJPQCg1jEjaRj1JppYk8VIIWPUU8QNkEdKVh2ZBnnmnYHpVlbct0GBS/ZDjiiw+UrYFJgdsVO1sw+lRtEQO9J6DtYaAR6U8Pt6CozkHrQWPpQNItLcnA3ZP40gmKklSR3qtuoD+1S0VoaInZxncM06NwevzY9Kz0lx7VPHLjoanlKuXyfRTilWJnPyio4LlSMOOPWte2aJ1+UjnvSRam0QW9iWwH+UHmp0gSItlRs9hmpYVLZVJEPqDUjAIck49fStLaC9o7jJNznaBv4wpHpTfLCIVdCG7ild1jYGJMjqaaLnfhTww6Z71JQxQCCqqeKZOgQ792DjFOJZTxww7VFcnewJNO4LcFl+QrkGkdt3G4YxVdpFQEY59ahM5xgVNxskmfC4BzVZm5p2GdQajcFTmgLig/NU0WVkXFVg3NTbyCCBRYakapkKsh3Yx0pZpSxDn71Z/m7mGeuKlWQvhF496TR0QmrF5DkjDEk+ta4JjgAIwzVm2cWSCeSO9XZpG2DPUUJWFKpzOxDtLSnjHvVKb5STnp6VfAIVjnGeTWRNIGLEZ64oQ3IXK9e4qS0OQc9c9cVWIB288k1chARcg9aa3MqmqJLqPcmQaKPvAc0VVzkaZ5sCT7UHPrTtoHSjbkV1XPm7Dv4Ae1OXmo+duAOKeoOaTKJKKAKdUmiQylApx+lAGaBqIdeaM0uPyowKRfKNxSgcUY9qcBTEoiAVIBikA5p38qk2jEVelL+NIfam80XLUR+R60nWkFKOvPSkWoCYoxTyvPFSJGTSuaRpkQBpyoSOlWkgOcnpViO1ORxQ2bRplFYjjJNPWE+lai2mf4e9SC1IPNI1jTM1IDkZFWFt8AEiryQgHBqdoAcAdqdzRUbmV5WOi05LcE54rRW2yeoxUy2p9vpU3NVQKC2vAPrUkVqMdM+1aCW/IHarcUKr25FHMWqSRQjtBjoKf9iO3JHFasaAjgVKIw2NvWq5gdIw3sgQPlqGTTwVyB+FdAYcjcepqPy+enSlzE+yTOXm0s84FUJrJ1zxXcCIMCCOnSqs9sh6gUOzRHs7HENEw6jmmFSOororyyG75aozWZVckZqQdNGSRmmjI6VbaEgniojGR60jN0+o1ZXHepoLxkbnPWoStRkY6UWTFaUTpLS4jmTP8Q64PUUjSSISQxIrAglkhcNGcH0PQ1fGrN/HCp9cGps1sLmtuaK3UjHBBPapIpdrbtvzD1FZseqx7vmgwPY1Z/tS2K9WHsRReS6D50y9LcLIwbHzdziq8twhXHeqMuoxH/Vhj+lRm+j3ZWEfic07sOZBNKCxw2aarbm6Z70pnhkP7yHafVTRH5QICzlQegI6UB7RF1JUEa9MjiqNxMSev/wBeppbd9gZH3jsR0qgXIJDDn1oFGSHh6kWQ5AzUKuCOcU5WGRTHzItxuc5B5qxCx3cH86qxKG5B4qwgIIzQaRkX7aSVTu5+laUcqy8t19Kz4ZVCHcpyOhFWIwGJ2kbjQaepLcuuxgM8CsckZI7VduSVjwTlvQVnEOWB6mkWnoPDYNWbdWfLA/ie1VQCASetWLNifbNFiZaovxrwBRSxjjnNFUc7POcUmKkwKXAroufO8rGKpFOAp4FGKVxqAg6Uc0Y9qeBSuaco3FOAowKXFK5pGImKcVzjFIBTyCKClAjxindqXApQMChsuNMQAE0tKBTsHpSubxgNxRinhfY1IsZJ6VNzSNMiCGpEiz71Yigy1aFpZNJIiKMs5CqPUnpRc0VOxnxQE1etrN5BhVOBXtPhv4J37XSHXLiK0tAoklZWBIU9vY1SvvCNouuwadok8skM8/lsxT5VG7A571p7KVrnPHFUZNxi72OSh8FXw8LDXXRDZeZ5Z9c1ueCPAN3r86u0Ei2qsA7Be1eya54M1ZdJh0mxkifRLYiQRnAkcgd/b2pbXxfY+HtAht7aNRdfelMg2qD/AFrZUVuzjeNqTg1S1bf3IqaT8MLHR3uryMK/kqTGZwGDYGenavPfiDp1oumWl3MtvDezEsI4k25TPpXQ+Lfi3Je6f9k0yARSOcPLzjHsDXlOo313qNw81/O88p43OcnHp9KmpWio8qOnAYTESkqtZ2MplXecDpUqqCeB2pflzUkQBPGRnFclz6FUxBEMgjHNS7QBjHNShNvakGQcnpUlxiMWM7hjp3qwqAHpTI3+bjFTNy3AOaENxBeMjoKkjwpGelRYOfpTyw3CmLlJXbJFRMoKnsaczD+HtUTPwaZPIM6Hrz7VFIeak/jHFRSK3vSuHIV5FDHBFVJosnAFXdvznJOfTFJsGfm6U0yZQMlrN2ySBimyaeWTIHT2rXZggOBmlgZSfmI57UpMycDmbqyaPPGBWe8e3tXVaiUwQOcCsSWNWJpcwvZ6GaBQy8VcaH0qGSMrTOecLFYimY9amdfaoyKpHPKI38aXJ96DSVV0YtDg5HU8U7JzUYowccHNBPNJF60vDASGG5T2qx5i3DFwgA9+ayQ1OVjng4+lJx6jUrlyYjkCP8SKSNcKACM+9Pi80ruV9wHBBq7HGrJ86rS2LU7EMZ5x2qeOXjnn0qORAP8AVsD7GogxQkMh5HBz096ls1hJGrbSKXAc4BrVkjVY8xAAmuTWV15zyKvxajIoA6kepoudC1LM7FQ2ODVFXw1JcXLSHOMZqvEcvyeKSLdi75gxip7M4yT61TGSwVRkk4A9a3LnTrfTtUhs7m9LBcfanjjz5LdSoH8WOKuxLl0HbXQ7ZEZGwDhlIPP1oq3qkM9vqbx3Vx9pIRCk2c70IG0/lRQZJ3VzzXA9KAKdigCtbnjqDG4pce1OxRii5SgJ+FLSgGnBM9qVzRU+43FAqXaRxik2+ooZapjMelGCT15qXZ7UojJPSpuaKmRhaeEJNTrF7VMsR9KXMbRpFdIvT86na2YAM67A3I96mji5A21ahhLkgg+mTSuaxp6lGOAntVhbf261pW1qOlTvCFACgc96DRRMtI8HgCrKsYtpU4YcipfJzIMdKZJGfNwR0ovZG6pJ6HfW3j3VJfC0ukyXUhdgse9uS6DsTXYfBfw/f6hqhvrkzxW1sytlv4j1wK8ZgzuUe9d5p3jnW7HQotKs7n7Pbxk/NGMO2fU1cKmt5PY5MVgZKm4YdJOTPojx14ij8O6BcXMgHnN+7hTPLk96+WtS1G41C7kkuJGbJJ68Cr+qavf6tiXULqW4dRwZGJxWO69x171VWo57E5blqw0W5ayZCQd4xjApGPzP7ipMZqOTqKwPZjAYnOcgAVZgRcD61XUEcEHFTI3zjnAFFzRwLWzGcZPeo5unIqwHXBAOcjtVeZwOP1pOxEUyBW+bpVxeVGPSs5TmXOeKkE/OATmknY1cCwz4569jTWJ6joaiaQDGDUUlySuMY96Lgok/m56Zp8fJ+tUYpAzd8VfgzkEdKFqKUbIcoO4A0sq4q2ixsBn71MuIwMn0qrGPNqZ8p5wBmmeYoOGGSauLGDn1xVGaMgkj6UtUPR6Fa8cZPpUdqxkODwPWqty7FiD1pkLtGeuamTKUdCa9YElV6AVTC56DvV2C3kupVRFyxPGK6a08LukQd+cjt2rJyOetUhTXvM5OK2DckVFc2hJwg7V3p0Dau0Nz6leoqjPpaIf9sUvatdDzZYiLehwNxaunXpVF0wa7q+047SuOOtc1qFi0Wcirp1UyebmMYikxzUrJg00rityXG5GVx3opWpMVSdzOSBsE5oHXmg0HpVIxaaJoJTG2VPHpWiJN6qePfFY9SRSMpyM4qWhc66msCrHNAIzgjBFVIrkEY71aVhIMj71S1Y0ixkiDkr+VQLu3cVbK7hULhgBjjmkbwmxTkLg9fakRDjNS7AMlSSPcd6YDkUG6dyRMgA7sH1rvorOfUvLvdQ8MXMtzIoLSR3AiWbj7zKeRn2rz+OTY6njIIIz0/Gu01e2tdS1WW9TxFYL52GMbSP8AIcD5Rx09KuJnU6f8H9CHWGu31eU6hALefaoEI6Rrj5QPbFFU3iW3vGjS5iulUA+dESVOR059KKTGttDhMCl289aft9qcFz2rS5xqFiPbS7eOKnSMntUqw8cmlctRKyqe5qaNRnnpUqxe/FTRw+1TctQIHj5z60LCT1q8keQBUqW+SQOaLlqBQWHIp6Q8itFYNp5HFKIe2O9S2bRiUli5GKmSLnmrbRAKc9fSnQx57YFJM2jTG29vlxxmtAQrEpbFCxhVDKOamVWcEYGCcU2y+Qp+cNxVOoPpTBMW2h+DntV37Eqybh96hrUMfu9Km7NYxgFvDzzzzUc0WHyK0IYsdcio5YgGJHenfQuFuYz41AbAOMe1aKY2gDg1UIwcdgasxEHFSjocbotDIUDqKay9eaGfA61GrbiRnNU2TGFwICj1zUSZZ8beKJgwO4A4J4JqzZwFnB6DvUNmqSSuKkTMMKuR61SuwYn2Dr3rpYWjjAj2j8aztTs0LGQMM+lJsiE7yszIEmwdT0pBNuG3nNOlGMqag2kHC9aVzp5USorH7o4o8o55NTxOqgBzipEKvLtVc+9HMiG2issW44zzUcsZUnPFaP2U+Zz36e1Sy2ihPm6epqiPaJGOqYGRUhumjA/lViS3AJ2Nz6VFsAUlxzQPmTLlpI0ihulSsw2nd1qrbSDBVeSewFR3DPg5PHWnzWRg43ZKbtEGM1XmvY9pxyTUA2qOQPy61BsyckfKO1JyK5EVJAd5b1p0MMk0oRBkk1YEQaQHacmux8NaJhhKygu2Ao7nNc9SpYitWjRjzSLvhPw7HEqyznMnTr0rsJ4o1iVVIAA596ln0R9Dj26jHIt0+CirygHoT61RRSxJP3fQVrCXJGzWp8tiK0sRPnvdFKRWO4EBs+lZ8+ns7McbQeK3vbAxTim7AY/J71m7PYzTscjd6c6x4bB4+U1gX+mCZHyOR0rvrqMOWU8helZEsAO4FcN3rPl97Q3jUaR5Ff2phmZSCMVQdcZya7TxNZbHLqv04rkJkwTkc12U5XR1RlzIrYFIwAqQqeuKYRmtAaGYpCKfjbQEyaaZlJaDQOtAGeKmEfyg4NN2/NwKq6ORrUrtw3HWrFvOQcNUUqYNR9Oc090QpOL0NyCTdjvTZuv9KzLa4aMgirjXCvyrc+hrJqx2wmnqKH6/ypynpg5qAMCSAetJzk8Gg6FI2dJ1JdPaVjZWd2XwMXKbgv0rVj8SKf8AmCaOOf8Angf8a5ePJUcipA/B54ouynGL1Z0X2v7bdTXH2eG3yAvlwrtQYHUD3oqQxWkaJ9kuvObC7l8ooBxzg559KKZPN2ONC5qZI/apTHzkCpEz/do5gUCMJjp19qmRODwKMZ56U+NCxx3pXKVMQR5XI6VOEwmKIVbfjHTir5hJHA4oLUSlGuGFXUXv+lAgIPtU6RlFB7UGigATHPanxxYfphetSqQVHHFTIBlsdMcVLY1Ez5UDS8HpU8aqgyee1M8omQkcYPSrSwHenHFCOqy2Y+JFA7kGp0gAOV6Gk2BVAzgnNSQqz/Kp5FO9iGhSgHvUqRgjOOahkimLYVcircCuSAUODU+0RD0VxqxYbGDVe6XpW/DZ7kzio7jS2YZ/Hiqck0ZxrxUtTkrg7e1LbMOecnPSr+oWLq33WA9xVKK2YOf51jzanqU5xlG6ZLye1Pt2COCBzmlit5WYjoAeuafLstgSw3EdeelDnYtWeiL13dveQW0cr/u7cFY1KgYBOe3Wo/ORAFXpjrXPXGouGJHY0W2qKWAdaiUmy44eysjohJkgqdxAzk01JN7ln57iq1tcRvkgcVciWLmpT7mcly9CCdI3ydtVpESOPOAKsz3Ma7lVeAOtYt5fE8EELnjIq3LojSEWxZVBUsT05qzpTHknv0NZP2ou2FHbBzWhYy4RQQV+tRqjSS0sdAkilcnrTyiSp877R3FZttIBJz+Aq3LgpgjpVqdtzzqisxk1pbjGzJNRy2SlDtXnFWLF180qynnvVs7ScZzmtLpmcqkouxhwRPA5MZ+c96rzh1zkZb3rbuPKiyVHbrXP3Fyd+ccZqJG9KTnqQbyCQ3UGnKjsucc54FNRfNk3Hj6VoRRdB2rNs2bsTaVZCS4XPTvXo2iabJMu4Z2wgHcO3p+tcx4fgRm27ct7+teieHreVgIFwYSQ0ik4yPrWULTnrqeDmdZ7I1dYs7uXSYrrU9T+0FV3JCeGBPH4iucVQEI2g7u/pXReLtRiv5bUQRmOGFPLXLAlsdziufwW4Pat60lzWieNRTUPeINoHT8qk2AxnoDSMp4Panb96kgAHFc6na9zVopSJjNZdxgFi4/KtmTkZ9azLuMZDYqOYuKOW1uJWgPGSe1ed3kZEzjFeka2Qqv8vAJ5rgp03yMV7nNdtF8x00k0ZLx/WozHzV9lzQYcDIroNZbGcFOeanSI44FTCAjHHFathYl8DHJ/Sk3Y56kkldmY0JVAAOagMZJzjFdBdWZjAyvzCqTwYUkjjvUc5zNpmJdr8oqp29q1tRi2QAjPJrLI4reEromSI92w5p6sCcjpUUh4x2qolzslwfuZ/KteW5h7XklqbVvIuQHXNWJ0UKGi3DNZyMCAVPB6Vcgm2jDZxWLVjup1Ljo+SoY4BIBb0969DbTIdJuNSvLfS4sQeVaackiGQTu3Jk5+8cV55GvmShIhksQADXoEthZ2NjMhnv5rrSpoVeQzbVG7lhGvbA4zRE0m9UQ+ILaK11qSOOJYSY0eSNekchUFlH0Paio9Zsls9TeKGSSWORVmjd+WZXGRu9+aKT3OimrxRzBkbHSnxsDgEdacsEo4IyP5U9ECsA4wahNGqZGyEZ44ptv1Ibt0q/LAWjBU/LWe2RJxTkbU9S/CucHvnBrVRVEYHesqy+dxt4PfNbQQ7c+n60os0lGwkMe45IGBUhQE4xU0UZMWRimOuDlcCrJRXkTZxTT2AqWQ8jPPrUNyfLXcKzZrBaklvDmUZJNaLKIkGeefyrFtrlzKAMYq69wd4DtxT5rIqUHce+HY4qxZwzNIqIuTU+mWE9yC0Me5R3Peus8P6WWjJkQqO+RzWPNKUrROaviY0kzPtdPkZUYMWJHIUZq6LBoiD5TMfQCuohhjijKxADNRykCQdCTWyw9lds8aWMcnsVLLTjIgO3b7Gr6WCD76AKD1qz5qiNAiHIPzNnr/AIUrOZIieoPrXRGlFI43Wk9tDPv9LtZom2oGGOtcddaRbrIdoIHTiuzkDQREqCSP1rlZX/0qSRhjB4WuTEKMbM9DBVppuzMqW3S3yozkdaw9QZFD4PI65712M8CXSiUDnHNc/qWnBtxUnGMYrnb1PfwleLeu5wsuS7dueBUQ4Occ1fvbZreZhIp9jiqjKG6VR7CkWLW5ZOM4Hersd5sGVc5PqayF46jvU7NuUAdaTSBpPc0zceYegx3qC8XeoYkAdqqI5HXJqRnIxu5HYUWJ2K6BlYEce5rTs1uZztjGUY4J96pqslxMiIvzE9vSu70fTTGkK7QAOpNKUrHLia6prUbpejmGFC2WkPOT0rTk0wyj7pz2IroLaGKBFJ+YgcZFW4Q7fPGuF9MVSp3Wp87VxsnJs4W70yaEEqTjuBVOGRMkMxHOMN1Br0a4tI7iMgja35ZrmNd0QpkFCOMhh3FJpw9DWhi4z92ZyesXXkQkAcniufjZCh3Bmc9Oa6G405cqsgJLcKc96jGjPEQZBtB6dzTu2evSq04xtcq2VuxKlRk9auYMbMXP3euKkJ2w+XbKQe7HvV/S7VryVbcoBkHeR3qZIU6unM9jf8KWgVI5bhSyud2F6kV6RptrGbyAXG2OO4yrhTjaMcVgaTpDxxRiFQYwgwew9q2pZD9iUArwdvXmjD+5dyPlMbV9tO6Mm8hW3uZoijgKxUKx5p1lGrSYx7ZNSTKzgM2WLdSeTUsURC/KCBjk+lTFXkZuWmpQvYwjEgZHpVcRh4uODmtCWGRl55qsY8NnPsaipH3ti4S03M+T5QQM/wCFV51UxnjNaVwm1G45I496zZgQCKzs4s1Tuc54jsC1lP5Zw4XePcV59aoTb7iOvWvUNSbbaXDsclUrzS1ZfJb/AHuK7cO1c6aV3F3KjxbmphgIbvxVpvuv0461YtLcswAU+9bymooc5WK1rZlmG4cDkV0emWjRksyHGOprW8P6I1xC8iwPIsY3NtGdo9TXTf2dFHZxy7ozuByoPI+tKnBz95nmYivd2RwOoW5cliOOgrOuLfCEAV0uoFTKQOgrKuUyOKwmtQizmdStwbQnHTNcw/A5r0GaDfEU29a841V/InkjB6MRXRhtdAqT5VcqXc3ULWfk5zU0h3NUBOCa9GKsebKV2W7C6MbbHOUP6VtJ81cwOT9K3dMlMke1jyOn0rOrHqjswtXXlZrW6BWUjrkd69ZtYNUe0ZL7QbW6mn2M8huQnnFR8rEA8n6da8othh1JG4Z5B7+1dzeJZarfPfwa5aW8Mm0+VOWWSDAxtAHXGOMVzR0PTfvW/wCD+hNr1nqYuWvtTh2eYwUlCCqEDheDxwOlFWdQ1SyntdZmiuC32oRQxxEHc5TGZWHbNFTLfQ6qXw2kjPa1UqMJ+NUrqwO3Kj9K6+ax2KQVKkcdKpSwqEwetcvK0cMKzRxbiaJcAHFVivzfN36V1F1bgMRt5Hes2axDZKg5HTFVzs9GjiYvcoW7BJB1zW9byq8YHp1rG2eTg49jxV60L5wvfkVpE7ZPmVzXVgCADwaJiq9cc1RcvH1JHtUbuzcsSau7JjDW44kmQZ6ZqLUMtEcVMrZTpzVK5nLMRjioZtFXYy3+VlZuK1NLtHvrjzCCI16A96zYlZ5ECkgEgGvTdGt0i0tJUi6g7iayd5aGOLxHsoq27Lei/JGsaKuzAzxWlPcLBKTFwCOQTWXauIVbGADUa7pHJJLelXGpypI8GUOZuTNEXjOAB1P6U/fLKFAJPOOlR2GmyyqX2HA6V02n2hWEBlG7ue9aQm56GM3GBnQRSYUFj15Aq3GsgHzKD9K044A3yxjocE1K+nvG7O6MqIdpbsDWzlK10czknuVXsZHtftLRKIc7Qdwyfwrnr/QhLOVtkdncZ2gZJ+ld8mmstok+UiBXI81uT7gVRMT+YjhvLOfvg4I96Jxcl7wqVZw1iebS2s9i7LNGyjuGGCPwrOukDkg/ka9b12WPUdNMOowxzSjhJwMMPr615xfWkcdwyL1A71xVqfs3o9D18Fiuf4lqcXq1nHcRlWGGHQ1ytzZyRvheR0zXoN7bnzORwa5nVLQiVtpwvXFZKR9Phq3NozGsrNpSTjK097MRucDA9TW5oiDysMVHfFaNxYRzQNtBye9VuazxHJLlZxMyohGOSaIIhM2OcVp3unOHARARnqau6TYEOvyhueeOKmU7K5pKpFK5a0HR9uyZs5HQV3ulWMkxyi5x0zVfRtOaSRQE/dg812cMDW0J2AKo4z6U6cL+9I+Wx+McpWRVttJVMGfOPUdK2dO0x7whbaFjD3c8KPxq82izxaUtzdFs7t2wcBV9T9anMl1PboskipABxGg2jH4V3wjZ7Hg1KzlqmZl/pUMKlRIkkg4Ij6D8ayZY1yIrhQyjoSK6m5iVIFYgYIzwa5/UWWQKsYx6061ohSm2eYeK4UsdRMiZEO7J9qozzPLHlyFVzgA12HjnTfN0WWcA+YvXjqK5XS7Y3EVozoxwPmPbNcVO92j6LD1oumn2IVt13CKMZJO5mI/QV0vh20EcjHHzvwPYURaY5jEqj5V4HHWuj0bTvsseWXMp6k9vYVNRS5rGWIxScLJmvZRs5ht0VmBOMA4+tO1GCGO7ZYnHl4+XPJq9odgLm7HnkpEi7mx6e/tUOsQJHqUkUSIAuAAhJGfxrScZez1PFU1z2KK2soVTtwvbjr7ip1KoAGOR6VbEjJHsbIZRjae1RyGI53AdMdaOXkfuhzX3KTqkjsIydv8AI1VmjIDEjkVfZEUcdaidgv3gCKTXcpPsYc5OCGzyOKzZweQa3ZVWZuNuQMgZrG1L5W+7gmuaatqdNOV9DHvV3Iy9Q3BFeYSRCG+nhAIVHIFemzZMoP8AD61w+tQoutXDKuAxBxVYeerOynLlTuUYoCSq8Ek5/Cun0rS2kxtHA7mq2iWBkkDMvfivQ9HtY4osygKo6iupU/a7vQ4cRXtoibw5s0u0u43eQSTRlBsOBz6+orE1KVgzRRtkDuK3NVkt2vX+wq627YChzlvcmq32NGPuea2atHlicSd3zM5Y2LEb2BI5qqdP3DOMgc811N/EII96jI6EVks/7hmK8ngVztWep0RelzmtQjVIm28EV5LrsbDU5lA6nIr2DUEzEwxkmvKdUUpqM4fJYNitsLL32RWV42MX7PIBnacVF5ZGdymtoS8geWSfWrCQB+qc12+0Zh7KLWjOa2n+6a0dNDLL0I71qy2igZ24pxshHZR3PmxkM+zywfnHvj0ocrqwQhyyTL1qFZgH4U4yfQd69MmvJbNtXgtdMtAtgsUlsptwxli4DHP8Wc5yK8xsiryouQCxABPvXczf2boupiB77WWvbRRF50TqoAxnauf4eaw2PWjaVir4sDf2/I5wvmRROIwoXywVB24Hp0oqpeeVc6hJPbPcSxvglrggyFu+SKKye56FO6ike26hpcmtS3WpyXNjatJIQ8Mj7SCPbHSuS1GwNvO8bMrlDjchyp+hr0Ozu7WK9UanYxTJ5xleT+M8dM9xnnFYOvJDPdyyW8QijdiUj/uisrprXc+fhJp26HEXNqrf6skjHOfWsu7smJG3qOcjtXq0NlobeF/LEUjawzBmdhgL7D2xXLXmlv8AeRTyegqpUZcqkjWnXV7HASx/OUlAz396uWUCgAnB9PatbW9OgjsomAlGoCRhIpA2hP4SD69awGkMLHBIXr9KiF4OzPXw9fnVi1fHdnOM9KoICMgHI96c1xvBGahXJYgd63vc74aIuRIznC4JqSawxywAIpLZWjlXaeorWiiWZC7E7hVKmpIznUcHoZFnFuu0TvnpXq8cKW2jFF5O2vOraMJqdrIRx5gBrvdTdxAiqTtPBNYxXI5Nnn5hJzcTNijaQhEyc81fht2WIqBg+p7mn2kCjGxipHIrRhjdXRwAwXnmuSdJ2Ob2iua2nqbSFBLICoHIqa41EA/u0KjtVFpDJIWbgY7etTQ2jSIZJGRApB+Y8sPamq7h7sDncFJ80ixZ34cvF9llmlcYTYcAH1rWtF1C4sVgkUrbxvluMnJ9as+ELVZbpiwcbBwV4Irp/wCy7RZpMB97fMV3n+Vd2HhUnBSbOKvVhGVkjDn8PyrbGZpTlVztxk1ENNMkQe0kWVSMlGOHX8K6ExS3dsE/eROODnhePasnUbB9PmFxFKCzA4BX25ronHl1S0MITctLnN3sYZXGCB6H1ridWjImYFNueldvPICBjPvnua5fUh5s5DAYzXk4yolqevg009Tmmw6tHJ/rO1clryyJG6RqzOx4wOldxfWpV1k9D19qytYVY7UyqMsOmKwhK+p7uEr8skc1o1kywq0wIc1sW2OUb161F5oIUsOCMHHapbaUGUBQAK3i9Drqzcrtjzp29ioG7PIJrZtdOGI0jTlew9ataJB5rlnHSu98J2tgt9NKWdQBhUOPTk5rSlh/avU8bF4901ZdDO0axeKKOEIXlcZAUc1oWqPcNJCi52Hkn+DFaVtcxWL3vlQ7bh/ljY/wKaktLqOGELFCBJnlvUV1ckbJXPFlVk25WK2JjzcSPMV4G5s05Lho3BypPbNJ+8eRgoIUcsO+KlvoYYZcRMSdvRhgg0K+6M32ZnXt4WkIUcHnGelUAN7dakveJgxB5NQsSDkVySqNy1OiMUloV9RjEkDxNyrDbj615zY3yWs76eB88ZIbI9+K9KnYGIt1OK4PVbMw+LFeSLKXMYZGXpuHXNLmalodmGkrOMjrfDtvNcW6+dgR4zgDvXT21mqnMvPHArO0tPLSKFSCMc1vptVCCOhGSewFddOCerPPr1G3oa1pA0FgZEthIvlEk4wz5/h9xWLc2SPp899FsRfMChMnK+wNdbpkmNMUhkDKCcE52g9Aa53VrOO1s/MkkKXMjbmhH3Bmt60LxOSnP3jm2djIGb5wDkhj9761FNJv3EqEOcgDt7VMQDnJ461DIOK8hpo9FNMryuQAcniq8kjN34qxKBtOaqAfKR71lrc1RXlLA8cA1l37lwMk8VrTAjpjisW9PXtzUzNqaKIXdIvcgbsVyVxbtNq07Med2MeldcJHSU+UDuVSeBWDaASXjuxzlya1oodSVro6LS9NMcCngcda6TTFRRHI4JCnPQHke1U9FmFv5ZdUkQngOMj6V0VqbU3N5dMyWhVC0Uarlcn+EV69KEbHk1JO+pztyhaYscHcc5AxTkG1B83NWpmV3LNjB5qq+0kn/IqGkmCd0U70F49vJwaoXMarEBg9OtakzhAQeSTWTfyDGCeKxnZas3hfY5+8UeYR6GvOPEtuo1iVlH3+SPSvSLk/OxPHGa4XV4zca86x5YtgAe9Rh3aV0azWhjwWZbBxWnFabUGAKu29rzjGMVe8gBRxzXVzNnO2c9dwsBziqEsT5ChTluBXR3NqzsdwNUbuBgijHKdMVUX3GmZ9pC25d/8AewQOT15r1LVP7TS5CWeg289oiKsLyWpkZkwMZYnOfrXC+H7ayup5f7Qvfse3BXERfefw6V2UUdkjHHim757eW/H603odcHt/wTE1Bpv7Qc3lqlpNgZiSPywBjg47Zoo1QImpP5V494hAxM4IJ46c+lFZN6nrUleKPfby3UsRtbHTnrWULZNsgaNid3DE8Y9K2ZWznJyTVF5VXzAepGKxrNXUj5qne1jJmdQVEeQRweetToB5QDDjrzVWYlWbGOOah+0OwO44I711RqWG4XKniGGOWEKoBbOQa821WF45mA7civQNSm5Yocn3ri9bKtk981zVpXlc78I3DQxo5Mg5GfarMZTjJO73FZrSbSW9OKVJQ0mRn6Zq4M9mM7m7blcE9TVxJ2BIzgVjpciMA5HSp475HHUZrZSRMtdzSkmG0MDhwc13XnfadPg6HcAa8vuJSY9yjmu28I3rXWlR7iMqdpBrmquzObEx0T7HWafCeCRk46VdYMxCoCBUUbkQgICCcCtCJCduTyBWFWeqgjzPNjkg6HP4VajjUA7gc9qSMc1YCdz1FZKCTuiHJ9TZ0G4dZhJGz+fgKUVMhlHTP+NdVsMi+bHhZ8hiC3B9j7VyWnTmBopGIaGM8cY25966HR50W0lm3iQGQs5HUV62GdlynnV1rzGlNcLFjf3HbmqTXjSSvsaNoxxgryTjrVfVbgLHleQ4ypJ6isWN2GW3YOfWtp1UnZEQp3V2VfEp3XYZQoXb2XFcndRbp8n0rr9QkUw4nYYzkHvXOSpH5zGNi654YjrXkYmClO56eGk4xsZssCujKQK5vULY+XKhA74FdkyA9BWffW6n5ioznmspU9NDtoVnGR5/PB+5WQDgDn61BEsnmoVA9SPauh8RWhisXeIcew6VQ8MQ/aw2fm2HlqFdKx6yxKcHM7XwpaAwBrknbnJ29cV0Nm32O9DwHDBvlyM1DottGbVAMYA5rQ8qFMlQN3rXbRTUE0fN16nNN3JjE6SebdB8yfNuP8VSXMTJs5TLAH5W9egNQSz3N6EVneQJwoA6CpI7YYjLNyeWBH6Vbd9IowV1q2OW18t8uxMoJGDyPzqK9lMb7QCT6mrzARRBsBfQVk3LlpGLHrRNKEbLccPeZVvnDbCfvZFQtyMcVPPhtmf4ccVC2CcflXFLWR0x0RVcnDrWLq0KtcW0pH3GwPbNa1x98jn61QvTmHkElSDUS7m0DXtlbYsgPOO1bET7LcvkknrmsKyuPNtgAMY4rajlh8phLuwV4xxz2ruptdDjqpktzdbbO3SJ3DjJcAYHXj61Bdahc3MKRzysyJ0BqvNOxhSMkEBien9agLHuaU5PuEYpD29qY5NJv460x3yOuK5mapEUx4YZ5NVhgrT3aqoYiPGeRWNrM2Wwk5wT9Kxbw85PArRmky3oKxtQf92Tn1qZLqb09wsdQ+xGZlVSXG0sRkqO+K5vTg3nsuON56/Wr4kAVlPUiqFjNtuGOOdxHFaUm7JEVlZ3O603ZJAqNj24q6GyTHuxs4OT1qtoMlkllc/a1drkr+5CngN6mmRnczEmvUivdVjzG7yYTtlyQeKrFmDZBI9qlkbPA4I61Unf0rnnvc1iR3UxAJY5NZM7lifzqxctnqapu3zHjoKyabNYtIpXowOR1rh9VG3VnYd8V3F7904x92uK1QbtZYdgFq6Ssxy2NKxQuoGK2oLUEA4qppMXyrxXRQQ4xnFdUY3OWTMeez384rLurPAIwK66SMYxgGqFzCu77taOIlI5TSdDvLy6lFlEJPLILZYLj8zXQr4Z1bA/0Zfr5qf41m3FrvusD5cnA5rq5NP0O0S/R7W6lNiY1lfzsb93BYDtg0nC6OynNo5DVLKe0uDBcpslTBKgg4yPaitbxBaRW+pOlpEUgKI8fJO5SuQee5orFx1PUp1Xyo9okOazbxTt3AVdZs81XmIxxj3qJ0+ZWZ8/BtMw7nIyQOtZdxOUfLZP41q3bbDg9+lYN6wzxg1i3bQ6oq5Wu5vMDP0PpXE+J7o+UQDgluorpr2XCsFrzzxvdtBHB5Zw7Mc0QTnJROhSVJc72KgunXoSakgvAGGetcwb6YqBv/HFJ9qmbkyH8K7/AGDF/aMVsjsRcg8npSi4I+7XJx306fx/nUo1Kc9xUewkbrM6dtUdT5spGc49s12vw5uWM08DHOMOMH14ryE30x/jx9K6X4d6rJZ+KLTcxKTN5TZPr0qKlB8rZE8whU91I+kbcfdHUitJABjOc1mwOFIY+mKuwybzwTXFvJs5JJl6FQXAP51c8kKm7JPtVW3wCMda0QRgAZ5rohBW1OeTdy1bBfKVGdWi9x3p8lpLA2c7YmHGCOarxTwSymLJUDliDjn096k1GDaI9tw8xb5QpYYH5Vtpy3WplbXVhJc2xRGWR2PQgjpWdfamsUTC1SRpD91ivy5rrNIsbmK0G8QhiBgbRxSX2l3M55kUgHIAAABrR0Zyje9iVVgpWPOLn7Y0ub0SK/XaRinpwq/MCT146V0WpqsDssmXcHknnmswMknauN4Xlludaq8y0RWePy3KMQSOuKilg3xnirtyVzGBxgdfWoySu3IIH8/emqa1QKXU5rXYh/ZpBALY2kfWmaQ9nb6TGljbeXOI/LuHzkSnPBHpWrqkKyZGMqw6Vl6XAiyzRZ4QhuOxrOPNGVkdakpUzo9Lfy4SdhDA4Iz1q6LlQf3ke4d1ziqdiNykD659amVQWAz16+tbptRsjjdmzT00BdsiZR8c4OefWti0hFxOMknJrEtZFj4UZJrpNBiLNvxxnOa6aKvuctbRXKviG0aGFGBG30Fc1Iec11Piy5wqwgsOM47GuTZsk1GIS5iqF+XUjlG7OOKrt2qeRsqapljniuGS1OyOxUuz8xFULp/3TgYztzVu7cl+mAazblv9YAcYU81lKJtE1tDkVownfNaUrgHbnI9a5/QJCIyRyeorWlk+XoM59a6KTvAxqr32Okk5A7UEgVBvBUAZznk0/qc4p2JHbqjdhmkkbHXAqNmUDJNS4MpMZIcHuaqO4AckVYnO08nr0qlcsFTJ6GspRuaxZUmk64PAFY99LlCv/Aa0ZnGxmHSsW8Yhxg8s2KzaOmm9SF2xu21naSPMnLN/fyRVqZuSFP1qlo7lZST64rWlHVGOJZ2ttds1ssIIEYYydBknGOtKsh7+tZ0LYI5PFW0PBJxXqWujzL2ZOZByaikkBzg4FQSSEdKrSS4T3NZukUpi3LdMMM+9UZcBx6U6SYbCe4rOubo4Hc1lKNjWMr7DNRmG8gdOlchKwl1adv8Aax+VbGozEkk8CuahmBvpTnGXP86UFa7NHsdxpC5Ra6GDhRXL6RIAF5FdDHOoXLECt4SMJItMBVa4xjJxQ1wo5yDisfUdSEfAbvVuaQlAiuBm4I659K35Zrm21WJL97JnmhWK4DjKbe3mY/i6c1x6XkjytIgYhMEsBkLzxmuslFnqNw11d2erQTyDMscUG5XOOSD2zTvpodlNW3IdXWZ9Tm+2hFmAUAR/cC4+Xb7YxRVLUb159YYyQPbrtVI4n6qgGFz+FFZvc7oRaij1d5QF6VVlk4zxXKz+NLNOUYEVmXHjJHz5YzXJLEReyPLjhpHSanMu0HjOa5y8uBk4IrKuNca4JLHiqb3wY9a53JydzuhR5VYsXk2Vbn2yBXmvjW4EmoJGpyIxz9a7ttSls7e5uYsbEXDMRnGfT3rye/uWubqSV/vOxNd2Ep+9zHPjJKMOQr55p61DmpUNeizzESU5aavShTz1pFEg61e01yl7AyNtYSLhvTmqIOalXgjFZyV1YqO9z6ltZGKR5cOMDkHIPFbVnJwcnFfM3hXxRfaBfJNE7TRdHgdjtYf0r1Ow+KWjzBRLb3UMrHGNoYZ+ua8t0JUpN7o7+dVFY9Zhl4BPSnz34C+XGf3p7g9K89/4TiyY7U81Md2WrFl4jtPM3G5TJ65OKh1+iRX1WW7R6La3JWLYrAHuTzmrenFjfwKQOcEe4rkrDVba6UCO5Td/d3jJreh1AQSwPAw3IoAx6966qVRaXOSpSauelPLHCgMjKo9zVIatbtNsGdv96uIn1F5cl3LE8kk1Et0oBIYk4rs+sR6HIsO92b3iZbWRTLBMpL/eQHv61yJYo3ykZzVxnLqxJyBVKQAGuatPmfMjppQ5VYmEwPBpjyHd8xJHuahJ5460rf6r5QCwNYptmjSIrs5Xj+EcVkRrBa6lcTSXPltKqhISpPmevPbFakjfuSD61gakytOjsPmRvlxWVR2dzopapo6SO5iQDa2Nw4AqWCfzH7ZrnrR92CTWrG4CqwPIppNO5k0r2N7S8PcqGJA6V6LZxrBaxqvQDNeV2txskV8dDXZXWvxyWKpDu3lAD7GvQw01y3Zw4mD5ij4vuo5byMRHO1efrXOs2RjvS3MjSSFmOSaiVGbpmsakuZ3NqceVJCO3ByaqSElCfWrExRBiV1Qf7RxWPqPiLRrEYnvYmI/hj+c/pXPbudKTeyJLsERr6k1lXsuzzCOcLVC58X21w+23hbZ13vx+lUpNXjuA6hgC/TnpWMpI6IwktzodEuTnnjf1wK1fM578muc06a3hMZkuoUUHnLgVrHW9ChUtPqdsmP8ApoK0omNWOtzQLbXK9eeaV5SmSDiueuvHng+2lZ5NTads/dhjLVlah8YtCiBSz0u5ufQvhAf511JLojBqR108nyhjk5NJDbTzuPl2qehNeW3vxlvpG/0XR7CFB0DEsaz7j4veIZMeVHZwH1WPP86dm9kCTPaLmxMsg3OwwMYAqlc2IyAS5wK8Ju/iD4nuXLNqsqZ/55gKKz7vxZr11E0c+rXboeoD4zWXsZs0UrHutxHbxhkeaNe/MgHFcRq3iTS4rjbCs06ITmSMZXPsa8oM8jElpHYnqSc0q3UyR+WkrCM/w54oWG7s0Va2yPQbzxNaKo8qJw7Djd0rOj8QTwv+4t4yCertya4uSWR1wzsfxqANLkBnYgdOa0hQjHUzqVXLc9ej8Y20Ck3dq2B1eKQMCfpWhYeNdDmXEsskB7eYOteMQsV6DJHarPmSSdCB7VpqiVSUj2W58TeHxHn+0Yievy5JrFv/ABppCZFsLi6OP4Ex/OvPobZpkYm7hTALYc4z7CqXnOrfK7cUc12L2COqu/Feo3D/AOi2Plx+jfMaktH8R6kyiC2UE9Nydq5WPULmMgxzMMe9amm+K9W06TzLa5dWxyc9qiUZ9EjRQgkW7y28SZb90kyxnDBF6ViFp4ZB9qikibpyveuhk8eXs0PlypbqxOS6phj9TWU+sTTMT58bKeqtUx51vFGkVDuaenakERSWFbNvqSyAHP05rlYbyzJ/fwqh9Y24pJdRsrcHyn4PqelFn2InTW6kjrrnUAiff4HauT1rVWAd1bgdPrWRPrkYBC+Y59SayLu9e5PICp6CtoUm3dnO6iitDRs9cv45GjEz+XMQJEX+LByOO9ewR3sFvci0ufFWpLcIFMi+UT5ZIBwx3dRmvDbEH7QrA4K8g+hr2LQrI6tcR6jqPh+YXdwoZil2sS3BAHzeW3PPt1rSUVeyLoTe8jS8QaZgz3UeoS3lxa7DN5q4ba33WBzyOlFW7i7eWO+jmtPKurhljkycCONOkYH9aKxktdD1qUny6nmIuVyAO/rUglZTnjHsc1RSNi5Co5PXgGn7XHTPPauZxIuX0u23Db0NTNK4AJFZyMUwCMGpQ5J5P4VDgNNDdaupW0q4iQkKfmYDviuFGS1d/d4i0u7kkTKNGVyfU1wpGDXdhnZM8zG6yQzZTlTAqQDJ9qcF4ro5jlUSEg9BQqMe1TeXk1Ki4pOQ1EjjU1MB7UoWngCouWoiLwakVjmm4xS4pNlpG7aa+6IEuU37RhWXr+NXoNdtpDhy8Te/Irk6fisXQg9TphiqkdDqxrNt5g23Dgjvgit3RvHtzpLKI74TQ5GY5BuB9vavN8n1pQcVH1eJUsVJ7pH0VpHxM0a+wlyrWzHqwO4V0R8V6BGqZ1S3G8cfN/P0r5UU9KduPck/Wn7HzMW4vofW0eq6dJH5seoWrRn+ISjFUL3xPoFqT9o1ezXHUCTP8q+Wd5AwCQPrTdw61XsvMzPpOX4ieFYyf+JkG/3EJqjcfFXwzGP3b3Un+7HXzwWpN9NUkgPdbj4t6JhhFZXjZ7naK4zxf4/bU1jGkLPZkNudmI+b0Fee76Qng0eyje7KU2tEd3pPxH1K0wt4kdwg/iA2tXQRfFhVbAsGK+7CvI9pxzxTVJGcGm6MGS6jPXp/i9KgAtNNQHv5j5FVZPjFrhUiO3soyeh2E4ry1Se9Lye9CpRjogvzbnoE3xU8SufkuLeP/dhFULr4ieJ7lSr6pIo/2FC/yrjs4o3VXKg1NmfxFqc7Znu5JT6sc1Re/uTIX85tx9On5VTJz9aTFLkj2L9pLua1lrE9vuDfvAemTyKfLrdw5ygVP1rHpRU+zhe9io1Z2tc0pNVuHTazLn1xVN5nf77Fj7moTQKpRS2QOUnux+4jpSljimAetOp3BREzmg8UuKDQPlEzmjHNGOaXFFwURmOtKAKcelAFFx8o3H5UMlPxS0rj5LjI2CnkHHtTtxHQ8UYp23NFyowdhYmDOA54PGfSnXSJDxHJvpmwZpsiknpQrClB2Kv2oBmDJu9OaqvLKw4cj0Aqw8OH6UnlcVrGyOKSk9GUH8zuWNMDsOcnNaJhyKryQd+9XdGTg0QCT3J9s0ZzzTWRkbkcUA4qlYgO5xSg0YpdtAF7TCPtIyAwHOPX2r1+DRk17XH1e11OzNvLtZRLLseDAA2FfbHavItHtLq5uP8ARLaa4KY3CKMvtHvjpXrvhPR7wWgkksLlWJ/ihYH+VZVDuwuul7HUarJDPevLC3mKqJH5hGC5UAFvxopfFAEd/wCUF2HyYsrjGDtFFc0p6npRlypJHj0F7LGCYpGTIwccZB6ipPtKRp87oo9zXDG8uG486TH1pRufBdifqa0eHPOeNXRHUz6rboSA4c+i1D/bShfliYn3Nc+q81KBjiq9jFE/Wps0dQ1a4vYFgfasSnIRe596zsU4KSOlPVM1aSRk25O7EVT0FORDxTwAKkAGKTkUo3EA4pcCl47UuM1NzRREC4pcU7FABpXKUBoyTS4pwGTzRtHvQUojeKKdto20AoDaKdigUByiZNG40uCKQ0CcQzSUp4FJQJxEBpDxSnNJimQ0ApDTsUh60CYZOAM0gGDxSr+FLRcaiGKDRRmi5VhKWj8KBk0XCwYIozS49aXFIaiIKKMUUD5RccUoFJTsUXLUbgKWkpRSuaRgFFLSYpDcQoAoxS4ouLlExS0uKAKC1ETBpeKX2oANK5SjqC9OlKPSlANOFItIQD0FOKbqBnNPUjOKNiuVFWSOotnPStCSMVWZMHiqUjmqUlfQg20wpntVgKKRkquYxlS0KkkIYdKqSW+PetPZxTGUc8VSmznlSMraRwRTwvNW5Yhjio0HUEVpzGHJYm0+/vtOdzp95PbF8b/Jcrux0zXsfgrWNTl0WOSbULpm5yWkJrzjw3Y2RtdT1G/tzdR2MaMtvuKh2ZsAsRztFem+HobXUPDK3GjwG1njBeWzDFht/vITzj1FRUeh04a0ZNsnuJ5LqdpJ3aRzxuY5NFW9ahit9S8uFAieVG20dMlQSaK4ne51819T5wWPPJ6VMB6dKmkhaMDcvXkUiJXoc1zylFoFGDzUiLlqFQ1KFwKls1jEVVp4GKF6UuKg1jEDSn3oAp2KRrGIgxilwaUClFK5ooCUuKcFyakEdK5rGmRYowan2AdqNntRcv2ZBijFThBmgxg9qLh7Mh4pNtTFAO1MYUyeQYRzTaec4FNNBnKI05NJz3NOxSMMjimZNWEBzSHrRjFLigVhKTHNOP0pMc0EuIYxRTj7UgoHYSloA9qXFA0hKUD0oxS0ioxDFFLjFBFBXKJ1oxSgUYoY4wuAFLQKX8aVzWMBMClxS0o5qTRRGmjmnAcmgg5z2oE4iAUoWlzgZNO2+lA+UZgUuPel2kGjp2ouVyht70oFC/NUqLlgPXii47DNhC5NKqnNXp4RHtTesgxnI7GoggOaH5ARBecUuMVMV46UwoSDxxUgyOkK5p+0+lKBQJq5AYyDx0o2dqnK+1N6NTuQ0kVmQjrTGQ4yKuOoPao9ozirizGUSiw9ahZBmrkqgE4qFh6irTOScTW8LPq8N1JNocEs8irtlVYvMUqezr0Ir0Twzpms2VvbyJY3sUyEsCsRGCTXnHhO+utP1uCWyLFydrRjJEqnqpA65r1GCPVEVnS31KGE5Kqxc7R6Z71FR9ApX1LWqT3M188l/GYrnaoZSm3gDjiiqLStK26R2dj/ABMck0VgzdK2h4wzNKF3kkr3pdnoKcFPSnV1tnKojAuM04Cjr0p4GO1I0jATFKBz0pdvvTsUjWMBPSnAZpyrzUip7VLZ0wpkYTjrUixg4qeOIntVqK2ZiBjmlc3jBIpxQ5bpxVtLfIPrWpbacR8zdKvQ2IJJIosUrHPm29qkNrhM966BrbadoQY9aT7OApUr1osNxOaaEjjFMERzgda6Q6bKImdY2KAcsBwKom1BYtg4FNIzbT2MeWM9aheI9TWxLCFYdOP0qjcLlyKA3M1lIFJU7rjr1qFxzU3JcBhpp9qcetJVGUoDee9LinUmKLmbiJzRS496MU7j5BMelJzThS0rh7MbzS49aXBowaLj9mJilowaBx70rlqDAikp2DSgGi5p7IbS/SnbaUDtU8xap2GAUYp+2lVOKOYfIN24PrTsDIxTlBJIApwj54FK41EjA5p4TB9qdt9aUgmncHG5GyjNGO9SFTShDSuHKR807Gadtz0pyqQaB2GKvNWNoCqV696fbrzwBuxSlMZFAhijJ6VLEMk0gXJ4qxGntk07iY5Yix4xSyW2Bk5q9BGMA4qyY1IGRxSJMT7OQM4pjQjFbTwjGVFQvAMZxigVzHaMhetVH61sToVQ9OBWPKfnGPrTREmWEt5DbmYKfLHU1WJ5zUvnP5Wzc2w9s8VA5zmnEylsQScnr3qOQflUh60OuEzWpyzZ1Hwzbbe6ilvPFb6lJCotpZCB0b5lBPQkd67+2sPEaSbhPMjZ/wBY10No985rz/4f2VpJHqN/fo8sNoinyUO0uzNgZPYV2L2lrfWEt1pIkRoRmezd95Rf76nuvr6VjUeoQ2LmuTxTatK8DI42qHdBhXcD5iPbNFV9biitNS8q3XZH5Mb4znkqCaKze5cdjxvbRilzS8mum4rCKDTwKB0pyqTSbNYQuAX1p6pkU9VzUqRmobOqFNCRx5NW4YAenNLHCSK09OtNzAtwo/WpudMYKwy2tfatG0tR5gO2rsUCbRtH4YrRt7Xdt4/CrRLVivHbeZgYxirQtsDAFaMcARQMU4qFPK1ZCRlPbc8irOm6TPqF5Fa20YaVmwBnFTuvfHNPtr2SzkjmhGZUO5T6H1pLfUqaly+7udP478L6Z4W8Ow2pvJZtZuGDMithEXuCK8vmh2rwa6DW9QvdYvnu9Smaa4YAFj6CsiRB0zTnJX0MqFGUY2m7sxZ4yA3HUdazJ156YNdBcKMENgj0rMuBubgcAY+lZ3NuSxiSqd3Iqu68nFaM6c561TdcE1Nx8hX2+9Jj2zUxU4phUincXsyPFJTytAWi5Dp6jMe1LT9ppdpo5h+zRH+FGKkC0u2jmH7MjANG33qQLk0qqScUmylTI9tAUDpU3ln0p4iJxSK9mQBeKcBVkQkj5aBCc0rmigVgtOCVaFvgZJH0ppQgcCi4cpFEikkNkD6U94tucdKlj3DBHB96lCFz0JpmZSRdj5bpipi5K4RABVjyCWORT44R0/pRYRUEPy5PJNKIutaSW3GSeBSiIZ+7QJyM3yDjOTinLE3AHStdFi8tgFBPqe1QOoAIGOvXFAlIomHBoEBJJ4q0RjoM00mgVyJFCnJ7UrJ3A4z1p/FKHKx7AflJzigCNV5qzCPWocipEf1pkmpBjZnoKe8qjgEVRNwEXjpVZ5vm60iWaXncdRSNKuOazGmwOtRvcEDg0Csa+rpa/wBkxTwSYnyVkT+RFcv1k57VLLIXYbjxTrW4jiR1eJZCehPaqRkyN8ADFQH1xUspyeBioiM9auKMZyGY5yeBUc0wCEKMmknPOAflqFWPO0cVqjjlI6rwNqE+mvJLEIyJF2SRyLuSRfQit/T72WzuxcWsgjmU5BHv1GPT2rI8A2iXAnmmi85Y2SNId2BLK5wqk9hwSfpXWWt09xe3No4024jiDFIkgCCbb94Iw5BwDgnriueafMbxatYg1DUJNRvTczqiyMqqRGMLwMcCiq+owx2t4VhcvC6LLEzdSjDIz79vworN+Y7djzQrS4pR1p3augqIgFTxpnFRLVqHpSZ009iWOLnpViKD5h1pYPvir9v3qTeO46KIDHBrZtLbIGF96ow/fWt+z+6fpUnTFaD7e2wc/wAqvwIVYECoLf8A1a1bj6VcSZFhwGHpVd9wPH1qVvuimmqbuKK0ITu8sLgAAk5xzTfJL8jj61Oe1Mk/1QpFblC4RgSAPmqnKgTqeTV/+P8AOor9VWKEqoBIOcCs29TWKMd4N+WPAFUbiIKp2itif7q1l33Cj60mxJJvUxrhME1VaLAyav3H3xUcnepLaRQMJ96iePBq8e9RDofrRcTSRUKEmnGMjtUo+9T26CnchLUriOlEee1WY+lOSgqyKoi9qcIvWrfc0q9aClFWKohyelOS2PXtVpOtX7YDb0FAcqM5LUkfStCHRrl7OS5W3kaBMbpAp2qT6mrQAw3Ar0Hwi7Hw1Nblibd72LdFn5W+o6GnFczsZVqnso8yR51aaOHtJp7l2gjVT5bEcO392st423EqOB616T8SVWPXYoUAWJIPlQDCr9B2rg2+6frRJWClPnVyoIsjJ600Q98c1oADYvFJ/GfpSQ2UVj3MBjk1ZjjRZApOCRSxf65PrS/8vqfWhkpEghzxjn1qRoVHzdqtR9W+tCdDTMmQGNTHkVFKFAGOtS3HVah70xWGg5yP1qN0IGScCnj7xplx/Wgllc7jkDNNCnNSD7rUJ0FIaI2GKZIccCppKrt1/GgdgB5wKA56imSfdNRt980EkkkxxzUbSnNJJ2qJ6ZDepIZSeKCOMls+1Rp1pWp2IbB8EYpoX0pEqxF1P0pmfQLTak4add6D+H1q9JpU6aNNqb25FqX2I+cYNUm/hru/EpI+GemqDhTcdO1b043ucNaTTR5qYCy7gtQm3fGQuBWvH/qYf96n6txIccfKKzvqOyNDwNdrbefBcyNBHKVdJgu7ypUOVYjuOoPsa68eVE73GzSrQyAhrqK5MuA3DGOLqGIJxnpXn+lffetPA3Hiom7MuMbo1b+8W7vC8SlIVVY4kPUIowM+/r9aKoR9RRWRa0P/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Desquamative gingivitis with edema and hemorrhage in this patient with mucous membrane pemphigoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Irregular erosions and a blister on the mucosal surface of the lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucosal erosions on the gingiva and palate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39017=[""].join("\n");
var outline_f38_6_39017=null;
var title_f38_6_39018="The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings";
var content_f38_6_39018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     Emily P Hyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     Scott Dryden-Peterson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     John A Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/6/39018/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/6/39018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12409041\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"3 by 5\" initiative, launched by UNAIDS and WHO in 2003, was a global strategy to provide antiretroviral therapy (ART) to three million people living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    in 50 developing countries by the end of 2005. Scale-up of services has been expansive, and WHO now estimates that 8 million HIV-infected persons were receiving ART at the end of 2011. Additionally, reductions in new HIV cases, AIDS-related deaths, and overall mortality have been related to expanded access to ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Despite these achievements, only approximately one-half of the patients who are eligible for immediate ART by WHO criteria are receiving it. UNAIDS and WHO have recently set the goal of universal access with a specific target of 15 million on ART by 2015 with increased emphasis on improvements in access, efficiency, and costs (&ldquo;Treatment 2.0&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of ART on HIV infection will be discussed here. The impact of ART in resource-rich settings and general information on the global epidemic are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/12/29898?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409048\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the estimated 2.7 million new HIV infections worldwide in 2010, 1.9 million have occurred in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/3\">",
"     3",
"    </a>",
"    ]. Twenty-two million people in this region are estimated to be HIV-infected for an overall prevalence of 5 percent. In some countries, the prevalence exceeds 20 percent. More than half of the HIV-infected population in sub-Saharan Africa is women and children. The HIV prevalence in Southeast Asia is substantially lower (0.6 percent), representing approximately four million HIV-infected people living in this under-resourced region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In Latin America and the Caribbean, infection rates vary by region, with estimated prevalences ranging from 0.5 to 2 percent. Markedly high rates of infection exist within certain risk groups, such as men who have sex with men, prisoners, commercial sex workers, and injection drug users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The global epidemiology of HIV is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link&amp;anchor=H5#H5\">",
"     \"The global human immunodeficiency virus pandemic\", section on 'Worldwide statistics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409055\">",
"    <span class=\"h1\">",
"     IMPACT OF TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H499459\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of available international funds for antiretroviral therapy (ART), earlier interventions (1999 to 2003) relied on the use of daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (cotrimoxazole) prophylaxis to prevent opportunistic infections (OIs), such as pneumocystis and toxoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Trimethoprim-sulfamethoxazole is also effective therapeutically against highly prevalent diseases in Africa and Asia, including bacterial infections and septicemia (eg, pneumococcus), enteritides (eg, salmonella, shigella, Isospora), and malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the late 1990s, randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    in C&ocirc;te d'Ivoire and Uganda demonstrated good tolerability and significant reductions in morbidity and mortality among HIV-infected patients who were not receiving ART, regardless of CD4 count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/8,9,11,12\">",
"     8,9,11,12",
"    </a>",
"    ]. Even as ART has become increasingly available, trimethoprim-sulfamethoxazole remains an important component of care for people living with HIV. Compared with no prophylaxis, prescription of trimethoprim-sulfamethoxazole is associated with large reductions in mortality among patients taking ART in large observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. Multiple analyses have also demonstrated the cost-effectiveness of trimethoprim-sulfamethoxazole prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H499466\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised regarding the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    resistance among bacterial and Plasmodium falciparum isolates with the use of chronic prophylaxis for HIV-infected patients. Although some studies have demonstrated increased rates of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/10\">",
"     10",
"    </a>",
"    ], no data yet suggest an increased rate of clinical failure with trimethoprim-sulfamethoxazole treatment or increased rates of resistance to antimicrobials other than trimethoprim-sulfamethoxazole in communities with high rates of prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/10,17,18\">",
"     10,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H499473\">",
"    <span class=\"h2\">",
"     World health organization guidelines for prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current World Health Organization",
"    <span class=\"nowrap\">",
"     (WHO)/United",
"    </span>",
"    Nations (UN) AIDS guidelines recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All adults and adolescents living with HIV who have CD4 counts &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Adults with advanced HIV infection as defined by the WHO (eg, stage III or IV disease) (",
"      <a class=\"graphic graphic_table graphicRef55105 \" href=\"mobipreview.htm?32/44/33485\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In those regions where CD4 counts are not monitored, WHO recommends",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis for all symptomatic patients (ie, WHO clinical stage II, III or IV) or for any HIV-infected patient at the discretion of the regional health services. However, implementation of these recommendations has proven to be a challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H499487\">",
"    <span class=\"h2\">",
"     Discontinuation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal timing for discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis after ART initiation has not yet been determined, and current WHO guidelines recommend life-long prophylaxis until further data are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409062\">",
"    <span class=\"h1\">",
"     EFFECT OF ANTIRETROVIRAL THERAPY ON MORTALITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9845923\">",
"    <span class=\"h2\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three meta-analyses of antiretroviral therapy (ART) trials in resource-limited settings, along with subsequent larger cohort studies and a randomized trial, have demonstrated that treatment-induced viral suppression and immune recovery lead to improved clinical status and reduced mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/21-39\">",
"     21-39",
"    </a>",
"    ]. Reductions in mortality are evident even among patients with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/21,22,36,40\">",
"     21,22,36,40",
"    </a>",
"    ], and the magnitude of mortality reduction has been generally similar to that in developed countries. One prospective cohort study in Uganda found that the life expectancy of 22,315 HIV-infected patients receiving ART was comparable with the national average, despite the use of less potent and more toxic treatment regimens than those in use in resource-rich settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, disproportionately high mortality has been observed among some patients soon after ART initiation, especially among profoundly immunosuppressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/22-24,38,41-43\">",
"     22-24,38,41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of more than 21,000 patients who were enrolled into HIV care in Zambia, 71 percent of the total number of deaths (n = 1142) occurred within 90 days of starting ART, while the remaining 29 percent occurred after 90 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/41\">",
"       41",
"      </a>",
"      ]. In a multivariable analysis, mortality was strongly associated with a low baseline CD4 cell count (range 50 to 199",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ;",
"      </span>",
"      adjusted hazard ratio [HR] 2.2; 95% CI 1.5-3.1).",
"     </li>",
"     <li>",
"      A meta-analysis of adults initiating ART in sub-Saharan Africa demonstrated that the highest mortality rates occurred among those patients with advanced AIDS; specifically, having a baseline CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and WHO stage 4 disease was associated with twice the likelihood of death (summary HR, 2.2; 95% CI 1.5-3.2) (",
"      <a class=\"graphic graphic_table graphicRef55105 \" href=\"mobipreview.htm?32/44/33485\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a separate meta-analysis of adults initiating ART in low- and middle-income countries, mortality rates ranged from 7 to 17 percent at one year after ART initiation. There was an increased risk of death with male gender, age greater than 40 years, low BMI, anemia, advanced clinical HIV disease, and low CD4 counts at initiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poor ART responses are also related to advanced age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/25\">",
"     25",
"    </a>",
"    ], bone marrow suppression, low body weight, and malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/26,41\">",
"     26,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the highest mortality rates occur among those with severe immunosuppression, greater survival benefit may be attained with expanded availability of ART prior to the onset of advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/27,36\">",
"     27,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of over 22,000 Ugandan adults enrolled in ART clinics, there was an association with lower mortality in patients who initiated ART at higher CD4 counts after adjustment for sex, WHO disease stage, and year of ART initiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/38\">",
"       38",
"      </a>",
"      ]. The relative risk of death was 0.75 (95% CI 0.65&ndash;0.88) in those with baseline CD4 counts between 50 and 99",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and 0.41 (95% CI 0.33&ndash;0.51) in those with baseline CD4 counts &ge;250",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      compared with patients who initiated ART at CD4 counts &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      Other observational data have also supported earlier initiation of ART in patients with CD4 counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      not only in reducing mortality, but also in improving overall rates of treatment-induced viral suppression compared with deferred ART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initiation of ART in patients with CD4 counts &le;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      has mortality benefit for all HIV-infected patients. In a randomized trial conducted in Haiti, 816 study participants with a baseline CD4 count between 200 and 350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were randomly assigned to either &ldquo;standard ART&rdquo; or &ldquo;early ART&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/39\">",
"       39",
"      </a>",
"      ]. &ldquo;Standard ART&rdquo; was initiated when the patient had the onset of clinical AIDS or had a CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      whereas &ldquo;early ART&rdquo; was initiated within two weeks of study enrollment. A significantly higher number of deaths occurred in the standard rather than in the early ART arm (ie, 23 versus 6 deaths; HR 4; 95% CI 1.6-9.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal timing of initiation of ART to maximize mortality benefits in resource-limited settings is uncertain. WHO guidelines released in 2010 recommend initiating ART at CD4 counts &le;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/46\">",
"     46",
"    </a>",
"    ]. These guidelines are currently being revised in the context of recent changes to ART recommendations in several developed countries (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    ). A randomized trial would be useful to determine the optimal timing of initiation of ART for HIV-infected patients with CD4 counts &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in Africa and other parts of the developing world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3410357\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional data are now available regarding the longer-term benefits of ART in resource-limited settings. In a multi-site longitudinal cohort with 29,175 patients who initiated care, 19,967 patients were followed for more than six months and 820 patients were followed for more than four years (median follow-up time 1.6 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/48\">",
"     48",
"    </a>",
"    ]. Overall, mortality and loss to follow-up were low (3 percent and 9 percent, respectively). Immune reconstitution was substantial among those with advanced immunosuppression (395",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at five years from a median nadir of 114",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     );",
"    </span>",
"    the trajectory of CD4 cell gain on ART was greater among those who initiated treatment at higher CD4 counts.",
"   </p>",
"   <p>",
"    In a separate study of patients initiating ART at multiple South African clinical sites, mortality rates at two to four years post-ART initiation were 12-fold lower than mortality rates at three months after ART initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/49\">",
"     49",
"    </a>",
"    ]. An estimation of life-expectancy of HIV-infected people on ART in Uganda suggested that patients engaged in care and on ART could live over 20 additional years, which is near normal for adults in the region; those who initiated ART at higher CD4 counts had longer life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/36\">",
"     36",
"    </a>",
"    ]. In a population cohort study of more than 101,000 individuals in rural KwaZulu-Natal, South Africa, after eight years of ART availability to the public (from 2003 to 2011), the average adult life expectancy increased by 11.3 years (49.2 years to 60.5 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23835331\">",
"    <span class=\"h2\">",
"     Gender differences in mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In resource-limited settings, HIV-infected men appear to have a higher risk of death than women despite ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In a retrospective study of 46,201 HIV-infected individuals in South Africa initiating ART between 2002 and 2009, the mortality rate was higher among men than women (8.5 versus 5.7 deaths per 100 person-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/51\">",
"     51",
"    </a>",
"    ]. Although men were older, had lower median CD4 cell counts, and were more likely to have advanced HIV infection (WHO stage III to IV) at ART initiation compared with women, a difference in mortality rate remained significant (adjusted HR 1.31, 95% CI 1.22-1.41) after adjusting for these and other variables. Men also had a higher rate of loss to follow-up than women, but even among those patients who achieved viral suppression to &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    on ART, the risk of death remained higher for men. A proportion of the excess mortality was thought to reflect the HIV-unrelated mortality differences observed between men and women in resource-limited settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9845930\">",
"    <span class=\"h2\">",
"     Second-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-line therapy is increasingly available for those patients in resource-limited communities who experience therapy-limiting toxicities or clinical failure, especially when due to the emergence of resistance to NNRTI and NRTI agents. Outcomes data remain mixed regarding those who change to second-line regimens. A large observational multi-center cohort in Asia and Africa demonstrated high failure rates in addition to substantial morbidity and mortality after change to second-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/54\">",
"     54",
"    </a>",
"    ], but other cohort studies have reported virologic suppression rates of &gt;70 percent on second-line regimens and demonstrated a beneficial effect of second-line therapy on mortality and immune reconstitution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure of second-line regimens has been associated with ongoing poor adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/57\">",
"     57",
"    </a>",
"    ], but emergence of PI mutations remains rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4941503\">",
"     'Drug resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5162338\">",
"    <span class=\"h2\">",
"     Recommendations from the World Health Organization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006, the World Health Organization (WHO) recommended ART in HIV-infected patients with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Based on emerging evidence that ART also leads to marked declines in mortality among patients with higher CD4 counts, WHO revised its treatment guidelines in 2010; it is now recommended that HIV-infected asymptomatic patients with a CD4 cell count of &le;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    initiate ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, the WHO guidelines recommend ART for patients with WHO stage 3 or 4 disease, regardless of CD4 cell count, for all TB patients, and for any patients with hepatitis B virus",
"    <span class=\"nowrap\">",
"     (HBV)/HIV",
"    </span>",
"    coinfection who require HBV treatment. In light of emerging data, the WHO plans to release new HIV treatment guidelines in 2013.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409069\">",
"    <span class=\"h1\">",
"     EFFECT OF ANTIRETROVIRAL THERAPY ON OTHER COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral therapy (ART) leads to a marked improvement in general health as measured by weight gain and a reduction in onset of opportunistic infections (OIs), even among patients with low CD4 counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/28,29,61\">",
"     28,29,61",
"    </a>",
"    ]. In an international trial of 1763 HIV-infected individuals, those randomly assigned to initiate ART at CD4 cell counts between 250 and 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    had fewer HIV-related clinical events compared with those assigned to initiate ART once CD4 cell counts were &le;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or there was an AIDS-defining clinical event (40 versus 65 events, respectively; hazard ratio [HR] 0.59; 95% CI 0.4-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A growing body of evidence demonstrates the benefit of ART in specifically attenuating the effects of HIV on a variety of highly prevalent coinfections in developing countries, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409076\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial additional morbidity and mortality from tuberculosis (TB) coinfection occurs in untreated HIV-infected patients in resource-limited settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] with evidence of a fivefold increased risk of active TB in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/62\">",
"     62",
"    </a>",
"    ]. This risk of TB increases with declining immunity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-infected patients may have active pulmonary TB without clinical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Furthermore, unsuspected TB is associated with higher rates of morbidity and mortality after initiation of ART compared with those without concomitant TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/65\">",
"     65",
"    </a>",
"    ]. Given the high prevalence of coinfection in many resource-limited regions, intensified TB case finding with screening, regardless of symptoms, may help in case identification and in reducing early morbidity when initiating ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/63,66\">",
"     63,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8959030\">",
"    <span class=\"h3\">",
"     TB incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread use of ART has been associated with a decreased incidence of TB and up to a 70 percent reduction in death among HIV-infected patients coinfected with tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/32,33,39,67,68\">",
"     32,33,39,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a treatment trial conducted in Haiti, 816 Haitian HIV-infected patients were randomly assigned to early ART (two weeks after enrollment) or to standard ART (initiation of ART when CD4 counts declined to &le;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or for the onset of clinical AIDS) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      prophylaxis administered to all study participants. Early initiation of ART was associated with a twofold decline in TB incidence over a median follow-up of 21 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reduction in clinical events observed in a large trial of 1763 HIV-infected patients randomly assigned to early compared with delayed ART was likely due to fewer incident cases of extrapulmonary tuberculosis (3 versus 17 cases in the early and delayed therapy arm, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/61\">",
"       61",
"      </a>",
"      ]. There was no difference in cases of pulmonary TB between the two groups.",
"     </li>",
"     <li>",
"      In a systematic review of studies evaluating the treatment of TB in patients infected with HIV, the use of ART was associated with a decreased risk of subsequent TB relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mathematical modeling has&nbsp;also suggested that ART will reduce the incidence of TB in HIV-infected people. One model has estimated that if all HIV-infected people&nbsp;in sub-Saharan Africa were initiated on ART within five years of seroconversion, the incidence of AIDS-related TB in 2015&nbsp;could be reduced by 48 percent (range 37 to 55 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/70\">",
"     70",
"    </a>",
"    ]. National surveillance data in different countries should be able to document such decreases&nbsp;in TB infections as ART is further scaled up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98350889\">",
"    <span class=\"h3\">",
"     TB treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with TB and HIV poses challenging clinical management issues. There are multiple pharmacologic interactions between ART and anti-tuberculosis medications with additive toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/71\">",
"     71",
"    </a>",
"    ]. Additionally, immune recovery secondary to ART can lead to paradoxical worsening of clinical symptoms in patients with tuberculosis; this clinical scenario is referred to as the immune reconstitution inflammatory syndrome (IRIS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, data from several trials demonstrate that the mortality reduction observed with early ART (within 2 to 12 weeks after initiating anti-tuberculous therapy) outweighs the potential morbidity of IRIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. Patients with TB meningitis may be an exception to this observation. In one trial of 253 HIV-infected patients with TB meningitis, there was no difference in mortality but an increase in serious adverse events among patients randomly assigned to immediate (within seven days of TB treatment initiation) compared with deferred (after two months) ART initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/76\">",
"     76",
"    </a>",
"    ]. These data and the timing of ART initiation in the setting of TB are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\", section on 'Timing of ART in the treatment-naive patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409083\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the beginning of the HIV pandemic, malarial infections have doubled in parts of sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/77,78\">",
"     77,78",
"    </a>",
"    ] with a higher incidence among those patients with low CD4 counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/79\">",
"     79",
"    </a>",
"    ]. In one observational cohort of 1371 HIV-infected patients in Uganda, incidence rates of symptomatic malaria infection were higher among patients with lower CD4 cell counts (eg, 140, 93 and 57 cases per 1000 person-years of follow-up for CD4 T cell counts &lt;200, 200 to 499, and &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/79\">",
"     79",
"    </a>",
"    ]. ART initiation in Uganda has been shown to reduce malaria incidence by 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/8/3209?source=see_link\">",
"     \"HIV and malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409090\">",
"    <span class=\"h2\">",
"     Cryptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The historically high mortality rates associated with cryptococcal infections in sub-Saharan Africa have also declined with the availability of ART. In a retrospective study of 127 patients with cryptococcal meningitis conducted from 1997 to 2005, those who initiated ART were 37 times more likely to survive cryptococcal infection than those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/81\">",
"     81",
"    </a>",
"    ]. Cohorts in Cape Town and Botswana have demonstrated that ART use was associated with significantly reduced inpatient mortality from cryptococcal meningitis (8 percent versus 21 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/82\">",
"     82",
"    </a>",
"    ]) and reduced mortality at one year (41 percent versus 76 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/83\">",
"     83",
"    </a>",
"    ]) compared with patients not yet on therapy at the time of admission.",
"   </p>",
"   <p>",
"    A paradoxical clinical worsening of symptoms in patients with cryptococcal meningitis can occur in the setting of ART initiation and immune recovery, similar to that in mycobacterial disease. Immune reconstitution with cryptococcal disease can be associated with increased intracranial pressure and significant morbidity and mortality if not appropriately monitored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Optimal timing of ART initiation for patients with cryptococcal meningitis is not yet determined, as conflicting data have emerged on mortality from IRIS associated with a diagnosis of cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. This issue is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38568?source=see_link&amp;anchor=H14913615#H14913615\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Immune reconstitution syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38568?source=see_link&amp;anchor=H14913657#H14913657\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Timing of antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20677405\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409097\">",
"    <span class=\"h3\">",
"     Hepatitis B and hepatitis C viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of hepatitis B virus (HBV) infection in Southeast Asia and tropical Africa are as high as 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/89\">",
"     89",
"    </a>",
"    ]; global rates of hepatitis C virus (HCV) infection are not as well documented since diagnostic testing is not widely performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/90\">",
"     90",
"    </a>",
"    ]. ART use in patients with HIV and viral hepatitis raises two main concerns: a) the effects of viral hepatitis infections on immune recovery, and b) the risk of drug-associated hepatotoxicity.",
"   </p>",
"   <p>",
"    Despite concerns regarding the potential for negative immunomodulatory effects of viral hepatitis on ART-associated immune reconstitution, recent data from resource-limited settings have not demonstrated worse outcomes for ART initiation in",
"    <span class=\"nowrap\">",
"     HBV/HIV-coinfected",
"    </span>",
"    patients. In studies from Thailand, Nigeria, South Africa, and Malawi, patients with",
"    <span class=\"nowrap\">",
"     HBV/HIV",
"    </span>",
"    coinfection had delayed CD4 gains in early response to ART, but attained equivalent immunologic recovery and virologic suppression at 48 to 72 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/91-94\">",
"     91-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the data on hepatotoxicity from the developed world, there is ongoing concern regarding the risk of drug-induced liver injury in",
"    <span class=\"nowrap\">",
"     HIV/hepatitis-coinfected",
"    </span>",
"    patients in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/95\">",
"     95",
"    </a>",
"    ]. In recent studies of",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients on ART from resource-limited settings, hepatotoxicity has been reported more frequently in patients with higher HBV DNA viral loads, but has not been treatment limiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/91,93,94\">",
"     91,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409104\">",
"    <span class=\"h2\">",
"     Leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of",
"    <span class=\"nowrap\">",
"     leishmania/HIV",
"    </span>",
"    coinfection is increasing worldwide. Over 500,000 new cases of visceral leishmaniasis are reported annually; regions that are considered endemic are expanding through India, Eastern Africa, and South America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/96\">",
"     96",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Due to overlapping areas of high prevalence, there are also data showing that coinfection with HIV and leishmaniasis is increasing. For example, in northwest Ethiopia, the proportion of patients with visceral leishmaniasis who were coinfected with HIV increased from 19 percent in 1998 to 40 percent in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the negative clinical impact of TB and malaria infection on HIV infection, coinfection with visceral leishmaniasis contributes to accelerated HIV disease progression and increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Many coinfected patients develop chronic relapsing leishmaniasis and early death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 791 cases in Tigray, the case fatality rate among leishmaniasis patients coinfected with HIV was four times higher than in patients with leishmaniasis alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a three-year prospective study of 356 HIV-infected patients with leishmaniasis, ART use was associated with decreased risk of relapse, although there was no effect on mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visceral leishmaniasis has been classified as an AIDS-defining opportunistic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1038347\">",
"    <span class=\"h1\">",
"     IMPACT OF ANTIRETROVIRAL THERAPY ON TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7722013\">",
"    <span class=\"h2\">",
"     ART for HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;High plasma HIV RNA concentrations are associated with an increased risk of HIV transmission through sexual intercourse. Evidence from large observational studies as well as an international trial suggests that antiretroviral therapy (ART) decreases HIV transmission through its effect in reducing HIV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/61,101-103\">",
"     61,101-103",
"    </a>",
"    ]. In the trial, 1763 serodiscordant couples were randomly assigned to immediate versus delayed (until the CD4 cell count was &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or there was an AIDS-related event) ART initiation for the HIV-infected partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/61\">",
"     61",
"    </a>",
"    ]. After 1.7 years of follow-up, 27 of the 28 virologically-linked HIV transmissions occurred among couples in the delayed ART group for a 96 percent reduction in HIV transmission risk. In a large population-based prospective cohort study in rural KwaZulu-Natal, South Africa, individual HIV acquisition risk declined significantly with increasing ART coverage in the surrounding local community; patients with a CD4 count &le;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    were eligible for ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/104\">",
"     104",
"    </a>",
"    ]. In a community in which 30 to 40 percent of all ART-eligible individuals were treated, an HIV-uninfected individual was 38 percent less likely to acquire HIV than someone living in a community in which fewer than 10 percent of ART-eligible individuals were receiving ART.",
"   </p>",
"   <p>",
"    The WHO released new",
"    <a class=\"external\" href=\"file://www.who.int/hiv/pub/guidelines/9789241501972/en/\">",
"     guidelines for couples",
"    </a>",
"    in 2012 that recommend consideration of ART for the HIV-infected patient in a relationship with an uninfected individual, regardless of CD4 cell count, to reduce transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/105\">",
"     105",
"    </a>",
"    ]. Providers should clearly counsel those patients with CD4 &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    that ART is offered to reduce transmission to the serodiscordant partner and will need to be continued for life. When resources for ART are limited, priority for ART initiation should be HIV-infected patients whose own health would directly benefit (see",
"    <a class=\"local\" href=\"#H5162338\">",
"     'Recommendations from the World Health Organization'",
"    </a>",
"    above). Other public health guidelines also emphasize the health benefits of earlier initiation of ART not only for improved outcomes of HIV-infected patients but also for prevention of new infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of HIV treatment on further transmission is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7722086\">",
"    <span class=\"h2\">",
"     Pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients at high risk of HIV infection, there has been long-standing interest in preventive measures to reduce transmission of new infections, such as pre-exposure prophylaxis (PrEP) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and other antiretrovirals or antiviral vaginal microbicides. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the need for more data to inform the optimal approach, PrEP with daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    may be an effective strategy for preventing HIV infection in uninfected patients at high risk of sexual transmission who are committed to medication adherence and close follow-up. Several trials in various high-risk populations, including men who have sex with men, heterosexual individuals with an HIV-infected partners, and heterosexual individuals in areas of high HIV prevalence, have demonstrated a reduction in the risk of HIV infection by 48 to 75 percent with daily use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. A separate trial in African women that did not show efficacy of tenofovir-emtricitabine in reducing the risk of HIV infection may have been substantially limited by non-adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/110\">",
"     110",
"    </a>",
"    ]. Details of these studies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link&amp;anchor=H49825196#H49825196\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Efficacy'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Variable results have been reported with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in a vaginal gel formulation to prevent sexually-acquired HIV infection in women. While one trial demonstrated an overall reduction in HIV infections by 39 percent with pericoital use of tenofovir gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/111\">",
"     111",
"    </a>",
"    ], a second showed no efficacy of daily use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/112\">",
"     112",
"    </a>",
"    ]. Additional studies are ongoing to further evaluate the efficacy of vaginal chemoprophylaxis against HIV infection.",
"   </p>",
"   <p>",
"    In cost-effectiveness analyses of PrEP, the use of oral or vaginal prophylaxis for prevention of new HIV infections in sub-Saharan Africa has been demonstrated to be cost effective, given the high prevalence of HIV and reported efficacy of PrEP from clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. However, PrEP remains costly, and the feasibility of scaling up PrEP in resource-limited settings remains to be determined, especially in light of the ongoing and unmet need for immediate ART for eligible HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409111\">",
"    <span class=\"h1\">",
"     COST AND COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the increase in costs associated with HIV treatment, the cost-effectiveness of antiretroviral therapy (ART) in resource-limited settings has been well demonstrated. Mathematical models of ART in C&ocirc;te d'Ivoire and in India demonstrated substantial life expectancy benefits and favorable cost-effectiveness ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Recent modeling studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/117\">",
"     117",
"    </a>",
"    ] and randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/39\">",
"     39",
"    </a>",
"    ] have suggested that initiation of ART at CD4 counts &le;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    is associated with better outcomes in resource-limited settings. Based on these data, the initiation of ART was recommended by the WHO for all patients with CD4 counts &le;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in the revised 2010 treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Implementation at this treatment threshold will increase costs of care, at least in the initial years of such a treatment strategy. Cost-effectiveness projections estimate that the five-year cost of initiating ART for patients with CD4 counts &le;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in South Africa alone could exceed US $1.4 billion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12409132\">",
"     'Ongoing challenges'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409118\">",
"    <span class=\"h1\">",
"     ACCESSIBILITY OF LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal method for monitoring",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients on antiretroviral therapy (ART) in developing countries remains debated, given the reduced availability and relatively high costs of CD4 cell monitoring and HIV RNA testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409125\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, routine monitoring for drug-related adverse events and immunologic and virologic responses to ART are considered standard of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8959134\">",
"    <span class=\"h3\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring for ART-related adverse laboratory events in resource-limited settings is impeded",
"    <strong>",
"    </strong>",
"    by reduced accessibility to health care providers and limited testing facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/121\">",
"     121",
"    </a>",
"    ]. Cost considerations must also be weighed against the benefit of routine laboratory monitoring in clinical management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multisite randomized trial in Uganda and Zimbabwe (the DART Trial), 3321 HIV-infected, ART-na&iuml;ve patients with CD4 &le;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were randomly assigned to routine laboratory monitoring after ART initiation (ie, every three months) versus clinically-driven monitoring. Mortality, progression of HIV, and serious adverse events were monitored as endpoints; clinically-driven monitoring was found to be noninferior to routine monitoring for drug toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/122\">",
"       122",
"      </a>",
"      ]. However, greater disease progression among patients in the clinically-monitored group, and earlier switches to second-line therapy in the laboratory monitored group, suggested an overall beneficial impact of CD4 cell count testing.",
"     </li>",
"     <li>",
"      A cohort study of 1800 patients in Haiti found that routine laboratory monitoring was cost-effective for assessing anemia before treatment and during therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ; however, routine monitoring of liver or renal function had no impact on overall patient care in this population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8959141\">",
"    <span class=\"h3\">",
"     HIV parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory monitoring for treatment failure helps to inform ART regimen changes. Multiple cost-effectiveness analyses have been published with variable results and conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/116,120,124-127\">",
"     116,120,124-127",
"    </a>",
"    ]. However, most suggest that CD4 monitoring is cost-effective in most settings and HIV RNA monitoring may be cost-effective in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/128\">",
"     128",
"    </a>",
"    ]. Given that much of the costs associated with treatment failure stem from more costly second-line ART regimens, the cost-effectiveness of these monitoring approaches will likely change as alternate regimens become increasingly available and less expensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/128\">",
"     128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The WHO will revisit its recommendations on the value of laboratory monitoring in the anticipated 2013 guideline revision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409132\">",
"    <span class=\"h1\">",
"     ONGOING CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the increasing availability of antiretroviral therapy (ART), it is essential to determine the most effective features of ART programs in order to target further interventions and to combat the clinical problems unique to developing countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409139\">",
"    <span class=\"h2\">",
"     HIV diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed HIV diagnosis reduces the survival benefit from ART, and the association between poorer outcomes and advanced immunosuppression is clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/129\">",
"     129",
"    </a>",
"    ]. Many patients who are diagnosed and enrolled in ART programs die prior to initiating ART or soon thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/130,131\">",
"     130,131",
"    </a>",
"    ], emphasizing the need for ongoing efforts for earlier diagnostic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite current WHO guidelines for earlier initiation of treatment, most patients are still profoundly immunosuppressed at the time of diagnosis and thus are at high risk for early mortality. An analysis of baseline characteristics of 36,715 HIV-infected patients from 12 countries in sub-Saharan Africa, South America, and Asia found that the vast majority of patients initiated on ART from 1996 to 2006 had CD4 counts well below 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at the time of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WHO has now recommended an &ldquo;opt-out&rdquo; approach to increase rates of testing, decrease stigma, and enhance linkage to care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/134-136\">",
"     134-136",
"    </a>",
"    ]. Use of rapid HIV testing to provide same-day results has also enhanced testing rates, although protocols to confirm these results are essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409160\">",
"    <span class=\"h2\">",
"     Linkage to care and access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access to care is also affected by community attitudes and stigma towards HIV status and misperceptions regarding HIV risk and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/138\">",
"     138",
"    </a>",
"    ]. Additional barriers include poor coordination of services, reduced educational level, cost of treatment, food insecurity, and transportation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/25,131,139-142\">",
"     25,131,139-142",
"    </a>",
"    ]. Lower baseline CD4 counts and unemployment have also been associated with poor rates of linkage to care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/143\">",
"     143",
"    </a>",
"    ]. HIV infection is often diagnosed earlier among females than males because of prenatal testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409167\">",
"    <span class=\"h2\">",
"     Retention in care and loss to follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical aspect of HIV treatment is the need for long-term care. Of patients who start ART, between 20 and 60 percent are lost to follow-up within one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. As ART program uptake increases, so do the numbers who fail to return [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/27,147\">",
"     27,147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss to follow-up has been associated with poor adherence, older age, advanced immunosuppression, low weight, and pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/25,139,144,145,148-150\">",
"     25,139,144,145,148-150",
"    </a>",
"    ]. High rates of death (12 to 87 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/151\">",
"     151",
"    </a>",
"    ] and early morbidity related to drug toxicity or opportunistic infections (OIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/152\">",
"     152",
"    </a>",
"    ] may be possible underlying causes for loss to follow-up. Potential interventions include provision of free care, better record-keeping to track patient visits, and the incorporation of ancillary services (eg, peer support groups and outreach services) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/139,144,153-155\">",
"     139,144,153-155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4941420\">",
"    <span class=\"h2\">",
"     Adherence to ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of ART adherence are similar to reported data from the US and Europe, depending on setting and method of measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/25,138,156\">",
"     25,138,156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasons for poor adherence in resource-limited settings are frequently related to cost of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/138\">",
"     138",
"    </a>",
"    ] and food insecurity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/142\">",
"     142",
"    </a>",
"    ]. Several studies in various African countries have demonstrated a lower rate of attrition and higher rates of viral suppression if medications are offered free of charge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/139,144\">",
"     139,144",
"    </a>",
"    ]. Adherence can also be negatively affected by concerns about stigma within the community, chronic alcohol abuse, and complicated medication regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adherence remains an important predictor of long-term success with ART. In a cohort of 207 patients on ART for two years in South Africa, patients with poor initial adherence to ART also had a more rapid progression to virologic failure (HR 2.82; 95% CI 1.19-6.66, p = 0.018) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4941503\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to cost considerations and lack of availability, drug resistance testing is not currently recommended by the World Health Organization (WHO) and is generally not performed in resource-limited settings. The extent of drug resistance in resource-limited setting is under prospective investigation with the establishment of a WHO and HIV ResNet collaboration to establish HIV drug resistance (HIVDR) early warning indicators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance appears to be a growing problem in resource-limited settings in which widespread ART programs have been implemented and there are additional concerns for the transmission of drug-resistant HIV. In a systematic review of studies and surveillance reports of antiretroviral resistance in resource-limited settings , the prevalence of genotypes with at least one drug resistance mutation increased to 3.7 and 7.4 percent in southern and east Africa, respectively, over the five to nine years following rollout of national ART programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/159\">",
"     159",
"    </a>",
"    ]. Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations were most common. Three other studies from sub-Saharan Africa found that the most prevalent genotypic mutations included the M184V mutation (conferring resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ), K103N (which confers resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ) or K65R (conferring resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/160-162\">",
"     160-162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients treated with a first-line ART regimen, the risk of drug resistance in the setting of virologic failure may be considerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/163-165\">",
"     163-165",
"    </a>",
"    ]. In a multi-center cohort study in sub-Saharan Africa, of the 142 patients who were not virologically suppressed on first-line ART at 12 months, 70 percent had at least one resistance mutation and 49 percent harbored resistance to two classes of antiretrovirals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/162\">",
"     162",
"    </a>",
"    ]. In a separate study from South Africa, 23 percent of 226 patients failing a first-line regimen harbored complex resistance patterns that predicted cross-resistance to nucleoside reverse transcriptase inhibitors (NRTIs), which could decrease the efficacy of an empirically chosen second-line regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients treated with second-line ART, the risk of drug resistance may be different. In a study from South Africa of 43 HIV-infected patients with confirmed virologic failure on second-line ART, 67 percent still had wild-type virus. This finding suggests that poor adherence instead of resistance was contributing to failure and may be a result of the different genetic barriers to resistance for protease inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/59\">",
"     59",
"    </a>",
"    ]. Additional data are needed to determine the etiologies of ART failure, the patterns of drug resistance to different regimens, and the rates and outcomes of patients with resistant virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/163,164\">",
"     163,164",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7722205\">",
"    <span class=\"h2\">",
"     Test and treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the data showing efficacy of ART in reducing transmission of HIV, there is increasing interest in the evaluation of earlier treatment as a feasible and cost-effective public health strategy to reduce the incidence of new HIV infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/61\">",
"     61",
"    </a>",
"    ]. One proposal that has sparked interest is that of routine voluntary HIV testing with immediate initiation of ART at the time of diagnosis, also known as &ldquo;Test and Treat.&rdquo; Mathematical models have predicted a wide range of effectiveness and costs that would result from implementation of a &ldquo;Test and Treat&rdquo; policy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/166-168\">",
"     166-168",
"    </a>",
"    ]. Further analyses regarding its feasibility and benefits are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4941580\">",
"    <span class=\"h2\">",
"     Costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs of ART and laboratory monitoring remain an ongoing and increasing concern given the greater number of people receiving ART and the need to expand the capacity of treatment programs so that all people can access ART when needed. The increased availability of generic drugs in Guyana, Haiti, Vietnam, and 13 African countries has led to increased procurement of monthly medication packs (from 6 million in 2005 to 22 million in 2008) and to an estimated cost savings of more than 323 million dollars over a four-year period (2005 to 2008) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/169\">",
"     169",
"    </a>",
"    ]. Cost issues are becoming increasingly important with the demonstration that initiation of therapy earlier in the course of disease results in improved clinical outcomes, highlighting the importance of prioritizing the choice and timing of ART regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/28,31,39,106,170-173\">",
"     28,31,39,106,170-173",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Another challenge is to expand effective treatment to patients who cannot tolerate first-line regimens because of either toxicity or virologic failure and resistance. Second-line regimens are now available in many countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/174\">",
"     174",
"    </a>",
"    ], although at considerable increased cost (up to five times that of first line medications) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/175\">",
"     175",
"    </a>",
"    ]. Cost-effective algorithms to guide regimen changes for treatment failure remain a subject of debate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/148,174,176,177\">",
"     148,174,176,177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns regarding funding for international ART programs persist, and debate continues regarding allocation of resources and use of available funds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/178,179\">",
"     178,179",
"    </a>",
"    ]. The President&rsquo;s Emergency Plan for AIDS Relief (PEPfAR) was renewed in 2008, although annual funding has not increased since then [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/180\">",
"     180",
"    </a>",
"    ]. As a result, a stable amount of PEPfAR funding is available to continue ART for patients already enrolled in ART programs, as well as to initiate ART for patients now eligible or just presenting. &nbsp;Additionally, debate continues regarding how to best use PEPfAR and other Global Health Initiative funds, as many competing needs vie for these limited resources (eg, Maternal-Child health) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/6/39018/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12409174\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the estimated 2.7 million new HIV infections worldwide in 2010, 1.9 million occurred in sub-Saharan Africa. (See",
"      <a class=\"local\" href=\"#H12409048\">",
"       'Epidemiology of HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , in addition to antiretroviral therapy, is associated with decreased mortality related to AIDS and opportunistic infections and to a decreased incidence of other infections that are common in resource-limited settings (eg, malaria, bacterial pneumonia, and enteritis). (See",
"      <a class=\"local\" href=\"#H12409055\">",
"       'Impact of trimethoprim-sulfamethoxazole prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of antiretroviral therapy has dramatically reduced both morbidity and mortality for those living with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      in resource-limited settings. The number of people being treated continues to increase rapidly. (See",
"      <a class=\"local\" href=\"#H12409062\">",
"       'Effect of antiretroviral therapy on mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy, with secondary immune reconstitution, also decreases the incidence of other prevalent coinfections in HIV-infected patients, such as malaria, tuberculosis, and cryptococcus. (See",
"      <a class=\"local\" href=\"#H12409069\">",
"       'Effect of antiretroviral therapy on other comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initiation of antiretroviral therapy decreases the risk of HIV transmission among discordant couples. Pre-exposure prophylaxis for HIV-uninfected individuals at high risk for sexually acquired HIV can also decrease risk of acquisition if used with consistency. (See",
"      <a class=\"local\" href=\"#H1038347\">",
"       'Impact of antiretroviral therapy on transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the costs associated with HIV treatment, multiple analyses have demonstrated that initiation of antiretroviral therapy is cost effective. (See",
"      <a class=\"local\" href=\"#H12409111\">",
"       'Cost and cost-effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Access to laboratory testing in many resource-limited settings continues to be limited; analyses suggest that CD4 count monitoring is cost effective in most settings and HIV RNA monitoring should be considered given implications for switching to second-line regimens. (See",
"      <a class=\"local\" href=\"#H12409118\">",
"       'Accessibility of laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Access to second-line antiretroviral therapy for those who have failed first-line is increasingly available. Decreases in drug costs for second-line therapy will enhance this availability. (See",
"      <a class=\"local\" href=\"#H4941580\">",
"       'Costs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV testing, linkage to care, and retention in care continue to be major factors limiting the success of ART programs in many settings. (See",
"      <a class=\"local\" href=\"#H12409160\">",
"       'Linkage to care and access'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     2012 Joint United Nations Programme. file://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/20120718_togetherwewillendaids_en.pdf (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/2\">",
"      Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA 2012; 307:2060.",
"     </a>",
"    </li>",
"    <li>",
"     2011 World Health Organization Progress Report. file://www.who.int/hiv/pub/progress_report2011/en/index.html (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/4\">",
"      Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 2008; 22 Suppl 3:S7.",
"     </a>",
"    </li>",
"    <li>",
"     file://data.unaids.org/pub/Report/2008/jc1528_epibriefs_caribbean_en.pdf (Accessed on August 02, 2010).",
"    </li>",
"    <li>",
"     file://data.unaids.org/pub/Report/2008/jc1530_epibriefs_latinamerica_en.pdf (Accessed on August 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/7\">",
"      Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/8\">",
"      Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, C&ocirc;te d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/9\">",
"      Anglaret X, Ch&ecirc;ne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, C&ocirc;te d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/10\">",
"      Hamel MJ, Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 2008; 79:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/11\">",
"      Mermin J, Lule J, Ekwaru JP, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005; 19:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/12\">",
"      Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/13\">",
"      Hoffmann CJ, Fielding KL, Charalambous S, et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS 2010; 24:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/14\">",
"      Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/15\">",
"      Pitter C, Kahn JG, Marseille E, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir Immune Defic Syndr 2007; 44:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/16\">",
"      Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in C&ocirc;te d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/17\">",
"      Malamba S, Sandison T, Lule J, et al. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am J Trop Med Hyg 2010; 82:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/18\">",
"      Sibanda EL, Weller IV, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis 2011; 52:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/19\">",
"      Date AA, Vitoria M, Granich R, et al. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010; 88:253.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Geneva 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/21\">",
"      Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in C&ocirc;te d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/22\">",
"      Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/23\">",
"      Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/24\">",
"      Hargrove JW, Humphrey JH, ZVITAMBO Study Group. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24:F11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/25\">",
"      Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007; 12:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/26\">",
"      Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008; 8:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/27\">",
"      Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/28\">",
"      Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005; 41:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/29\">",
"      Manosuthi W, Chaovavanich A, Tansuphaswadikul S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect 2007; 55:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/30\">",
"      Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/31\">",
"      Ngowi BJ, Mfinanga SG, Bruun JN, Morkve O. Pulmonary tuberculosis among people living with HIV/AIDS attending care and treatment in rural northern Tanzania. BMC Public Health 2008; 8:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/32\">",
"      Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/33\">",
"      Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/34\">",
"      Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/35\">",
"      Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis. Int J STD AIDS 2008; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/36\">",
"      Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/37\">",
"      Peterson I, Togun O, de Silva T, et al. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS 2011; 25:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/38\">",
"      Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/39\">",
"      Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/40\">",
"      Egger M, May M, Ch&ecirc;ne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/41\">",
"      Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/42\">",
"      Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/43\">",
"      Walker AS, Prendergast AJ, Mugyenyi P, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/44\">",
"      Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011; 6:e28691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/45\">",
"      Fox MP, Sanne IM, Conradie F, et al. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS 2010; 24:2041.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision. file://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (Accessed on March 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/47\">",
"      De Cock KM, El-Sadr WM. When to start ART in Africa--an urgent research priority. N Engl J Med 2013; 368:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/48\">",
"      Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/49\">",
"      Hoffmann CJ, Fielding KL, Johnston V, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/50\">",
"      Bor J, Herbst AJ, Newell ML, B&auml;rnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/51\">",
"      Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med 2012; 9:e1001304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/52\">",
"      Dou Z, Xu J, Jiao JH, et al. Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008. PLoS One 2011; 6:e22707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/53\">",
"      Druyts E, Dybul M, Kanters S, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS 2013; 27:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/54\">",
"      Pujades-Rodr&iacute;guez M, Balkan S, Arnould L, et al. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/55\">",
"      Fox MP, Ive P, Long L, et al. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/56\">",
"      Win MM, Maek-A-Nantawat W, Phonrat B, et al. Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand. J Int Assoc Physicians AIDS Care (Chic) 2011; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/57\">",
"      Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 2012; 61:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/58\">",
"      Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/59\">",
"      Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012; 7:e32144.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (Accessed on October 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/61\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/62\">",
"      Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/63\">",
"      Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/64\">",
"      Oni T, Burke R, Tsekela R, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 2011; 66:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/65\">",
"      Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/66\">",
"      Kranzer K, Houben RM, Glynn JR, et al. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/67\">",
"      Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/68\">",
"      Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 2008; 48:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/69\">",
"      Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/70\">",
"      Williams BG, Granich R, De Cock KM, et al. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 2010; 107:19485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/71\">",
"      El-Sadr WM, Tsiouris SJ. HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008; 29:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/72\">",
"      Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/73\">",
"      Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/74\">",
"      Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/75\">",
"      Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/76\">",
"      T&ouml;r&ouml;k ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/77\">",
"      Francesconi P, Fabiani M, Dente MG, et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS 2001; 15:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/78\">",
"      Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/79\">",
"      French N, Nakiyingi J, Lugada E, et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/80\">",
"      Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/81\">",
"      Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 2007; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/82\">",
"      Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008; 49:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/83\">",
"      Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral na&iuml;ve and experienced patients in South Africa. J Infect 2010; 60:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/84\">",
"      Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/85\">",
"      M&uuml;ller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/86\">",
"      Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010; 50:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/87\">",
"      Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009; 49:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/88\">",
"      Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/topics/treatment/HIV-HBV_summary_evidence.pdf (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     file://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html#incidence (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/91\">",
"      Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/92\">",
"      Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/93\">",
"      Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/94\">",
"      Moore E, Beadsworth MB, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010; 61:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/95\">",
"      Soriano V, Puoti M, Garcia-Gasc&oacute; P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Leishmaniasis: Burden of disease. 2009. file://www.who.int/leishmaniasis/burden/en/ (Accessed on February 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/97\">",
"      Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/98\">",
"      Wolday D, Akuffo H, Demissie A, Britton S. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun 1999; 67:5258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/99\">",
"      ter Horst R, Collin SM, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/100\">",
"      L&oacute;pez-V&eacute;lez R, Videla S, M&aacute;rquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/101\">",
"      Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/102\">",
"      Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/103\">",
"      Attia S, Egger M, M&uuml;ller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/104\">",
"      Tanser F, B&auml;rnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, Guidance on couples HIV testing and counselling, April 2012. file://www.who.int/hiv/pub/guidelines/9789241501972/en/ (Accessed on October 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/106\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/107\">",
"      Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/108\">",
"      Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/109\">",
"      Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/110\">",
"      Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/111\">",
"      Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168.",
"     </a>",
"    </li>",
"    <li>",
"     MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women, November 2011. file://www.mtnstopshiv.org/node/3909 (Accessed on October 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/113\">",
"      Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/114\">",
"      Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/115\">",
"      Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21 Suppl 4:S117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/116\">",
"      Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings--the case of C&ocirc;te d'Ivoire. N Engl J Med 2006; 355:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/117\">",
"      Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/arv/rapid_advice_art.pdf (Accessed on October 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/119\">",
"      Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/120\">",
"      Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/121\">",
"      Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/122\">",
"      DART Trial Team, Mugyenyi P, Walker AS, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/123\">",
"      Koenig SP, Schackman BR, Riviere C, et al. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis 2010; 51:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/124\">",
"      Bendavid E, Young SD, Katzenstein DA, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/125\">",
"      Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007; 21:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/126\">",
"      Vijayaraghavan A, Efrusy MB, Mazonson PD, et al. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 2007; 46:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/127\">",
"      Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/128\">",
"      Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/129\">",
"      Muyingo SK, Walker AS, Reid A, et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2008; 48:468.",
"     </a>",
"    </li>",
"    <li>",
"     Muwanga A, Easterbrook P, Schaefer, P, et al. Losses to follow-up in a large ART program in Uganda (abstract 840). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/131\">",
"      Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are \"lost to follow-up\" in Malawi. Bull World Health Organ 2007; 85:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/132\">",
"      Bassett IV, Walensky RP. Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis 2010; 50 Suppl 3:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/133\">",
"      ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA), Keiser O, Anastos K, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization/United Nations Program on HIV/AIDS. Guidance on provider-initiated testing and counseling in health facilities. file://whqlibdoc.who.int/publications/2007/9789241595568_end.pdf (Accessed on August 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/135\">",
"      Weiser SD, Heisler M, Leiter K, et al. Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns. PLoS Med 2006; 3:e261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/136\">",
"      Ivers LC, Freedberg KA, Mukherjee JS. Provider-initiated HIV testing in rural Haiti: low rate of missed opportunities for diagnosis of HIV in a primary care clinic. AIDS Res Ther 2007; 4:28.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for appropriate evaluations of HIV testing technologies in Africa, 2002. file://wwwn.cdc.gov/dis/pdf/HIV%20Test%20Guidelines%20Africa/pdf (Accessed on August 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/138\">",
"      Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/139\">",
"      Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     Geng E, Bangsberg D, Musinguzi N, et al. What becomes of the defaulters? A sampling-based approach to determine outcomes of patients who become lost to follow-up in ART scale-up programs in Africa (abstract 842). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/141\">",
"      Posse M, Meheus F, van Asten H, et al. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 2008; 13:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/142\">",
"      Weiser SD, Tuller DM, Frongillo EA, et al. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One 2010; 5:e10340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/143\">",
"      Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/144\">",
"      Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/145\">",
"      Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/146\">",
"      Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009; 9:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/147\">",
"      Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/148\">",
"      Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115.",
"     </a>",
"    </li>",
"    <li>",
"     Wang B, Losina E, Stark R, et al. Loss to follow-up in community clinics in South Africa: role of CD4 count, gender, pregnancy (abstract 841). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/150\">",
"      Geng EH, Glidden DV, Emenyonu N, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health 2010; 15 Suppl 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/151\">",
"      Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/152\">",
"      de Cherif TK, Schoeman JH, Cleary S, et al. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis 2009; 9:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/153\">",
"      Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 47:101.",
"     </a>",
"    </li>",
"    <li>",
"     Nash D, Korves C, Saito S, et al. Characteristics of facilities and programs delivering HIV care and treatment services are associated with loss to follow-up rates in programs from 7 sub-Saharan African countries (abstract 838). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/155\">",
"      Losina E, Tour&eacute; H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a C&ocirc;te d'Ivoire appraisal. PLoS Med 2009; 6:e1000173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/156\">",
"      Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/157\">",
"      Ford N, Darder M, Spelman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One 2010; 5:e10460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/158\">",
"      Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis 2012; 54 Suppl 4:S245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/159\">",
"      Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/160\">",
"      Barth RE, van der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/161\">",
"      Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/162\">",
"      Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/163\">",
"      Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/164\">",
"      Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/165\">",
"      Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/166\">",
"      Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/167\">",
"      Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/168\">",
"      Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/169\">",
"      Holmes CB, Coggin W, Jamieson D, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 2010; 304:313.",
"     </a>",
"    </li>",
"    <li>",
"     French National Agency for Research on AIDS and Viral Hepatitis. Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults (ANRS 12136 TEMPRANO). 2008. file://www.clinicaltrial.gov/ct2/show/NCT00495651 (Accessed on February 19, 2009).",
"    </li>",
"    <li>",
"     National Institute of Allergy and Infectious Diseases (NIAID). Preventing Sexual Transmission of HIV With Anti-HIV Drugs. 2009. file://www.clinicaltrial.gov/ct2/show/NCT00074581 (Accessed on February 13, 2009).",
"    </li>",
"    <li>",
"     World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health system - 2006 revision. 2006. file://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (Accessed on February 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/173\">",
"      Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010; 7:e1000382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/174\">",
"      Beck EJ, Vitoria M, Mandalia S, et al. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 2006; 20:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/175\">",
"      Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/176\">",
"      Rosen S, Long L, Sanne I, et al. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc 2011; 14:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/177\">",
"      Levison JH, Wood R, Scott CA, et al. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis 2013; 56:587.",
"     </a>",
"    </li>",
"    <li>",
"     No time to quit: HIV/AIDS treatment gap widening in Africa. file://www.doctorswithoutborders.org/publications/reports/2010/MSF-No-Time-to-Quit-HIV-AIDS.pdf (Accessed on October 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/179\">",
"      Voelker R. One casualty of global economic crisis: uncertain finances for HIV/AIDS programs. JAMA 2010; 304:259.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.pepfar.gov/press/80064.htm (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/6/39018/abstract/181\">",
"      Denny CC, Emanuel EJ. US health aid beyond PEPFAR: the Mother &amp; Child Campaign. JAMA 2008; 300:2048.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13980 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39018=[""].join("\n");
var outline_f38_6_39018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12409174\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409041\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409048\">",
"      EPIDEMIOLOGY OF HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409055\">",
"      IMPACT OF TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H499459\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H499466\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H499473\">",
"      World health organization guidelines for prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H499487\">",
"      Discontinuation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409062\">",
"      EFFECT OF ANTIRETROVIRAL THERAPY ON MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9845923\">",
"      Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3410357\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23835331\">",
"      Gender differences in mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9845930\">",
"      Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5162338\">",
"      Recommendations from the World Health Organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409069\">",
"      EFFECT OF ANTIRETROVIRAL THERAPY ON OTHER COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409076\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8959030\">",
"      - TB incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98350889\">",
"      - TB treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409083\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409090\">",
"      Cryptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20677405\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12409097\">",
"      - Hepatitis B and hepatitis C viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409104\">",
"      Leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1038347\">",
"      IMPACT OF ANTIRETROVIRAL THERAPY ON TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7722013\">",
"      ART for HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7722086\">",
"      Pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409111\">",
"      COST AND COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409118\">",
"      ACCESSIBILITY OF LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409125\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8959134\">",
"      - Adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8959141\">",
"      - HIV parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409132\">",
"      ONGOING CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409139\">",
"      HIV diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409160\">",
"      Linkage to care and access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12409167\">",
"      Retention in care and loss to follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4941420\">",
"      Adherence to ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4941503\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7722205\">",
"      Test and treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4941580\">",
"      Costs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12409174\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/44/33485\" title=\"table 1\">",
"      WHO clinical staging HIV adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38568?source=related_link\">",
"      Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/8/3209?source=related_link\">",
"      HIV and malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/12/29898?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_6_39019="Test early detection CRC";
var content_f38_6_39019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Testing options for the early detection of colorectal cancer and adenomatous polyps for asymptomatic adults aged 50 years and older (Multi-Society Task Force)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tests that detect adenomatous polyps and cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FSIG every 5 years,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSPY every 10 years,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DCBE every 5 years,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CTC every 5 years*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tests that primarily detect cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annual gFOBT with high test sensitivity for cancer,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annual FIT with high test sensitivity for cancer,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        sDNA, with high sensitivity for cancer, interval uncertain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FSIG: flexible sigmoidoscopy; CSPY: colonoscopy; DCBE: double-contrast barium enema; CTC: computed tomography colonography; gFOBT: guaiac-based fecal occult blood test; FIT: fecal immunochemical test; sDNA: stool DNA test.",
"     <br>",
"      * CTC, available at the time of the development of these guidelines, is no longer commercially available in 2012.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Levin, B, Lieberman, DA, McFarland, B, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology, 134(5), 2008. Copyright &copy;2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39019=[""].join("\n");
var outline_f38_6_39019=null;
var title_f38_6_39020="Coombs test in AIHA";
var content_f38_6_39020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Significance of the pattern of positive direct antiglobulin (Coombs) test in the diagnosis of autoimmune hemolytic anemia (AIHA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anti-IgG",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anti-C3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Occurrence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibody",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antigen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        AIHA",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Rh protein complex",
"       </td>",
"       <td>",
"        Not seen in SLE; aldomet-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Drug-induced",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Drug attached to Rh complex",
"       </td>",
"       <td>",
"        Penicillin and aldomet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Drug-induced",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Fludarabine and cogeners",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        AIHA",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Glycoprotein",
"       </td>",
"       <td>",
"        Antibody fixes complement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Drug-induced",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        Drug + protein",
"       </td>",
"       <td>",
"        Drug affixed to protein; needed to detect in serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Drug-induced",
"       </td>",
"       <td>",
"        IgM or IgG",
"       </td>",
"       <td>",
"        Drug + protein",
"       </td>",
"       <td>",
"        Drug not firmly affixed to protein; drug needed to detect serum antibody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        AIHA",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Antibody of low affinity (may be detected with enzyme treated red cells)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        AIHA",
"       </td>",
"       <td>",
"        IgM or IgA",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Warm-reacting antibody detected with specific anti-isotype antisera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Cold agglutinin disease",
"       </td>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        Polysaccharide",
"       </td>",
"       <td>",
"        Cold agglutinins in high titer in serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Paroxysmal cold hemoglobinuria",
"       </td>",
"       <td>",
"        IgG",
"       </td>",
"       <td>",
"        P antigen (polysaccharide)",
"       </td>",
"       <td>",
"        Antibody fixes complement in the cold. Hemolysis occurs when sample/patient is warmed. Donath-Landsteiner test may be positive.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIHA: autoimmune hemolytic anemia; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wendell F Rosse, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39020=[""].join("\n");
var outline_f38_6_39020=null;
var title_f38_6_39021="Pulmonary function with age";
var content_f38_6_39021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Pulmonary function with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 353px; background-image: url(data:image/gif;base64,R0lGODlhIQJhAdUAAP///wAAAACZZsDm2UCzjIDMs4iIiERERLu7uxERESIiIoCAgEBAQN3d3ZmZmTMzM+7u7qCgoODg4NDQ0MzMzKDZxlC5luDz7DCsg3DGqWC/oLDf0BCfcGZmZvD59pDTvNDs4yCmecDAwPDw8Hd3d1VVVaqqqmBgYBAQECAgILCwsJCQkL+/v1BQUH9/f3BwcDAwMAAmGQA5JgBCLD8/PwB8UgAcEwBpRgCPXwBfPwByTAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAhAmEBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfACAHLywbIz9DDDQEU0dbXuh0d2NzdsRQBDd7j5KgH20QLzOvs7e7v8PHy8/T19vf4+fr7/P3+/wADChxIsGA9PsrEOQlQrqFDKQz3HCABJeLDi78GaNzIsaPHAQVCihw5wCIeBwkgVMTI0szHlx43jJxJk6YGAjhz6tzJk4OA/59AgwodSrSo0aIETCpS2jKUB5hQNVaoSZWmBZ5Ysx7dyrWr169gwwrAkLWszgxVKzBFtLbpkQtRoX6oSjek2bsExOrdy7evUbJ4s9al+yEuzAt22hpSrAiE4ZeD6QbOisGv5cuYt07GaiEy1QqPP3q4xphQ6ShTq2bYzDNE5tewLXNgvVOD55obQnsc7Xaxo9NQMsS2HIL22ds0c+vm2Ls38EDPnYCku5wjiObYKUX/sz27d1/d+4T/Th7X+D3n/YhQD2d9eVTp88TfIyGABD7177fJ//7U/Dv/5aHOAnwM6IaB/ZUSYB0L3pFCACjw8WCEbUyYoIK/QRIBMxHosf/hMh2u8WEAIV4YSoNzoEgHA8wwoAeLy7i4BowByGgiKCrGkWMcE7AzAR49rvNjGkEyM+SNnuz4hpJvnMDOCXg4uQ6UaUjJDJVIdsJkG1uyMUKNG0bA4gh2fMlAmGOiYSaaAZCZJSddrhGnGhIMGdEE+tFRpxB35lnGngD0+SacGUYyZxaHKpHooHgsaoajaUBKhaRFUMqoHJaGkSkZmz7RaaeXclkoJKA28WmohDZSKhirLnEqqpq0qoWsXdCKxKuwYmLrFbvO6geuuVrSaxXDYlHsEMAGq92ojxzLJxzOKuurqpJEm6y0hjKrrXzQYltJtCtlK1633k4CrqfV/kr/brni6mHAMgcslO64S7I7bx4kPFANuu2it66929IBATVRnAuRuvUC3KweJgSgwDLoCKEOPPf6m7DC1OaBkjgUJGCCqRXrcS3GbOmBQAJDHOAMEwYXjLAbLZPsqh4QJOAMOAiA3K/I/8pcsskPB7AyyyFze7HPPzMSM798jIz0IEsrWnSjPT9tWsCLWFu11YJEnYTXRNMLM9eHgH2E2VKLLSrZhaBd6dQAbs32y1nDnZjcczeN9VJ0s+E20n8jazeDeOfNc8ak9i2n4V3vnYjWRzOuNt87Gz225Nw5jogLiqsRuMyfB+pNp5xj3nnZ3pRueiuhh756qK0f4kA7HRgQ/y8RCDywjAJDv45d7InYPoTwQyizMvG+/675H8gjD8A5pgR9fALLPOBA8nQAj0jztwvhsRwnqySEAQ8I0QEzJew7Bu/jJ5AzACREjH3hVwffvfPfy5HA9UKwf8AD4mhACfi3PmfUjIDzy97y/MA9IkBPDiS4HTggkBA1sG+CCbwb4g7RwCE0jCIAcJ4aMEiCEoSwfBa8WQDEl8EULbAPzVtHvBygO4f1bg0PcMb+TrgG9h2whQrc4DHIFz4AVDAN7IPfDuEnPyB67oW9mMYDIvYAfQFAgAgEg/TaV70sOhEN2nvGAQLwPgBA4HzLSN8XU6W0NbrRCmF0BAve2Jw4Cv9RFXOk49ryMEZmlDFtietDHi+nx8XpQWUuqxzVIlfIMxQLkeEKpN4Y2cgyPJIZvZvYOwYXREJW0pF+mJ36ALmwyRnyk6D81R+/xkkXUhKVmtJDAwAYwpToTJIW8yQsxzAsCPRRAatkpSLj9spdesGObTTlE43JKShC7XRgZGYz75jMSepSmsd0ZuOUGSlsigGZdeNmNL3JKm1CB5qpJGc2qRlOa+5RnVwAJ+Xc6Td4rrOapaTnKe05LXyas57F5OcU5Pk4dD5KoFsgaNJy+U6EwvGfmRNnOh36UHbOk6EApWhF/WlRwgVUo7dsZz4xuk+QHqyjCz3cNU3KNJFCdJn/K2VpSC/60m5+VKa3qqk+FxlTnJKSpih1ZU99mtOg+kaiByVqS4HKUZ42VKk/LegwNThUqBJBoahDqiWtOlOp4lKlT+WqEbB61J3aVKzCbKpLLRdWtArOqG0z6FbdWlS1MpWYVRUrWeOq1WnSdax9UIYX6zpSsGb0r1flQwMSsMSwfZWth0Xss2jGOwUM9mytxBT99CoRilg2HfHIrI42y9VhRbB/lwXsVD2a19Iekh1NJKxOJxpZyR5qBO6hwme7alfWtpWuXWoBA0aAggDAoAq7dWxhIVtSrnYkJDHgZQQ2BIMAqMCvy3UqGgAlKHI6ZiNzEclVcsKVG/BSBC8I/8AEGEAgXoqWtF9YE4nSBES4bCQ1IRkvTnziF8DgBC0yGEMKGPAgALAXu7NN6hqstAwsPe0pG5GJSG6SE9f4pTg5sY1IQLMRxES1CxM7wZeu697VdlINRVrGkUL1XJGsJieV8ctsctIZkRSmw1+IUwRWgNsFuOmb772pGGhko+Z8VyMz2clldjIT6wgVDC94wVmzi1cRcQgb9tVIePOrE/72xb8EQItIOpLVMCygyHN9rHbVUFwK5SLLA8BvASiMEwv3BcM40XBIlKMR3uhqDCtAwQIGvQA/ldPET14DgkoBYY1IOCQvxkmM+zJjnNQ4JBzWiIdZ0SUaLSO3sUS0Zv/dwJ9JtFgkSraMTi5dgBtr5DrB6FIECD1oQ+c4yK0dA6j7cOQBbLkA+iWAl/kC5iYzpyF7rZ9ZLQFnOdNZ2JYBs5j3zBE/v6dLI2hBjVSgXgTDFb58aPQAHl2ASBPAznzBMwH0XIBMD2DT3up0jACQghV4u7cnnsOp7QJj2ax6JK4eAKwx16UArODMBm4vkEU9WjH0+tep9guTSXLsRhZcBWcmrr1LrOYqL6HZIwn2sPci7ZHweQAmDW4AUoCC4tr6nlSWQ6Nj4GydoHsv6ma3u62NWGxXF0RpjrkXOEJuc0+aL5UmAKvdDe8VhWHXGJvTBETwY44LPQm9TrJOloz/Ex0QAOBOVgS3SdyFUoNuDAcWQr3vvQgbcOTXIo/2ccZc8bdVgkVo1sKiScYkCYgABicQgeBToPBQ8wHkE7Y5ceZO7Y3wfKOSqM8yXn4FC/mMSZpcR4kMfwZxF10nR98LDnSic440HaaSSO8ypMyFEW1eYUwSEwoGzIC0W10LqQG9v2kM9o0MXHR9PQRxmYGCqmOByJcfQwSgfvssaIArE6f7RowlV0SMCOhaSHG3+Q4GCRR61rSmfDyH3vg+N3fNjniQ+le+BQYHwMEAU5IIAiACT9Of7XelKiQm0IL1MEQELbBiVSBfYtIm3PcF3icB4Edo4pdQuPZbCUYE3CUE/3hygGWAW8Z3awwHbik1foBzBvPHfLXygLW1gSeVfGYQgvjnVSRlgomEgmWggs2Hb4lGC65jC7FHawvgJCKYBGgkNPLighD4CjdYC0xif58WBVY0Oyz0YWuFfrJQhDYYBgsYflRAPkHYcfpnhE9zLLNDMEOQee1AgudXNuvgDOtAEUU0Pig0KV0YSrakXBG4gqaxSmQEAODwMY2VRG6IMY5RGOByh3L4bUIGHXb4Pp91Wni4QpCXK0gGbNAGFBYwLAhwAOJgAHE4M0JYgmaISYGSM7PDMYxYQrzCKE8hYThxFLNhAWohS78UTLJFiLkGCIKILMvgPkOQQwDQWH34Hv9wMRWrEXpCURy2ARpNl2zPFHy0eIgdMzRElIm96BZ/OGfndhRkgRa58XiYJYvnpIzccYhGFAD8I0WxdYIN8YhXMXJCgRMhoRGNyIJzOIOd2AyfKAQNwz9jBIsvaA2nyG+qqHStJnAwl3/wyFyzIIV18IvlRgDCGBTE2G7vpmBPOJFbOIW+MI03cXNCcY0FkI2zGFFa6FtcaAtaBonqGBTsWADuWJEdSIOjdgsIuQUQ5o9GsYoB+XstWGZXV4ORQAOcJwpwIRPBeBQPaYw6SZAt6XFkyFuX4BhTkZHWGGYdOQDamJRltZMvuSyHRgklmY5HkZIrKSzxyJJKuYlZqAj/M1kAqViTAFkYOLkJyLhNy6YIEwgAFeiBgxCUC9mQQFGUEekfYymSBskIBEhfDsgHTkmNGhkUHJkbp6cKcdmNc6kI7gd/iFIHXRmJSPF1KkmV5hGY+TaYjKB9AniZa5CWa1kUNnljsQaaPFmWjoB8A/kFejmURuGXbzkMkUmL1Wd9VzabVpCYUPkXUumYo+OaWWlYkWB5wNkEmXmSQAGWnnkRuwmSOekIe4eXSfCIqUkUqxmWdYScDTeZi2B2IygE/WibRYGbJlKdvcmBh9CDVKCQOVCNxImNf8ko7umNdGInFNiAnzCNXmkU0lmVsCOe8JkGhWmAoMCdecGWnTED/+AJewhaiG1QmZmQngxJlOsGkTgZk7Gwn+T5BqQZCQo5nEXRmPnphPYiotc5B7KJCAKqmUSRkh4ZjRZIkQVpB64nCA76jzU2oaYJgzpqlXTQZnqgoXz5Ew/plhKZo0h5lHiQnW1wovaZolJplEMYbxX6kfthH2owo9D5EzY6naFJodzIm30gn1nwoxDajij3nsHSSyVwi6lldyH5CErKobbhpFcJpXUwS9VAAs8hhUVopUs6Flm6okXKpYGlAGfZpWQwo4sZnZx5o9/yhn3QAQohMaFllm3goGNqk515BWzKn7DiLAYwSpqYp22goQ+6nh3qp1xgnslIpHhwAB+zVP9p2gWIGpVooaVkQKWSeXZ5MEs3NIguuQWU+pWXaqZrwJzKZqx4oAzrcKdv5apUIKpsyZlCCgc9yle4uqONugSwyqGdQat7EKO3Sq3lKq5M8KvEWYyMCgglOq2AaqQt2awEWpzQmggYSgiq465RaggxMB371a1wWgkLmoFo5aJxcK632ZYCyQl1eZc9J6lbIK9FUQMdKqymAKLYArFggJFXWqP+OhoiO6SSNVnLOgboSKNCMWMLm1acxjwyZK0B0Fi5szvJmqoaCwD9qJaxShTFka4VG0k3y0DdE47jw4jGMz5NO6euqZDqSRRkQa+POVBEyDxNqwxCMA3i8EAtOof/FYCiKIufBsqyqwAu7+JHYAsAHQCpu7irZdurR/B8QEGzpYp6beu1uMMMtFS3aPqyTOBrSZugWgK4xcMQs/M+ZMsuJAuFgMm0gds+1fBBUuuohiuXSwtDX2sRJJAA1UBDPsu574qvkNmyiYW3qLq4rOuyqduufxu7wNe5xVq7hjBIBEuuBSsKZrOyrjC5sFm5fxp1Qeu3qjCwqlu4s+u5QPuBrjuiNyK8rJO8Uxa946qvUnqg0ou7amoKbxsAVuQ8E5G7yDu9L+oJxFMC5QMOCjENrEq9ykK8ZAkKxOMAdKuLPIS+zvu7zRsKwgMBU8SGQsC/4du7drBY+riN2roJ/+PbPQNDAfALvembB2jUwKr1wJogPHPbqSVAAiIkp7niLLWorM97CcTzP+KDEsmVwPmaGBqMp1gJwd1TRSpRM9BonTHMIKskhuywlN9hvZ8rMjPcuhx8IUSsu0bMq+BbHku8unrwg4UqxJnAuwF8t09MwknCvSOLveN0vd0bf2BMW1J8vP/ru2qMIWOsxSkMw2cMrz0sx+p7CcGrqVv8umxEx2nsxXwMH35cv2X8pHGcxZI7yEHHxIZcLvYrmKlwx9/7xjxcyLR7wZLMxbCLxmRcx6IZsoFMtZxMuZ7cxoccysU7yprsxgBcyY/8ySWMyN3nn3YJoBYryxjbBxdLy/+vbMpy0LCn4Mt/AMx9TMqFELCnYMx/gMybnMd5cK+n4Mx/AM3LfMnr2iKrwK6AgM3TvMqAEK6p4M2BAM7DnMqIgKSsYM6EgM5zvMiGQKym4M5+AM+MDMtiYKuoYM+AgM+qvMbx+Qqnygf/LC2NbLvXRs8ETQ4DfdBDbNAK3Q0J3dDKw8sQ7R0PPdFuUdEW3RKtYxAc3dEe/dEgHdIiPdIkXdImPRDAS79bmpynnNGt2sksLcox7dJMeaaO3NLjSdNKK9M5rZz3q9M2y9OKW4Y2DdRBjdNDrbw/bdQbDNM97dRJndHHMtWYnL1MzaKvWdQ3rdVXTQR5ZwdfXQdhDdb/fDDWXX3WaJ3War3WbN3Wbv3WsaC/8KISOhsAU8sGP7gyfbQMR3wGB0C3dX3Xa7DXd0jYfU0GFFBDORPYZ107V2QzTksHS8iIkEQHowvYslLZQqDZcLBYICQEcdvWB3A9oV0HWPg8P+sGBlBZoJ3ZN8TZb0CKl9vWFLAyOju4cPCF+7LXqZ0GJ9MA+tva1dOpbsDbm+2JcPAAQaMA1XDbxH3VDRBbBGxCc4ASTShKb8DAABDcRDDddIDdQwDebqAAINQBbWhGD0DdXV2JSDDCSwKOblDXy0Dc7g0z8F3ctq0U9e3Sq92Ejo2scFCJl5gSszTgTfgG3P3fCNwGBV5L/xDQ4Jh44Guw2uJQAvGi4L2d0YQNqSiRRnHQAK9oRiFe3XTb4QGg3m7gS7uTMyruMIdNBnVKvuJg4igO1zZ+4zie4zq+4zze4z7+40Ae5EI+5ERe5EZ+5EhO5IulAM/tBWOErUnuENYq2FCgO3YbBjWjABIe5Rjxg03+BMpA5V5AqBnO5eVAPdSzMiB+i0BIAb905SEkjk9L3dTTABAQ40DYMMxAEQ2TAOdjAm6O3NMg5mZODrNjWQ5zwECoOwYAAQqg5eCAMg4EhjoMAbNjQvkIAA9TRo4ujnq+DCbwMHC+i5Je6BgxRo1OPQgwMOEAAIz+heswSrrDQnVqOwFgAtfTwA6NTqiY1OdDEDSOPQSMZeoYkevr0AGsLg6vnuhIMEbqowwPA6m5TtxjZEKM7uthmy8QI+ylTuwN8S4lvrOaLucPk+pACOJN+C4ItEWufuJCUAImwOidbgDYTgTngw6D7u0PUe7CLo6J7TAPcz2B7uGBi+LvUupnxAyWaALU8+hCg+2snkbiQ+b67h2LBYZLYOVDcD6fvQVZvuUV/xDj+8JKsOTiUDMYvwVPHvIs3/Iu//IwH/MyP/M0X/M2f/M4n/M6v/M83/M+//NAH/RCP/REb1JBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TLC: total lung capacity; VC: vital capacity; IC: inspiratory capacity; ERV: expiratory reserve volume; RV: residual volume; FRC: functional residual capacity.",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reproduced with permission from: Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J 1999; 13:197. Copyright &copy; 1999 European Respiratory Society. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39021=[""].join("\n");
var outline_f38_6_39021=null;
var title_f38_6_39022="Risk model accuracy";
var content_f38_6_39022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Fictitious risk model accuracy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ability of a fictitious cancer risk prediction model with a concordance of 1.0 to discriminate between women who will be diagnosed with breast cancer and women who will not.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elmore JG, Fletcher SW. The risk of cancer risk prediction: \"What is my risk of getting breast cancer?\" J Nat Cancer Inst 2006; 98:1673. Copyright &copy; 2006 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39022=[""].join("\n");
var outline_f38_6_39022=null;
var title_f38_6_39023="Rx MS moderate severe sx I";
var content_f38_6_39023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with moderate to severe mitral stenosis (MS) and moderate to severe symptoms (NYHA functional class III to IV) - Part I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"     <br>",
"      &bull; There is controversy as to whether patients with severe pulmonary hypertension (pulmonary artery systolic pressure &gt;60-80 mmHg) should undergo mitral valve replacement to prevent right ventricular failure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_6_39023=[""].join("\n");
var outline_f38_6_39023=null;
